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ABSTRACT

The development of new screening methods for the early detection of cancer
remains one of the foremost challenges facing modern cancer research. The emergence of
new analytical technologies and their application to “omics”-based approaches has
provided researchers with powerful new tools for molecular biomarker discovery that may
benefit early screening of cancer. This dissertation outlines several key advances made
toward the application of urinary metabolomics to cancer biomarker discovery. The term
urinary metabolomics here refers to the investigation of small metabolites in urine as
potential disease biomarkers. The advantage of using this approach lies in its noninvasive
sampling characteristics and robust analytical feasibility. The dissertation begins with the
development of two analytical methods for the determination of sarcosine in urine for the
early detection of prostate cancer. The next three papers discuss the analytical challenges
facing the determination of pteridine derivatives in biological samples and present a new
method to adjust their levels to patient hydration status and time since last urination.
Briefly, pteridines and their derivatives function as intermediates in the metabolism of
various vitamins and cofactors, where altered levels of pteridines have been reported in the
urine of patients with several types of epithelial cancers, among other diseases. The
following paper explores the possibility of using urinary metals as potential cancer
biomarkers in a proof-of-concept study. The final two papers investigate the biological
variation of urinary pteridines in order to better understand how urinary metabolites
naturally fluctuate, and apply this information to a new method for the comprehensive
determination of pteridine derivatives in urine. Taken together, this body of research
presents new opportunities and challenges in the discovery of new cancer biomarkers.
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SECTION

1. INTRODUCTION

1.1. CHALLENGES FACING EARLY CANCER DETECTION
Cancer is among the leading causes of death worldwide with over 8 million deaths
reported in 2013.1 Moreover, the global burden of cancer is expected to increase as risk
factors for developing cancer, such as smoking, obesity, and sedentary lifestyles, become
more prevalent.2 Early cancer detection can reduce disease mortality by identifying
premalignant and malignant tumors at an early stage of development when treatment may
be more effective. However, conventional screening methods, such as medical imaging,
mammograms, and colonoscopies, often involve invasive procedures that may be
uncomfortable for patients or require advanced medical facilities that limit accessibility
and affordability. False positives that result when a screening method cannot distinguish
indolent and aggressive disease further contribute to the problem of overdetection and
expose patients to unnecessary treatment. Overdetection resulting from insensitive
mammograms and prostate specific antigen (PSA) screening has become especially
problematic in the management of breast and prostate cancers, respectively.

3-5

For

example, the extent of overdetection in breast cancer management is estimated to be as
high as one in three breast cancers, prompting the American Cancer Society in 2016 to
recommend new guidelines aimed at reducing the frequency of mammogram screening by
raising the suggested age for women to begin screening and decreasing the frequency of
periodic screening among women over 50.6 In this way, new screening methods for
detecting cancer earlier and more reliably are needed to better identify individuals who are
at increased risk for developing cancer.

1.2. THE EMERGENCE OF URINARY METABOLOMICS
Modern research on early cancer detection has shifted focus onto the development
of molecular biomarkers capable of reflecting underlying cancer biology. Whereas

2
conventional screening methods have limited spatial and temporal resolution that require
the tumor to grow to a minimum size before detection is possible, molecular biomarkers
are capable of providing details prior to disease onset and throughout the natural
progression of the disease. Collectively, the applications of advanced high-throughput
technologies to reveal the biochemistry of cancer and other diseases is referred to “omics”
approaches, and can be classified by type of molecule studied. For example, genomics is
concerned with the genetics of a given condition, while proteomics is concerned with the
proteins involved in a given condition, and metabolomics involves the investigation of
small metabolites in relation to a given condition, among other specialty subclasses.
Previous efforts to characterize the genomes and proteomes of cancer have revealed
remarkable complexity and heterogeneity, even among histologically similar tumors.7
Nevertheless, the discovery of potential screening biomarkers from these genomic and
proteomic studies has remained limited by difficulty in implementing such screening
methods. Specifically, genomic analysis can readily reveal whether an individual is at
increased risk for developing cancer, but analysis of genes alone cannot provide
information on whether a malignant tumor already exists. Moreover, genomic analyses are
generally limited to tissue samples for which an invasive biopsy from the suspected cancer
site must be taken. Transcriptomics, concerned with the relationship between gene
expression and disease, is an emerging “omics” approach that successfully bridges
genomics with a responsive set of molecular biomarkers with better translatability to bodily
fluids, such as serum.8 Protein biomarkers have greater applicability to cancer screening
methods than genetic markers while maintaining a high degree of disease specificity.
Nevertheless, protein analysis in a clinical diagnostic setting requires specialized analytical
techniques and invasive sampling techniques. In contrast, metabolites represent the final
response of an organism to environmental, genetic, and disease factors

9, 10

. The

responsiveness of metabolites to disease phenotype enables monitoring of subtle changes
in the pathophysiology of multifactorial diseases, such as cancer11. Although the
relationship between cancer development and cellular metabolism is complex and can be
unique to individual tumors, cancer metabolism is often characterized by increased
glycolysis and increased fatty acid synthesis, among other metabolic processes needed to
support rapidly dividing cells, collectively referred to as the Warburg effect. 12-15

3
Furthermore, metabolites may be sampled noninvasively in a myriad of biospecimen types,
such as exhaled breath, saliva, and urine, with a greater variety of analytical techniques
than is possible for genomic or proteomic biomarkers.16, 17.
Among these biospecimen types, urine confers several advantages to cancer
screening applications and is particularly well-suited for metabolite analysis17, 18. Namely,
urine can be sampled noninvasively and economically in large volumes suitable for longterm storage. Urine further does not contain proteins, immunological factors, cells, and
other matrix components common to serum and tissue lysates that require substantial
pretreatment of samples prior to analysis. Nevertheless, the application of metabolomicsbased approaches to cancer biomarker discovery in urine has only recently benefitted from
the remarkable technological breakthroughs that have supported other “omics” strategies.
Although urinary metabolites have been studied in relation to cancer for decades (e.g.
20

19,

), urinary metabolomics presents several challenges that comprise some of the major

themes of this dissertation. For example, unlike genes or even proteins, metabolites can
occur physiologically where their urinary levels become altered in the presence of cancer.
This consideration requires the application of rigorous statistical models to determine
whether a given metabolite concentration will be considered abnormal. The significance of
this feature is highlighted by the shortcomings of the PSA test for prostate cancer in which
PSA and other kallikrein proteins can become elevated due to benign prostatic hypertrophy
and other conditions.21 Moreover, urinary metabolites must be adjusted to patient hydration
status and time since last urination. As this dissertation will later present, conventional
strategies for rendering these corrections may be flawed or inappropriate for a given study
population. Finally, the human urine metabolome is remarkably complex with over 4000
reported metabolites,22 a feature that complicates the sensitive and specific determination
of urinary metabolites due to the high potential of interfering compounds. This dissertation
will outline the development of several analytical methods embedded with innovations to
overcome these challenges. These new developments in the application of urinary
metabolomics to cancer biomarker discovery have led to significant progress in a rapidly
expanding and evolving field.

4
1.3. ANALYTICAL TECHNIQUES USED IN URINARY METABOLOMICS
Quantitative techniques for urinary metabolites can select from a rich variety of
standalone and hyphenated analytical platforms for the optimal detection of selected
metabolites. Mass spectrometry is a preferred detection method given its excellent
sensitivity and multiplexing capacity. For quantitative analyses, tandem mass
spectrometers in particular can provide fast acquisition times, a variety of possible scan
modes, and wide dynamic ranges that allow these instruments to monitor trace level
metabolites to primary metabolites such as amino acids within a single run. Tandem mass
spectrometry may be further hyphenated with separation techniques, such as gas
chromatography, liquid chromatography, or capillary electrophoresis for enhanced
separation of urinary compounds and increased multiplexing capacity. Briefly, gas
chromatography – tandem mass spectrometry (GC-MS/MS) is useful for the quantitative
analysis of volatile compounds, and through the use of chemical derivatization, an
additional subset of normally non-volatile compounds. However, the small number of
volatile compounds present in urine and the potential selectivity issues and complicated
procedures involved with chemical derivatization have generally limited its application for
this purpose.23
Liquid chromatography continues to be the most widely used separation technique
in the determination of urinary metabolites. The technique is best suited for the analysis of
non-volatile and thermally labile compounds that comprise the overwhelming majority of
urinary metabolites. The analytical capabilities of the technique have recently benefited
from new column technologies including the development of novel stationary phase
chemistries and reduced particle sizes that enable highly selective separation of metabolites
in urine matrices. Liquid chromatography can further readily interface with a range of
detector types, including mass spectrometry, UV absorbance, and fluorescence. However,
liquid chromatography – tandem mass spectrometry (LC-MS/MS) continues to be the most
common configuration given its superior sensitivity and selectivity and relative
accessibility compared with other analytical techniques. Moreover, reference level
accuracy can be obtained with this configuration through the use of stable isotope internal
standards and isotope labelling strategies. For this reason, LC-MS/MS has been
implemented in clinical diagnostic settings for the quantitative determination of various
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metabolic biomarkers. This dissertation covers several advances made in the development
of multiplexed LC-MS/MS methods for the simultaneous determination of pteridines and
other compounds.
Finally, capillary electrophoresis presents another high-resolution separation
technique for the analysis of highly polar or ionic compounds. Capillary electrophoresis
has found limited applications in urinary metabolomics and cancer biomarker discovery
given its poor reproducibility and challenges associated with its hyphenation to certain
detector types, such as mass spectrometry. However, recent innovations in interface
designs and advanced separation modes have overcome many of these earlier challenges.24,
25

Taken together, these technological innovations have enabled extensive metabolic

profiling in urine, resulting in the discovery of new putative biomarkers for the early
detection of cancer.

1.4. URINARY PTERIDINES AS MODEL BIOMARKERS
Recent urinary metabolomics studies have revealed an array of putative biomarkers
ranging from modified nucleosides26 to kynurenine pathway intermediates27 to pteridines28
to many others. Among these, the clinical investigation of urinary pteridines has best
exemplified progress made in the application of urinary metabolomics to cancer biomarker
discovery through the translational challenges that have been overcome and is discussed in
great detail later in this dissertation. Briefly, pteridines and their derivatives function as
intermediates in the metabolism of several vitamins and cofactors. Pteridines are one of the
most widely studied classes of metabolites in urine, owing to their original isolation in
urine and the resulting analytical methods that were developed for their quantitation in
urine.29 Although many of these early studies examined the putative roles of pteridines in
cancer given their relationships to the DNA nucleotide and folic acid metabolic pathways,
and reported elevated levels of several such pteridines in certain epithelial cancers,30-34 the
clinical investigation of urinary pteridines and their biological function in cancer have until
recently been frustrated by limited analytical capabilities. However, the biological function
of some pteridines, such as 5,6,7,8-tetrahydrobiopterin (BH4) and neopterin, have been
elaborately studied and provide important context for the probable roles of other pteridine
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derivatives in cancer. Briefly, BH4 is derived from guanosine triphosphate and functions
as an essential cofactor for several notable classes of enzymes, including amino acid
hydroxylases involved with neurotransmitter biosynthesis, nitric oxide synthase which
regulates vasodilation and neuroprotection, and alkylglyercol monooxygenase which
mediates the biosynthesis of ether lipids involved with structural components, chemical
signaling, and more. For this reason, BH4 deficiencies can present a spectrum of clinical
disorders, and is consequently used as a screening biomarker for several diseases.
Meanwhile, neopterin and its derivatives are produced selectively in monocytes,
macrophages, dendritic cells, and endothelial cells following activation by the cytokines
and interferon gamma (IFN-γ) released by T lymphocytes and natural killer cells in a
similar manner to BH4.35 As a result, neopterin has been studied extensively as a marker
for activated cellular immune response in an array of medical conditions, ranging from
bacterial and viral infections to autoimmune diseases to cancer. In addition to BH4 and
neopterin derivatives are many other pteridines and related lumazines that have been
reported in humans, but whose biological function and biosynthetic pathways remain to be
established.34. This dissertation presents several analytical methods for the determination
of these compounds in urine and cell lysates in order to better understand their roles in
cancer as putative screening biomarkers.
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ABSTRACT
Metabolites impart a significant importance to the understanding of biological
reactions, and consequently, to the development of diagnostic and therapeutic techniques
for specific diseases. Furthermore, there has been recent interest in metabolite
concentrations present in urine for potential noninvasive disease diagnosis. The detection
of specific metabolites, however, presents certain analytical difficulties such as low or
ambiguous specificity of the techniques. This study developed a new technique, utilizing
oxidative, enzymatic production of formaldehyde from the metabolite to produce a pHinduced change observed by fluorescein in acetone. This probe displays high sensitivity
towards pH imbalances, and coupled with high enzymatic specificity, forms an accurate
method to measure metabolite concentrations. Sarcosine was used as a model analyte in
this study due to its potential for serving as a prostate cancer biomarker. Sarcosine was
treated with sarcosine oxidase to generate formaldehyde, which was further oxidized to
formic acid, and subsequently measured by the corresponding change in fluorescein. A
good linearity was revealed with a correlation coefficient of 0.9961 and a detection limit
of 20 nmol·L−1. This method was applied to sarcosine analysis in nine urine samples. The
results suggest that this is a viable, cost-effective technique for determination of sarcosine
in urine samples without interferences such as alanine.

KEY WORDS
Sarcosine, sarcosine oxidase, fluorescein, assay, urine analysis
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1. INTRODUCTION
1.1. Background
Tests for prostate-specific antigen (PSA), a common marker for prostate cancer
diagnostics, cannot accurately differentiate between benign prostate conditions and active
prostate cancer.1 This well-practiced technique, which relies upon an abnormally high
presence of the antigen in serum, thought to be correlated with increased prostate gland
size, is also well-known for being both false positive- and negative-prone.2 It has further
been shown that the mortality rate does not significantly improve with PSA screening.3
This lack of sufficient diagnostic techniques for prostate cancer highlights the need for
more effective screening methods.

Whereas many diagnostic techniques rely on the presence of antigens, like PSA,
metabolites can serve and equally important diagnostic role. Indeed, metabolites, as the
intermediates and products of metabolic exchanges, have an intimate relationship with
systemic changes in an organism. An important implication of this is that of carcinogenesis;
while cancer has been traditionally seen in terms of gene regulation, affecting control and
signal processes, disjoint from metabolites, it is becoming increasingly apparent that
metabolites operate as key functions in the development of several types of cancer through
numerous mechanisms, such as modulating various signal transduction systems.4

Effective analysis and quantification of such metabolites in applicable media may
then characterize the progression of certain cancers when practical difficulties would
otherwise exist.5,6 An example of this concept, applied to prostate cancer, was utilized in
an attempted metabolomic profiling of biopsy-positive prostate cancer patients and biopsynegative prostate control individuals that suggested a correlation between sarcosine levels
and progression of the disease.7 This finding brought about great interest in determining
sarcosine in various media, and although the correlation between sarcosine and prostate
cancer has since been refuted8,9, it adds stress to the importance of metabolites, such as
sarcosine, as novel markers for cancer diagnostics.
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Analytical methods for direct determination of metabolites from cells, plasma, or
urine often include a combination of liquid chromatography and gas chromatography with
mass spectroscopy. However, the major disadvantages of these techniques are high
instrumentation costs and the interferences from other chemicals; for example, in the case
of sarcosine, alanine has the same exact mass as sarcosine and often co-elutes with it,
traditionally

complicating

normal

chromatographic

techniques.10

Although

chromatographic techniques have been reported to fully separate alanine and sarcosine, 11,12
these techniques require instrumentation not generally available to clinics.

Substrate-specific enzymes, however, have shown to be useful analytical
reagents.13,14 One class in particular is the oxidoreductases, which often produce reactive
oxygen species (ROS), such as peroxidase and hydrogen peroxide, respectively, being first
reported in 1846.15 In the case of sarcosine, sarcosine oxidase serves as a catalyst in the
oxidative demethylation of sarcosine, an intermediate metabolite, to glycine,
formaldehyde, and hydrogen peroxide. Direct determination of sarcosine can be difficult,
but indirect quantification can be achieved by this reaction. Indeed, an established
analytical assay for sarcosine includes the sarcosine oxidase-mediated demethylation of
sarcosine to hydrogen peroxide, which reacts with 4-aminoantipyrine and phenol to yield
quinoneimine dye (Scheme 1)16. The disadvantage is that such colorimetric analyses can
be skewed in complex matrices like urine and blood.

Scheme 1. Colorimetric assay of sarcosine via production of quinoneimine dye.
Sarcosine + O2 + H2O + Sarcosine Oxidase → Glycine + Formaldehyde + H2O2
2H2O2 + Phenol + 4-aminoantipyrine + Peroxidase → 4H2O + Quinoneimine Dye

A proposed solution to this skewing is the fluorimetric determination of sarcosine.
One particular subset of fluorescein derivatives, including the commonly used 2’,7’dichlorofluorescein diacetate (DCFH-DA), is currently being recognized for its high
specificity to reactive oxygen species. Many of these compounds have reported detection
limits in the nanomolar concentration range, providing useful probes for oxidative stress in
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cellular systems.17,18,19,20 Their premise was based upon the theory that non-fluorescent
fluorescein derivatives will fluoresce upon oxidation by hydrogen peroxide and other ROS,
and that this fluorescence is directly proportional to the concentration of ROS present.21

Indeed, this subset of fluorescein derivatives is growing every day, and the
specialized probes cited above formed the original basis of the proposed method for their
relative structural and synthetic simplicity to newer compounds. Although this type of
probe has the capability to indirectly quantify sarcosine by production of hydrogen
peroxide via sarcosine oxidase, there exists several limitations: (1) as fluorescein
derivatives, they are highly sensitive to pH changes and (2) hydrogen peroxide
decomposition needs to follow a radical pathway. Under optimal conditions, the oxidation
of sarcosine is significantly favorable to the further oxidation of formaldehyde to formic
acid. The associated pH change from this was found to be more significant than that
oxidation of fluorescein by radicals formed by hydrogen peroxide decomposition. In
addition to this, the basic conditions under which sarcosine oxidation occurs seemed to
have favored the decomposition of hydrogen peroxide into water and oxygen gas, not
radicals. Furthermore, synthetic preparation of these specialized fluorescein derivatives is
often complex, and the direct purchase is expensive, when compared with pure fluorescein.
In this study, a novel and low cost enzymatic technique has been developed for
determination of sarcosine in urine samples, not by measuring ROS formed from hydrogen
peroxide decomposition, but the pH change associated with formaldehyde being oxidized
to formic acid.

1.2. Reaction Mechanism
The developed method relies simply on the pH sensitivity of ordinary fluorescein.
Under acidic conditions (pH<4), the non-fluorescent lactone form of fluorescein exists in
high concentrations. Prepared in acetone, it is nearly the only form present and is
furthermore readily soluble. Upon exposure to a basic reagent, lactoid fluorescein will
readily change to the highly fluorescent monoanionic and dianionic forms. Thus, changes
to the pH of a standard reagent can be quantitatively determined by the lactoid fluorescein,
even with low concentrations and/or volumes. For the determination of sarcosine, this can
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be achieved by an enzymatic oxidation of sarcosine to glycine, resulting in hydrogen
peroxide and formaldehyde as byproducts, and subsequent oxidation of formaldehyde to
formic acid and methanol (Scheme 2). In the presence of NaOH and heat, the Cannizzaro
reaction proceeds converting the formaldehyde to formic acid and methanol while
degrading the hydrogen peroxide without forming interfering radicals. The conditions of
the Cannizzaro reaction catalyze the decomposition of hydrogen peroxide to water and
oxygen gas with minimal ROS being formed. The resultant decrease in pH from the formic
acid results in a quantifiable deviation from the standardized pH of the solution without
interference from radicals from hydrogen peroxide. In this way, the coupling of an enzyme
and ordinary fluorescein provides two advantages: (1) high specificity for sarcosine, and
(2) a relatively cost-effective alternative to current methods such as DCFH-DA and LCMS analysis.

Scheme 2. Proposed method for the determination of sarcosine.
C
Sarcosine + O2 + H2O + Sarcosine Oxidase 37


 Glycine + Formaldehyde + H2O2

, 50C
Formaldehyde NaOH


 Formic acid + Methanol

, 50C
H2O2 NaOH


 O2 + H2O

Lactoid Fluorescein in acetone (non-fluorescent) Formic
Acid
 Dianion Fluorescein
(fluorescent)

The combination of the two steps, substrate-specific enzymatic production of
formaldehyde followed by conversion to formic acid coupled with subsequent fluorimetric
analysis by fluorescein, supplies an effective, indirect, analytical technique for metabolitespecific determinations without interference from ROS. This idea was demonstrated by the
determination of sarcosine in urine and further comparison to the same samples being
analyzed using LCMS/MS methods9 where alanine is presumed to be an interference.
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2. EXPERIMENTAL
2.1. Preparation of Sarcosine Oxidase
Sarcosine oxidase from Corynebacterium sp. (lyophilized powder, 5-10 units/mg)
was purchased from Sigma-Aldrich (Saint Louis, MO, USA). A 20 mmol·L⁻¹ potassium
phosphate solution was prepared from ultra-pure water and potassium phosphate
monobasic, and the pH was adjusted to 8.3 with 1 mol·L⁻¹ sodium hydroxide. To 1 mL of
buffer was added 0.7 mg enzyme. The reagent was prepared fresh and chilled at 4 degrees
Celsius.

2.2. Preparation of Sarcosine Stock Solution
The sarcosine and Tris-HCl buffer used in this study were purchased from SigmaAldrich (Saint Louis, MO, USA). Ultra-pure water was generated using a Milli-Q
Advantage A10 water purification system, 18MΩ (Millipore, Billerica, MA, USA). A 200
mmol·L⁻¹ Tris-HCl buffer was prepared with ultra-pure water and Tris base, and the
resulting pH was adjusted to 8.3 with NaOH. This represented the optimal pH of sarcosine
oxidase and fluorescein. A stock 2.5 µmol·L⁻¹ sarcosine solution was prepared in the
buffer.

2.3. Analysis of Sarcosine Standard Solutions
Into a 250 µL Corning Costar 96 flat bottom plate were added insertions of the
sarcosine stock solution. These insertions were based on the sarcosine concentration range
(200-1400 nmol·L⁻¹) reported by LC-MS/MS analysis of urine samples diluted 750 times.
This insertion was supplemented with enough Tris-HCl buffer to make 75 µL. The plate
was then heated to 37 oC. To this was added 25 µL cold enzyme reagent, and the plate was
then incubated at 37 ᵒC for 30 minutes. Upon incubation, the plate was chilled to room
temperature, 5 µL 500 mmol·L⁻¹ NaOH inserted, and re-incubated at 50 ᵒC for 10 minutes
to ensure complete formation of formic acid. The plate was then cooled to room
temperature again, and fluorescence readings were taken. Upon which 5 µL 15 nmol·L⁻¹
fluorescein dissolved in acetone was added, resulting in a total volume of 110 µL per
sample. The plate was then shaken in double orbital fashion for two minutes and analyzed
two hours later.
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2.4. Analysis of Urine Samples
Urine samples (n=10) were provided by the Central Missouri Urology Clinic. The
set was comprised of five normal samples and five prostate cancer positive samples. Prior
to subjection to the method outlined in this study, the samples were analyzed via liquid
chromatography with tandem mass spectroscopy.9 The supernatant of the samples were
then properly diluted in buffer solution whereby 75 µL was inserted into the well plate.
The procedure then followed that of the sarcosine standards.

2.5. Instrumentation
Fluorescence emission spectra were obtained with a BMG Labtech Fluorstar
Omega (Ortenberg, Germany) plate reader equipped with a xenon lamp. Excitation and
emission wavelengths were attuned to 485 nm and 520 nm, respectively. The lamp was
allowed sufficient time to warm prior to measurement. Data was collected and analyzed
via BMG Omega software.

3. RESULTS AND DISCUSSION
3.1. Spectral Properties
It is well observed that fluorescein can exist in several forms: the highly
fluorescent dianion form, the moderately fluorescent monoanion form, and three neutral
tautomers: the quinoid, lactone, and zwitterionic. Furthermore, fluorescein is highly
sensitive to both pH and solution, and the proportion of the forms present is consequently
dependent upon those as well. The colorless, nonfluorescent lactone form has the greatest
proportion (>99%) in acidic conditions (pH<4.3), while the highly fluorescent dianion
form is found best in pH conditions greater than 6.37.22 Dissolution in acetone, however,
achieves an equally high proportionality of the lactone form while providing a relatively
acidic environment (pH=6.1) similar to that of urine. Therefore, addition of base raises
the concentration of the fluorescent forms to the optimal conditions of fluorescein
(pH=8.3). Figure 1 illustrates the difference between fluorescein fluorescence in acetone
and in buffered solution.
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Figure 1. Emission spectra of 300 μmol·L−1 fluorescein in (1) acetone (pH= 6.1) and (2) in
buffer solution (pH=8.3) at 25°C.

3.2. Linearity, detection limits, and reproducibility
Sarcosine standard solutions were incubated with sarcosine oxidase in basic
conditions to generate formic acid in order to produce a measureable pH change. A stable
calibration curve (Figure 2) was obtained from a set of sarcosine standards ranging from
23 nmol·L−1 to 1704 nmol·L−1. A fairly linear relationship was observed over this range
with a correlation coefficient of 0.9961. The limit of detection was determined to be 20
nmol·L−1 with a signal-to-noise (S/N) of 3. Reproducibility was measured (n=5), yielding
a standard error of 4.2%. Based on this data, it was concluded that this technique is
applicable over the given concentration range.
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Figure 2. Calibration plot constructed from sarcosine standards ranging from 23 to 1704
nmol·L−1 (R2 = 0.9961).

3.3. Determination of Sarcosine from Urine
Ten urine samples were analyzed via liquid chromatography with tandem mass
spectroscopy (with known interferences from alanine) and via the proposed fluorimetric
determination of sarcosine. Analyte concentrations were compared for the undiluted urine
samples with the comparisons shown below (Table 1). Three preparations of each sample
were prepared to provide validating statistical significance. Consequently an acceptable
degree of reproducibility was established. All samples fell within the calibrated range
except for one which initially yielded an undetectable amount of sarcosine. Similarly this
sample produced a significantly low value by LC-MS/MS techniques as well. This zero
value may be credited to the relatively high limit of detection (20 nmol·L−1) of the
fluorimetric method compared with that of LC-MS/MS (0.6 nmol·L−1). In order to supply
a non-zero value, the urine sample was diluted less until a detectable signal was achieved,
and the base urine concentration was subsequently calculated. Nonetheless, the data
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suggests the fluorimetric method generally produces lower sarcosine concentrations than
the LC-MS/MS technique. This is expected because the LC-MS/MS technique utilized
provides only a partial, if any, separation of alanine and sarcosine whereas the fluorimetric
method, due to its enzymatic nature, displays a much higher specificity for sarcosine.

Table 1. Reported sarcosine concentrations in urine samples (n=10) by two methods: (1)
LC-MS/MS and (2) fluorimetric method, and their corresponding percent differences.
LC-MS/MS (mmol·L⁻¹)

Fluorimetric (mmol·L⁻¹)

Percent Difference

342.53

320.18±10.13

-6.53

278.50

251.22±6.54

-9.80

695.90

545.84±22.43

-21.56

195.92

201.15±4.33

2.67

1061.19

572.39±32.11

-46.06

136.68

195.45±4.99

43.00

268.33

248.28±12.15

-7.47

185.71

136.37±7.36

-26.57

333.45

315.78±4.23

-5.30

149.89

45.82±4.97

-69.43

Although a general decrease in sarcosine concentrations has been observed, the
decrease is not statistically significant (P-value = 0.23, paired t-test). This insignificance is
actually expected; LC-MS/MS is a very precise analytical tool, much more so than
fluorimetry. Despite its insignificance, the general decrease can reasonably be attributed to
the utilization of the enzyme. The fluorimetric assay consisted of two general types of
interferences: non-enzymatic oxidation of fluorescein, and inhibitors and substitutive
substrates of sarcosine oxidase. The former, including urine acidity and oxidative
components, was neglected due to the 750-fold dilution of the urine in 200 mmol·L⁻¹ TrisHCl buffer. These buffered urine solutions were observed to have an equivalent pH as the
sarcosine standards. Furthermore, it was found that the average pH of the unbuffered urine
samples varied only slightly to that of unbuffered sarcosine. Since the change in
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fluorescence, not the final fluorescence, was used to determine sarcosine, the very minor
deviations in buffered urine pH were negated. The employment of a strong buffer in very
dilute samples also increases the application of the assay to other biological fluids, because
the buffering capacities of said fluids can also be negated when compared with that of the
strong buffer. Although inhibitors to sarcosine oxidase (including many inorganics) are
likely present in urine to a small extent, sarcosine oxidase was provided in excess to the
estimated sarcosine to counter this fact. One key substitutive substrate was present,
however, d-Alanine. To assess the impact of its interference, d-alanine standard was
compared with d-alanine treated with sarcosine oxidase under similar conditions using LCMS/MS. An insignificant percentage (0.34%) of the d-alanine was found to be degraded
by sarcosine oxidase. This determination corroborates previously reported numbers. Thus
by eliminating possible interferences, it can reasonably concluded that the general decrease
observed by the fluorimetric method can be attributed to the use of sarcosine oxidase.

A comparison plot of the two methods is shown below (Figure 3). It is evident that
the rate of change reported by the fluorimetric assay is much more pronounced as sarcosine
concentrations lower, compared with that of the LC-MS/MS method, implying increased
relative sensitivity of the fluorimetric method to lower concentrations of sarcosine. This is
reasonable: prior to fluorescein exposure, the pH of the sample was significantly above the
pKa of the buffer (pKa=8.06). Thus, as the sample pH approached the pKa of the buffer by
production of formic acid, the buffering capacity was increased, explaining why lower
sarcosine concentrations experienced a greater respective change in fluorescence than
higher concentrations. This certainly presents a limitation to the fluorimetric assay
described herein, but also implies an enhanced sensitivity to sarcosine concentrations near
the lower limit of quantitation.
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Figure 3. Correlation between the fluorimetric and LC-MS/MS techniques used to analyze
sarcosine concentrations in 10 urine samples (R2 = 0.8466).

Furthermore, sarcosine levels, as well as any other metabolite, can vary greatly
among urine samples due to a large array of factors such as fluid intake, prevalent diseases,
diet, and more. Thus for clinical purposes, sarcosine alone cannot be used as a marker. As
such, a ratio of sarcosine levels to creatinine, analyzed with LC-MS/MS acting as a sort of
internal standard, was constructed. Although creatinine was not determined using the
fluorimetric method, there are a host of quantitative methods for creatinine, and
furthermore, creatinine may also be determined by the fluorimetric assay by converting it
to creatine with creatinine amidohydrolase, and subsequent conversion to sarcosine by
creatine amidinohydrolase. This ratio can be used for cancer comparisons, and although
diagnostic comparisons between cancer positive and cancer negative samples were outside
the scope of this current study, this data was readily available and further illustrates that
this simple fluorimetric method can be applied to diagnostic purposes (Figure 4).
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Figure 4. Comparison of sarcosine-to-creatinine ratio for LC-MS/MS and fluorimetric
methods.

3.4. Recovery
Spiked recovery tests were conducted utilizing three different sarcosine
concentrations. The sarcosine was added to the same urine sample prior to dilution in the
following doses: 20 mmol·L⁻¹, 100 mmol·L⁻¹, and 500 mmol·L⁻¹. Analyte recovery in the
low concentration was 86.45%, while recovery in the middle concentration was 106.32%,
and recovery in the high concentration was 102.45%.

4. CONCLUSION
This study aimed to present a novel fluorimetric technique for determination of
sarcosine in urine by enzymatic production of formic acid to produce a pH change
subsequently measured by fluorescence change of fluorescein. The utilization of the highly
specific sarcosine oxidase has eliminated interferences caused by the presence of alanine,
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at least to a further extent than the LC-MS/MS technique used alongside the fluorimetric
method. Although sarcosine has been successively separated in other LC-MS/MS
techniques, the concept of a fluorimetric method provides a much more economical
determination of sarcosine than these more advanced chromatographic techniques. The
methodology presented here can further be applied to a large array of analytes which can
act as substrates to enzymes, especially to oxidases. For example, d-amino acid oxidases
(DAO) act on a similar mechanism as sarcosine oxidase, producing a keto acid, and
ammonia and hydrogen peroxide as byproducts. In this case, the keto acid may be evaluated
directly very similarly to the one described here. Even though the sensitivity of this
technique is lower that the LC-MS/MS method, it provided a fast and low cost technique
for sarcosine analysis. The real novelty of the study is the coupling of the highly-specific
enzymatic approach with the economical fluorimetric analysis to provide an alternative
technique for sarcosine analysis in complex matrices, such as urine; thus, the basis of a
quick, accurate, and cheap clinical diagnostic tool has been established.
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ABSTRACT
Since sarcosine and D,L-alanine co-elute on reversed-phase HPLC columns and the
tandem mass spectrometer cannot differentiate them due to equivalent parent and fragment
ions, derivatization is often required for analysis of sarcosine in LC/MS systems. This study
offers an alternative to derivatization by employing partial elimination of sarcosine by
enzymatic oxidation. The decrease in apparent concentration from the traditionally merged
sarcosine-alanine peak associated with the enzymatic elimination has been shown to be
proportional to the total sarcosine present (R2=0.9999), allowing for determinations of
urinary sarcosine. Sarcosine oxidase was shown to eliminate only sarcosine in the presence
of D,L-alanine, and was consequently used as the selective enzyme. This newly developed
technique has a method detection limit (MDL) of 1 µg/L (ppb) with a linear range of 3 ppb
- 1 mg/L (ppm) in urine matrices. The method was further validated through spiked
recoveries of real urine samples, as well as the analysis of 35 real urine samples. The
averages recoveries for low, middle, and high sarcosine concentration spikes were 111.7%,
90.8%, and 90.1%, respectively. In conclusion, this simple enzymatic approach coupled
with HPLC/MS/MS is capable of resolving sarcosine from D,L-alanine without the need
for chemical derivatization or specialty chromatography columns.

KEY WORDS
Sarcosine, Sarcosine Oxidase, HPLC/MS/MS, Alanine, Enzymatic Elimination

29
1. INTRODUCTION
Metabolic diagnostics is a developing area in disease identification, deviating from
the traditional antigenic-based diagnostics [1]. As the intermediates, final products, and
byproducts of cellular processes, metabolites are highly representative of biochemical
changes within the body. Likewise, it has been shown that metabolites are highly involved
in carcinogenic processes through a number of modes, and consequently, they may be used
as diagnostic analytes [2]. However, a number of analytical techniques lack the specificity
required in the complex matrices, such as serum, blood, and urine, in which these
metabolites are naturally found, presenting significant analytical difficulties to the
elucidation of the diagnostic roles of the metabolites [3,4].

This was recently highlighted in 2009 by the metabolomic profiling of biopsypositive prostate cancer patients and biopsy-negative prostate control individuals that
suggested a correlation between urinary sarcosine levels and progression of the disease [5].
This claim was later refuted by two independent studies [6,7], which in the process placed
further stress on the requirement of specificity for the analytical techniques employed. In
particular, these sarcosine-based studies relied on a combination of liquid and gas
chromatography with mass spectrometry. These methods, however, have inherent issues in
the case of biological sarcosine. Gas chromatography is not well-suited for the separation
of matrices involving non-volatiles, lending separation to liquid chromatography. In
biological assays, L-alanine is co-present with sarcosine, and exists as an isomer of
sarcosine. In untreated samples using reversed-phased columns, sarcosine and D,L-alanine
co-elute, requiring further sample preparation for liquid chromatography such as chemical
derivitazation [8]. Indeed, derivatization-based separation of sarcosine and D,L-alanine has
been achieved by at least two independent studies [9,10], improving upon previous studies
on sarcosine as a marker for prostate cancer [11]. The isomerism of the two compounds
affects mass spectrometry as well, each possessing an identical precursor mass, 89.0932
Daltons. Furthermore, fragmentation in tandem mass spectrometry fails to resolve the two
isomers due to equivalent fragmentation. Thus, without specialized, chemical preparation
of the samples, sarcosine and D,L-alanine cannot be accurately determined by the methods
outlined above [12].
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One preparation technique, overlooked by these traditionally chemical-based
studies, involves the use of biological catalysts as analytical reagents. Indeed, substratespecific enzymes have been shown to be highly effective in analytical chemistry [13,14].
In the case of sarcosine, there already exists a fluorimetric assay for urinary sarcosine
employing enzymatic oxidation of sarcosine to detectable byproducts [15]. Despite its
success, this technique lacks the robustness of chromatographic - mass spectrometric
techniques while maintaining a complex reaction scheme. It does, however, effectively
demonstrate that enzymatic selection for sarcosine over D,L-alanine in urine samples can
be used for sarcosine analysis.

Since alanine and sarcosine co-elute on reversed-phase columns in high
performance liquid chromatography with tandem mass spectrometry (HPLC/MS/MS)
techniques, one large, merged peak that represents the total sum of urinary alanine and
sarcosine is observed. Hence, selective enzymatic degradation of one of the species, such
as enzymatic oxidation of sarcosine by sarcosine oxidase, will result in a marked decrease
from the original peak. If the percent sarcosine degraded is known, then it follows that the
resulting decrease in apparent concentration is proportional to the original amount of
sarcosine. In this way, analysis of sarcosine involves only partial enzymatic elimination of
the analyte, not indirect determination from byproducts and subsequent reactions. This idea
is examined herein by the determination of sarcosine in urine as well as further comparison
with the fluorimetric method [15] (as shown in Scheme 1).

Scheme 1. Proposed reaction scheme for the determination of sarcosine.
𝑆𝑎𝑟𝑐𝑜𝑠𝑖𝑛𝑒 𝑂𝑥𝑖𝑑𝑎𝑠𝑒, 37℃

Sarcosine + Alanine →

Sarcosine byproducts + Alanine

Thus, an alternative, enzymatic approach combined with HPLC/MS/MS, has been
proposed for urinary analysis of sarcosine without using either derivatization.
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2. MATERIALS AND METHODS
2.1. Chemicals
Sarcosine oxidase from Corynebacterium sp. (lyophilized powder, 5-10 units/mg)
was purchased from Sigma-Aldrich (Saint Louis, MO, USA). Glycylglycine used as an
enzymatic buffer, sodium hydroxide as a pH modifier, as well as three standards, including
sarcosine, D,L-alanine, and creatinine were also purchased from Sigma-Aldrich (Saint
Louis, MO, USA). Additionally, acetonitrile (LC/MS grade) and formic acid (99.9%) used
in the preparation of the mobile phase was purchased from Sigma-Aldrich (Saint Louis,
MO, USA). Ultra-pure water was generated using a Milli-Q Advantage® A10 water
purification system (Millipore, Billerica, MA, USA). Synthetic urine was purchased from
LoSo-UriSub™, CST TECHNOLOGIES, Inc., (Great Neck, NY, USA). L-glutamine
isotope (C5H1015N2O3) was obtained from Cambridge Isotope Laboratories (Andover, MA,
USA)

2.2. Preparation of Glycylglycine Buffer and Sarcosine Oxidase
A 0.2 M glycylglycine solution was prepared from ultra-pure water and
glycylglycine, and the pH was adjusted to 7.4 with 1 mol·L⁻¹ sodium hydroxide. A buffered
sarcosine oxidase stock solution was prepared from these reagents from which standard
reagents of 1.77×10-7 units/mL were prepared fresh and kept at 4 oC until use. This
concentration of sarcosine oxidase was found to have the highest specific activity with its
sarcosine substrate in the range of 1 ppb to 1 ppm (data not shown).

2.3. Preparation of Sarcosine Stock Solution
Stock solutions of sarcosine were prepared from ultra-pure water and sarcosine
standard. The stock solutions were prepared at 10, 100, and 1000 ppb for no more than two
weeks at 4 oC.

2.4. Analysis of Sarcosine Standards
Sarcosine and creatinine were added in equivalent concentrations ranging from 1
ppb to 1000 ppb as well as 50ppb D,L-alanine and 50ppb L-glutamine to a final volume to
500μL of ultra-pure water. Upon thorough mixing, the vial contents were subjected to

32
HPLC/MS/MS analysis to determine pre-enzymatic concentrations. After pre-analysis, the
same sample was then heated to 37 oC, and 500 µL of cold enzyme reagent was added. The
direct addition of the enzyme resulted in a 2-fold dilution. The vial was then incubated at
37 oC for 30 minutes. The sample was quickly cooled down to room temperature, and
injected into HPLC/MS/MS for post-enzymatic sarcosine concentration. Samples were not
run in parallel (pre- and post-enzymatic) because even minute differences in sample
sarcosine concentrations significantly affected enzymatic activity toward the lower limit of
the linear range.

2.5. Analysis of Urine Samples
Urine samples (n=35) were provided by the Central Missouri Urology Clinic. The
samples were comprised of 15 normal samples and 20 prostate cancer positive samples.
The urine samples were centrifuged to remove the particulates. The supernatant was diluted
250-fold with ultra-pure water whereupon 250 µL of these diluted urine samples were
transferred into a sample vial with 250 µL ultra-pure water. This resulted in a final 500fold dilution of the urine samples. Pre- and post-enzymatic analyses as well as enzymatic
reaction followed similar protocol as that of the sarcosine standards.

2.6. HPLC/MS/MS Analysis
A Luna phenyl-hexyl column (3.0 μm, 3.0×150 mm, Phenomenex, USA) and a
Shimadzu UFLC system (Columbia, MD) comprised of a degasser (DGU-30A3), two
pumps (LC-20 AD XR), an autosampler (SIL-20AC XR) and a column oven (CTO-20A)
were used for the separation of sarcosine. HPLC was performed at 25°C under a flow rate
of 250 μL/min using a gradient system with the mobile phase consisting of A: 0.2% formic
acid in water and B: 0.2% formic acid in acetonitrile (100%). The gradient program was:
initial 98% A and 2% B; linear gradient to 60% A and 40% B in 5 min; return to initial
conditions in 0.1 min at a flow rate of 250 μl/min, followed by equilibration for 10 min.
Run-to-run time was 15 min. The sample injection volume was 10 μL. An API 4000Q trap
MS/MS system (Applied Biosystems, Foster City, CA) was used for the quantification of
sarcosine in urine samples. Sarcosine and alanine were detected in multiple-reaction
monitoring (MRM) mode (m/z 89.9/44) with ESI-positive ionization along with L-
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glutamine serving as an internal standard (m/z 148/130). Creatinine was also quantified in
MRM positive mode (m/z 114/44.1) to account for the renal dilution [16]. Creatinine has
been used in many clinical studies as an internal standard since its concentration strictly
corresponds to urine dilution [8,16,17]. All species were determined simultaneously.

3. RESULTS AND DISCUSSION
3.1. Interference of Alanine
To assess the impact of its interference, an untreated D,L-alanine standard was
compared with D,L-alanine treated with sarcosine oxidase under identical experimental
conditions using the HPLC/MS/MS outlined above. An insignificant percentage (0.28% ±
0.12% for n=3 trials) of the D,L-alanine was found to be degraded by sarcosine oxidase.
Such consistently low degradation suggests that sarcosine oxidase fails to act appreciably
on D,L-alanine. Indeed, these results corroborate that reported in the fluorescence study
[15]. It is therefore suggested that the sarcosine oxidase acts selectively toward sarcosine
in the presence of D,L-alanine. Since D,L-alanine is being treated quantitatively as
sarcosine, the proportionality of the molar signals was assessed through the ion affinities
of the two species to identify possible correction factors. It was found that alanine
possessed an equivalent ion affinity to sarcosine (n=5 for 5 ppb, 50 ppb, and 500 ppb)
(Figure 1). This implies that no additional proportionality calculations are necessary since
the mass spectrometer resolved both compounds identically.

3.2. Enzymatic Degradation of Sarcosine
Sarcosine standard solutions were incubated with sarcosine oxidase in order to
partially eliminate it from the merged sarcosine-alanine peak. In order to accurately
quantify sarcosine, the determination of the amount of sarcosine degraded is necessary.
This was determined by treatment of standard sarcosine samples with sarcosine oxidase
under similar conditions. The enzymatic degradation of the sarcosine standards
demonstrated typical enzyme kinetics as shown by the sigmoidal curve in Figure 2.
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Figure 1. Extracted ion chromatogram (XIC) of the standard sarcosine and D,L-alanine
under optimized conditions by HPLC/MS/MS.

Partial, constant degradation was observed between 50 ppb and 500 ppb Indeed,
the curve flattens as the enzyme becomes saturated, implying degradation occurs as a
function of available substrate. As an enzymatic assay, a time dependence exists, in
addition to the concentration dependence; however, after the designated reaction time
where the majority of the sarcosine has been degraded, slight variations in reaction times
afford only negligible degradation differences. Indeed, this degradation curve, which
showed decent reproducibility among repeated trials (N =3), was constructed with each
data set to improve the analytical quality of the assay. Most importantly, these results reveal
the relationship between the original amount of sarcosine and the absolute amount of
sarcosine degraded shown as the following:
[𝑆𝑎𝑟𝑐𝑜𝑠𝑖𝑛𝑒 𝐷𝑒𝑔𝑟𝑎𝑑𝑒𝑑] = [𝑂𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑆𝑎𝑟𝑐𝑜𝑠𝑖𝑛𝑒]𝑥(𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝐷𝑒𝑔𝑟𝑎𝑑𝑒𝑑)

(1)
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Figure 2. Percent degradation of sarcosine standard solutions from 5 ppb to 500 ppb with
8.85×10-8 units of sarcosine oxidase.

3.3. Linearity, Detection limits, and Reproducibility
Sarcosine was determined from known and unknown samples by first constructing
an initial, pre-enzymatic calibration curve from sarcosine standards and the resultant peak
areas. Since enzyme was added directly to the pre-enzymatic samples, all initial
concentrations were consequently halved. Post-enzymatic peak areas were used in the preenzymatic calibration curve and subsequently doubled to yield dilution-corrected postenzymatic concentrations. The difference between the pre-enzymatic and post-enzymatic
concentrations, representing the absolute amount of sarcosine degraded, was then
determined. The percent degradation corresponding to the absolute amount of sarcosine
degraded was found from the enzymatic degradation data. Normalization of the observed
decrease in sarcosine concentration by the percent degraded, as given by the equation
above (Equation 1), then afforded the original sarcosine concentration. Thus, the
analytical determination may be expressed by the following equation (Equation 2):

[𝑂𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑆𝑎𝑟𝑐𝑜𝑠𝑖𝑛𝑒] =

[𝑆𝑎𝑟𝑐𝑜𝑠𝑖𝑛𝑒]𝑃𝑟𝑒−𝑒𝑛𝑧𝑦𝑚𝑎𝑡𝑖𝑐 −2[𝑆𝑎𝑟𝑐𝑜𝑠𝑖𝑛𝑒]𝑃𝑜𝑠𝑡−𝑒𝑛𝑧𝑦𝑚𝑎𝑡𝑖𝑐
%𝑆𝑎𝑟𝑐𝑜𝑠𝑖𝑛𝑒 𝐷𝑒𝑔𝑟𝑎𝑑𝑒𝑑

(2)
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A stable calibration curve was obtained from a series of sarcosine standards ranging
from 1 ppb to 500 ppb spiked with 50ppb D,L-alanine. A highly linear relationship was
observed over this range with a correlation coefficient of 0.9999. The method limit of
detection was determined to be 1ppb at a signal-to-noise (S/N) ratio of 3. Reproducibility
was measured (n=3), yielding a relative standard deviation (RSD) of 1.8% for these
sarcosine standards. Based on this data, it is suggested that this technique is applicable over
the given concentration range under the given chemical environment.

By considering the matrix effects of real samples, synthetic urine was used to
replace the buffer solution in the preparation of the sarcosine standards. The pH was
adjusted to physiological conditions (pH = 7.4) with 1.0 M NaOH. The synthetic urine was
also diluted by a factor of 500 to mimic real urine sample analysis. This high dilution factor
served to minimize matrix effects such as pH differences among real urine samples.

15

N

isotope-labeled glutamine was added to vials at a concentration of 50 ppb as an internal
standard. The calibration curve was reconstructed with samples ranging from 1 ppb to 1
ppm (R2=0.9996). The limits of quantitation and detection were found to be 3 ppb and 1
ppb, respectively, in this new matrix. These limits correspond closely with those generated
by the fluorimetric study (compare with limit of detection of 2 ppb). Despite its comparable
limit of detection, the fluorimetric assay is limited by its sole analysis of sarcosine; the
HPLC/MS/MS technique presented herein may be applied to the simultaneous analysis of
numerous chemical species, such as creatinine and glutamine.

3.4. Recovery
Real urine matrices (n=3) were spiked with known concentrations of sarcosine
standards, all of which fell within the linear range of the technique. The spiked
concentrations were low (5 ppb), middle (50 ppb), and high (500 ppb). The averages of the
recoveries for each level were determined to be 111.7% ± 3.7% (RSD 3.3%), 90.8% ±
1.1% (RSD 1.2%), and 90.1% ± 1.6% (RSD 1.8%), respectively, for the low, middle, and
high injections. In the case of the low concentrations, a positive interference exists, which
may be linked to marginal degradation of D,L-alanine by sarcosine oxidase and other
chemical species or to positive modulation of sarcosine oxidase. Nevertheless, this level of
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precision is sufficient for biological matrices like that of urine, and is primarily attributed
to the high dilution (500 fold) of the samples. It is noted, however, that with the high
dilution comes a loss in accuracy. Nevertheless, as shown by the recovery data, this
uncertainty is reasonable, and the technique is considered analytically valid.

3.5. Real Urine Analysis
Real urine samples taken from healthy subjects (n=15) and prostate cancer-positive
patients (n=20) were analyzed by the enzymatic technique. Samples were diluted 500 times
with ultra-pure water in order to fall within the linear range as well as to minimize matrix
effects including pH differences. These sample sets were run in triplicate to provide
sufficient statistical validation. Standard solutions containing 50 ppb sarcosine, 50 ppb 15N
isotope-labeled glutamine, and 50 ppb D,L-alanine standard samples were evenly dispersed
throughout the sample as a quality control measure. The calibrated sarcosine
concentrations were corrected for dilution to provide the final urinary sarcosine
concentration.

The experimental results suggest that the enzymatic approach (average urinary
sarcosine concentration = 13.67 ppm) has a superior separation compared with the
incomplete separation achieved by the optimized HPLC/MS/MS method alone (average
urinary sarcosine concentration = 35.69 ppm). Indeed, the optimized HPLC/MS/MS
method without enzymatic treatment failed to separate sarcosine and alanine due to their
similar retention times in reversed-phase columns as expected. Assuming then, that the
non-enzymatic method represented 100% of the sarcosine-alanine mixture, it can be
deduced by the comparison of the two methods that average urinary sarcosine comprises
approximately 40% of the sarcosine-alanine mixture. This concept may be extrapolated to
concurrently estimate the amount of urinary D,L-alanine. This idea has not been
extensively addressed in this study, however,

With sufficient separation, then, accurate comparisons between normal and prostate
cancer-positive urine samples can be made using liquid chromatography with tandem mass
spectrometry for sarcosine as a potential marker using this technique. Since analyte
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concentrations can vary greatly among samples due to number of reasons, including dietary
intake, genetic disposition, fluid intake and retention, among other factors, sarcosine
concentrations were normalized to creatinine concentrations analyzed by HPLC/MS/MS
[16, 17]. Indeed, creatinine is often used as a urinary normalization factor due to its high
concentrations in urine samples. In this way, it is representative of the overall solute
concentration of urine. Creatinine was analyzed simultaneously with sarcosine and its
internal standard, 15N isotope-labeled glutamine.

This study reports a negligible difference (p = 0.115, two-tailed t-test) of urinary
sarcosine concentrations between normal and prostate cancer-positive urine samples
(Figure 3). Despite this, the validation of sarcosine as a prostate cancer biomarker was not
the intent of this study. Indeed, a more detailed clinical study with more control over the
cancer patients and healthy subjects would be required to afford more conclusive findings.
Nevertheless, this method provides an accurate analytical platform for the analysis of
sarcosine in urine and other biological samples as an alternative to HPLC/MS/MS analysis
utilizing derivatization. Moreover, the sarcosine-alanine isomers are but one of many
metabolic isomers that have presented difficulties to HPLC/MS/MS techniques. Others
include amino acid isomers, such as leucine and isoleucine, as well as isomeric fatty acids
and oligopeptides, all of which possess selective enzymes. With non-invasive diagnostic
techniques increasingly being developed, demand for high-throughput analyses that can
discern among interferences is critical. In this way, the study more broadly demonstrates
the novel application of selective enzymes to isomeric interferences using high-throughput
HPLC/MS/MS techniques for quantitative bioanalysis.
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Figure 3. Comparison of urinary sarcosine concentrations adjusted to urinary creatinine
concentrations in healthy individuals (n=15) and prostate cancer patients (n=20).

4. CONCLUSIONS
As an alternative solution to derivatization for the separation of sarcosine and D,Lalanine under HPLC/MS/MS analysis, a simple, enzymatic method has been developed
and validated in this study. The premise of the technique rests on the fact that selective
enzymatic elimination from an isomeric pair that traditionally generates a merged peak on
reversed-phase HPLC/MS/MS will result in a marked decrease in apparent concentration
proportional to the original amount of the eliminated species. Sarcosine oxidase was used
as the selective enzyme in this study, and was shown to be selective for sarcosine in the
presence of D,L-alanine. The difference in calibrated sarcosine concentrations, before and
after enzymatic treatment, when normalized to the percent degraded, yielded the original
concentration of sarcosine (R2=0.9999) within the linear range of 1 ppb – 1ppm. The
method is simple, sensitive (MDL is 1 ppb), and shows a good reproducibility (RSD =
1.8% for sarcosine standards in synthetic urine). It is comparable with current fluorimetric
studies, but offers a more robust solution as a potential screening technique through the
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simultaneous analysis of other analytes. In short, this study presents the coupling of highthroughput HPLC/MS/MS with the selectivity of enzymes to form an analytical platform
for the broad analysis of biological samples including metabolic isomers.
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ABSTRACT
Recent preliminary studies have implicated urinary pteridines as candidate
biomarkers in a growing number of malignancies including breast cancer. While the
development of capillary electrophoresis – laser induced fluorescence (CE-LIF), high
performance liquid chromatography (HPLC), and liquid chromatography – mass
spectroscopy (LC-MS) pteridine urinalyses among others have helped to enable these
findings, limitations including poor pteridine specificity, asynchronous or non-existent
renal dilution normalization, and a lack of information regarding adduct formation in mass
spectrometry techniques utilizing electrospray ionization (ESI) have prevented application
of these techniques to a larger clinical setting. In this study, a simple, rapid, specific, and
sensitive high-performance liquid chromatography – tandem mass spectrometry (HPLCMS/MS) method has been developed and optimized for simultaneous detection of six
pteridines previously implicated in breast cancer and creatinine as a renal dilution factor in
urine. In addition, this study reports cationic adduct formation of urinary pteridines under
ESI-positive ionization for the first time. This newly developed technique separates and
detects the following six urinary pteridines: 6-biopterin, 6-hydroxymethylpterin, dneopterin, pterin, isoxanthopterin, and xanthopterin, and as well as creatinine. The method
detection limits for the pteridines are between 0.025 and 0.5 µg/L and 0.15 µg/L for
creatinine. The method was also validated by spiked recoveries (81-105%), reproducibility
(RSD: 1-6%), and application to 25 real urine samples from benign and malignant breast
cancer samples through a double-blind study. The proposed technique was finally
compared directly with a previously reported CE-LIF technique, concluding that additional
or alternative renal dilution factors are needed for proper investigation of urinary pteridines
as breast cancer biomarkers.

KEY WORDS
HPLC-MS/MS, urinalysis, pteridines, breast cancer biomarkers

45
1. INTRODUCTION

Improvements in early cancer detection techniques for breast cancer, including
clinical breast examination (CBE), mammography, ultrasonography (US), and magnetic
resonance imaging (MRI), have contributed to an approximately 25% increase in incidence
detection rates in the United States since the 1970s.1 Despite the increased awareness,
confident diagnosis is non-ideal, instead relying on a combination of the above techniques.
For example, routine CBEs, which are considerably more cost-effective than
mammography as preliminary assessments of malignancy, are characteristically poor
indicators of malignancy, with positive predictive values and diagnostic sensitivities
reported at 1-10% and 25-60%, respectively.2-6 Hence, the practical value of CBEs is often
questioned since CBEs fail to improve mortality rates as many cases go undetected until
later stages and high false positive rates lead to additional anxiety, cost, and the possible
need for invasive techniques.

Mammography as a preliminary assessment for malignancy offers significantly
improved diagnostic sensitivity over CBE with reported sensitivities ranging from 63% to
98%.7-9 Such values can be deceptive, however, since mammographic sensitivity decreases
to 30-48% in cases of dense and heterogeneously dense breasts, which have been shown to
have up to a fivefold increased risk of cancer compared with fatty breasts.10-12 Generally
large interradiologist variability further obscures accurate cancer detection rates in imaging
techniques like mammography.13 While US and MRI have been found to be more sensitive
than mammography alone in cases of invasive cancer, only the combination of CBE,
mammography, and confirmational MRI has been reported to have nearly 100% diagnostic
sensitivity.12 Thus, while confident breast cancer detection can be achieved with available
techniques, the development of a simple and rapid biomarker-based analytical technique
with comparable diagnostic sensitivity would be vastly superior to the relatively complex
and uneconomical combination of analyses currently used. One possible biomarker-based
solution to this involves urinary pteridines.
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Urinary pteridines are an emerging class of metabolites that may be monitored noninvasively and are increasingly being preliminarily implicated in a number of
malignancies, including breast cancer.14 Pteridines as biomarkers are not without
challenges, however. Despite the diversity of the pteridine family, with such wide
implications, the possibility of urinary pteridines serving as ambiguous indicators of
malignancy must be considered. Thus, adequately large panels need to be examined with
special attention placed on ratios of the individual pteridines toward specific malignancies.
Pteridine urinalysis in particular has overcome significant analytical challenges over the
past decade enabling the recent flurry of studies investigating pteridines as potential and
novel biomarkers.15-21 Examples of typical pteridine urinalysis difficulties include:
thermally and photocatalytically labile compounds, poor solubilities in common solvents,
the presence of three oxidation species, and relatively low urinary clearance. Nevertheless,
capillary electrophoresis – laser induced fluorescence (CE-LIF) has emerged as a capable
analytical platform to quantify urinary pteridines.15,

17, 19

Indeed, the minimal sample

preparation required by CE-LIF urinalysis and its high cost-effectiveness compared with
more advanced chromatographic techniques are certainly appealing advantages. However,
current CE-LIF techniques are limited by two fundamental problems: (1) the inability to
simultaneously quantify non-fluorescent creatinine as a renal dilution factor, and (2) the
platform is inherently non-specific and consequently subject to relatively high interference
levels from the complicated matrices in real urine samples.
High-performance liquid chromatography – tandem mass spectrometry (HPLCMS/MS) presents an alternative to CE-LIF that can sufficiently address these two
problems. Indeed, the high-throughput nature of HPLC-MS/MS is better suited for the
identification and validation of urinary pteridines as indicators of malignancy while CELIF may represent the most sensible and economic choice only after such potential
confirmations. These considerations are not novel, either, as a couple of HPLC and LCMS/MS techniques for selected pteridines have recently been developed.18, 22 Nevertheless,
these studies have thus far been limited in scope by either considering a narrow panel of
urinary pteridines, failing to examine possible adduct formation in ESI-MS/MS techniques,
or incorporating either impractical asynchronous or no corrections for renal dilution. By
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considering these limitations, in this study, an optimized HPLC-MS/MS has been
developed to separate and quantify six pteridines and creatinine (Figure 1) simultaneously
in urine samples as an alternative technique to a CE-LIF technique previously used to
implicate urinary pteridines in breast cancer.15 Since this previous CE-LIF technique
reported positive correlations between urinary pteridines in positive and negative breast
cancer samples, rather than corroborate these findings, this study further examined the
ability of the urinary pteridines to discern benign from malignant breast cancer urine
samples.

Figure 1. Chemical structures of eight urinary pteridines (fully oxidized) and creatinine:
(a) pterin, (b) 6-hydroxymethylpterin, (c) pterin-6-carboxylic acid, (d) d-neopterin, (e) 6biopterin, (f) 6,7-dimethylpterin, (g) xanthopterin, (h) isoxanthopterin, (i) creatinine.
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2. EXPERIMENTAL
2.1. Chemicals and Materials
Isoxanthopterin, pterin, D-neopterin, xanthopterin, 6-biopterin, pterin-6-carboxylic
acid, ammonium oxalate, ammonium hydroxide, and sodium hydroxide were purchased
from Sigma-Aldrich (St.Louis, USA). 6,7-Dimethylpterin and 6-hydroxymethylpterin
were obtained from Schircks Laboratory (Jona, Switzerland). Potassium iodide and iodine
were purchased from Fisher Scientific (New Jersey, USA). Synthetic urine was obtained
from CST Technologies Inc. (New York, USA). Ultrapure water was generated by a MilliQ Advantage® A10 and Millipore Elix® water purification system.

2.2. Instrumentation
A Luna phenyl-hexyl column (3.0 μm, 3.0×150 mm, Phenomenex, USA) and a
Shimadzu UFLC system (Columbia, MD) comprised of a degasser (DGU-30A3), two
pumps (LC-20 AD XR), an autosampler (SIL-20AC XR) and a column oven (CTO-20A)
were used for the separation of the urinary pteridines. HPLC was performed at 25°C under
a flow rate of 0.3 mL/min using a gradient system with the mobile phase consisting of A:
0.1% formic acid in water and B: 0.2% formic acid in acetonitrile. The gradient program
was characterized by an initial 2 minute pre-equilibrium of 20% A followed by a linear
increase to 37% A in 5.5 minutes. Run-to-run time was 7.5 minutes with a sample injection
volume of 10 μL.

An API 4000Q trap MS/MS system (Applied Biosystems, Foster City, CA) was
used for the quantification of urinary pteridines. All ions were monitored in scheduled
multiple-reaction monitoring (MRM) mode with ESI-positive ionization. Optimized flow
injection parameters include: ion spray voltage: 5500V; curtain gas: 14 psi; collision gas:
6 psi; GS1: 35 psi; GS2: 35 psi; and source temperature: 425°C.

2.3. Standard Preparation
Approximately 2 mg of each pteridine and creatinine was accurately weighed and
dissolved in 15 mL of ultrapure water and 500 µL of 1 M ammonium hydroxide. Upon
complete dissolution by sonication and vortexing, all components were added together with
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enough ultrapure water and 500 µL of oxidizing solution (4:2% w/v potassium iodide to
iodine in ultra-pure water) to generate a stock solution of 10 mg/L of each component.
Calibration standards were prepared from the stock solution by serial dilution in ultra-pure
water and enough synthetic urine to generate a 0.5% solution of synthetic urine to mimic a
200-fold dilution in real sample analysis.

2.4. Urine Samples and Preparation
Real urine samples (N=25) were provided by Mercy Hospital (Springfield, MO) by
consenting women (age range: 25-80) referred to the Mercy Hospital Breast Cancer
Treatment Center as a double-blind study. Pathologies (benign or malignant) were
independently determined by Mercy Hospital through a combination of CBE,
mammography, US, MRI, and biopsy methods.

Real urine samples were stored in a freezer at a temperature of -80°C. Upon fully
thawing the samples to room temperature, a 100 µl aliquot of urine sample was placed in
a yellow centrifuge tube containing 850 µL ultrapure water, 40 µl of oxidizing solution,
and 10 µl of 2.0 M ammonium hydroxide. The sample was then thoroughly mixed and was
incubated for 30 minutes at 4°C followed by centrifugation at 5000 rpm (2571 g) for 20
min at 4°C. Upon centrifugation and filtration with a 0.22 µm membrane, a 10-fold dilution
was made by adding 100 µL of the filtrate to 870 µL of ultra-pure water and 30 µL of 440
mg/L ammonium oxalate, giving a final dilution factor of 100.

3. RESULTS AND DISCUSSION
3.1. Oxidation Pre-treatment
Most pteridine urinalyses reported thus far have incorporated an oxidation pretreatment step with the rationale being that the fully oxidized species are substantially more
stable than the reduced dihydro- and tetrahydro-pterin species and that the fully oxidized
species also affords the strongest fluorescence response in CE-LIF techniques.17, 23 While
a variety of oxidizing agents have been investigated, including tri-iodide ions via potassium
iodide-iodine solutions, permanganate, and manganese oxide, potassium iodide-iodine was
chosen in order to represent an easier adaptation of the model CE-LIF technique. Since
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previous studies had concluded that a 1:2 proportion of 4%:2% (w/v) potassium iodideiodine solution to urine was sufficient to fully oxidize all pteridines, this study maintained
these oxidation conditions. To further consider adverse reactions with the tri-iodide ions,
untreated and treated pteridine standards (which were shown to be 95-99% oxidized as
labeled) were examined via direct infusion. The presence of tri-iodide ions did not
significantly alter pteridine response under these oxidation conditions.

3.2. MS/MS Optimization
ESI-positive ionization with 0.1% formic acid yielded the highest ionization
efficiencies for all oxidized pteridines and creatinine. Formic acid content above 0.2%
suppressed pteridine ionization for xanthopterin, isoxanthopterin, 6-biopterin, and pterin6-carboxlyic acid. The adduct formation potentials of the oxidized pteridines and creatinine
were then examined under various conditions via direct infusion into the MS/MS unit at a
concentration of 100 µg/L prepared in 0.1% formic acid in ultra-pure water. Q1 ions were
monitored under Multiple Channel Analyzer (MCA) mode with a flow rate of 0.2 mL/hour.
The scan range was set from 5 m/z below the expected molecular ion to 200 m/z above to
monitor singly charged ions as no doubly charged ions were preliminarily observed.
Dissolution with sodium hydroxide afforded significant sodium, [M+Na]+, and in some
cases disodium, [M-H+2Na]+, and tri-sodium, [M-2H+3Na]+, adducts in 6,7dimethylpterin, d-neopterin, 6-hydroxymethylpterin, pterin, and pterin-6-carboxylic acid.
Sodium adducts in these standards comprised over 60% of the total signal, and in the case
of fully unsubstituted pterin, 83% of the total signal, thereby affecting pteridine detection
sensitivities by splitting the signal among various adducts. In contrast, dissolution with
ammonium hydroxide favored the protonated adduct, [M-H]+, in all pteridines but
xanthopterin and pterin-6-carboxylic acid with resulting ammonium adducts, [M+NH3]+
and [M-H+2NH4]+, representing only 32% of total xanthopterin signal and 31% of the total
pterin-6-carboxylic acid signal, respectively. The Q1 scans for pterin dissolved in sodium
hydroxide and ammonium hydroxide were shown in Figure 2 to demonstrate the formation
of sodium adduct ions of pteridines. In addition, a significant creatinine dimer (48% of
total signal) was found at 227 m/z. Because real urine has significant sodium and
ammonium cation populations, all adducts with relative abundances of over 30% for each
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respective compound were considered as quantitative precursor ions. MS/MS ions pairs
were then systematically optimized with direct infusion and flow injection analysis for all
quantification and confirmation pairs including all major adducts (sodium and ammonia)
for the eight fully oxidized pteridines and creatinine. The optimized MS/MS parameters
were summarized in Table 1.

Figure 2. Q1 scans of 100 µg/L pterin in 0.1% formic acid in ultra-pure water dissolved
with (a) sodium hydroxide and (b) ammonium hydroxide.
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Table 1. Optimized MS/MS conditions of 8 urinary pteridines, creatinine, and their
common adducts.
Compounds

Declustering
Potential
(DP, V)

Collision Energy
(CE, V)

114.034/44.000

56

33

6

114.034/86.000

56

19

14

Creatinine Dimer

227.503/113.900

1

21

4

6,7-Dimethylpterin

192.534/165.300

96

31

10

192.534/147.000

96

31

12

213.999/196.200

101

19

12

213.999/86.300

101

27

14

238.423/220.300

31

21

14

238.423/178.200

31

29

10

254.156/206.200

51

27

12

254.156/190.200

51

31

12

276.088/216.200

81

27

14

276.088/234.100

81

27

24

194.293/176.300

31

23

14

194.293/106.100

31

39

10

216.210/204.000

86

25

12

216.210/199.100

86

15

26

164.431/119.000

76

31

8

164.431/91.900

76

41

4

185.891/114.100

71

35

8

185.891/86.200

71

45

16

180.113/135.400

76

33

10

180.113/163.100

76

27

10

180.113/135.400

76

33

10

180.113/163.100

76

27

10

196.115/168.500

91

23

10

196.115/112.200

91

35

6

213.754/141.200

66

21

8

213.754/141.200

66

31

6

208.110/190.100

66

19

12

208.110/180.300

66

23

10

229.787/186.300

61

25

18

229.787/212.200

61

17

14

225.084/208.100

36

17

14

225.084/190.100

36

23

12

Creatinine

6,7-Dimethylpterin+Na
6-Biopterin
D-Neopterin
D-Neopterin-Na
6-Hydroxymethylpterin
6-Hydroxymethylpterin+Na

Pterin
Pterin-Na
Isoxanthopterin
Xanthopterin
Xanthopterin+NH3
Xanthopterin—H+2NH4
Pterin-6-carboxylic acid
Pterin-6-carboxylic acid+Na
Pterin-6-carboxylic acid+NH3

Ion Pairs
(m/z)

Collision Cell
Potential
(CXP, V)
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3.3. Adduct Reduction
Although adduct speciation was analytically considered by ultimately summing the
calibrated concentrations, sodium scavenging additives were considered as an additional
safe-measure in real urine samples where high sodium and relatively low pteridine levels
may obfuscate pteridine detection through adduct formation. Indeed, this concern was
substantiated by monitoring adduct formation in 100 µg/L fully oxidized pteridine
standards dissolved with ammonium hydroxide and prepared in 0.5% synthetic urine
(representing a 200-fold dilution of real urine), which afforded sodium adduct formation
comparable to pteridine dissolution with sodium hydroxide. Thus, in real urine samples,
active measures to minimize sodium adduct formation must be taken for ideal pteridine
detection.

While desalting and trap columns may be used to remove free sodium cations, these
techniques are indiscriminate and alter the oxidative environment by also removing the triiodide ions, thereby possibly and more detrimentally affecting pteridine detection.
Therefore, in this study, in situ sodium scavenging additives including ascorbic acid, oxalic
acid, and ammonium oxalate were examined based on their previously reported cationic
adduct reduction in MALDI techniques.24 The sodium adduct reduction capabilities of the
three compounds were evaluated by direct infusion of 100 µg/L fully oxidized pteridine
standards prepared in 0.5% synthetic urine and spiked with 10 mg/L additive under MCA
scan mode and a 200 m/z scanning window. In comparison to the control that contained no
additives, combined sodium and ammonia adducts for all eight pteridines were decreased
53% by ammonium oxalate, 37% by ascorbic acid, and oxalic acid instead promoted
ammonia adduct formation without significantly affecting sodium adduct formation to
yield an overall 10% increase in total adduct formation. In addition to cationic adduct
reduction, the mild reducing agents, ascorbic acid and oxalic acid, also afforded minor
reduction (3-12%) of the quantitation ions for xanthopterin, isoxanthopterin, and 6biopterin. More importantly, the sodium scavenging capabilities of ammonium oxalate
seem to be accentuated in real urine samples, up to 99.4% in some samples. Indeed, the
MRM transitions for sodium and ammonia adducts in some real samples were entirely
undetected. While this phenomenon was not thoroughly investigated, the authors presume
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this is caused by the association of free sodium and ammonia with excess organic matter
and the highly charged, filtered and precipitated proteins. Excess ammonium oxalate was
therefore added during the final dilution of real urine samples to counteract adverse cationic
adduct formation. The final concentration of ammonium oxalate used (13 mg/L ≈ 0.1 mM)
was found to afford the maximum adduct reduction with minimal pteridine ion suppression
in 0.5% synthetic urine.

3.4. UFLC Optimization
The

structural

isomers,

xanthopterin

and

isoxanthopterin,

must

be

chromatographically resolved for quantitation with MS/MS. A Phenomenex Luna phenylhexyl column was found to sufficiently separate the two isomers under a wide range of
liquid chromatographic conditions including flow rate (0.15-0.40 mL/min) and mobile
phase constitution. (0.0-0.2% formic acid in water, acetonitrile, and methanol). In
comparison, the previously utilized LUNA amine column provided inferior resolution
under the conditions described above.22 Upon column selection, chromatographic
conditions were systematically optimized for all eight pteridines and creatinine (see
Experimental for optimized conditions). The resulting chromatogram, including separation
of xanthopterin and isoxanthopterin, was shown in Figure 3.

Figure 3. Overlaid extracted ion chromatograms (XIC) of eight urinary pteridines,
creatinine, primary adducts, and confirmation pairs with nominal concentrations of 100
µg/L under the optimized UFLC-MS/MS conditions.
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3.5. Method Performance
Under the optimized HPLC-MS/MS conditions, calibration curves for all pteridines
and creatinine were constructed to demonstrate linearity under an appropriate analytical
range. Because some pteridines exhibit significant adduct formation in 0.5% synthetic
urine, even after treatment with ammonium oxalate, and fragmentation efficiencies were
furthermore widely distributed among the various adducts, calibration curves were
produced from standards by monitoring MRM transitions alongside an accompanying Q1
scan. The Q1 scan allowed for absolute concentration determination by considering the
signal proportionality among the various adducts for each respective pteridine. For
example, a nominal 100 µg/L pteridine standard with a 20% monosodium adduct formation
potential represented 80 µg/L [M+H]+ and 20 µg/L [M+Na]+, from which appropriate
calibration curves may be produced. The desired calibration range was set to 1-1000 µg/L
based on previous studies indicating that the monitored pteridines should fall within this
range after a 200-fold dilution.15, 17 As shown in Table 2, all compounds were highly linear
with linear regression coefficients above 0.9998 under the selected analytical range.
Moreover, the method was found to be highly sensitive with detection limits ranging from
0.025 to 0.5 µg/L. These sensitivities are comparable to the model CE-LIF technique and
marginally better than previously reported HPLC and LC-MS/MS techniques. Because
urinary creatinine concentrations are on average 1000-fold higher than that of pteridines,
creatinine analysis varied from that of pteridines. Creatinine levels in 200-fold diluted urine
range from 500 to 5000 µg/L. At these levels, creatinine ionization saturation produced a
sigmoid calibration curve, requiring the construction of a non-traditional calibration curve
in order to simultaneously quantify it with pteridines. Linearization was achieved by
doubly inverting creatinine concentrations and detector response (cps), providing a new
linear regression coefficient of 0.9972 for this elevated range. This approach, in addition
to pteridine analysis, was validated through spiked recoveries in real urine samples (Table
3). The data in Tables 2 and 3 clearly demonstrate that the method is highly sensitive and
reproducible for all eight pteridines and creatinine in real urine samples. Finally, this
method compares well with other pteridines studies, as shown in Table 4.

were used to quantify the two pteridines in other samples.

6,7-Dimethylpterin and Pterin-6-carboxylic acid were undetected in most real samples at 200-fold dilutions. Dilutions of 100-fold

**

Creatinine has been displayed in terms of mg/dL.

*

Table 2. Linear Range, IDLs, MDLs, retention Times, and encountered ranges in urine of the HPLC-MS/MS method.
Compounds
Linear Range
R2
IDLs in DI
MDLs in
Retention
Encounter
(µg/L)
water
Synthetic
Time
Range
(µg/L)
Urine (µg/L)
(min)
(µg/L)
*
0.15-500
0.9998
0.1
0.15
1.74
20-174
Creatinine
500-5000
0.9972
0.025-1000
0.9999
0.025
0.025
2.74
115-3816
D-Neopterin
0.2-1000
0.9999
0.1
0.2
3.43
158-2933
6-Biopterin
0.5-1000
0.9999
0.1
0.15
3.57
35-2796
Xanthopterin
0.25-1000
0.9999
0.1
0.1
3.76
50-413
6Hydroxymethylpterin
0.3-1000
0.9999
0.25
0.3
4.08
25-854
Pterin
0.4-1000
0.9999
0.4
0.4
4.20
22-2714
Isoxanthopterin
0.1-1000
0.9998
0.05
0.1
4.82
0-20**
6,7-Dimethylpterin
0.5-1000
0.9999
0.5
0.5
4.88
0-4695**
Pterin-6-carboxylic
acid

56
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Table 3. Summarized results of triplicate recoveries (%) of three varying concentrations of
eight urinary pteridines and creatinine in a spiked real urine sample.
Low (1 µg/L)
Compound

Medium (10 µg/L)

High (100 µg/L)

Recovery

RSD

Recovery

RSD

Recovery

RSD

Creatinine

95.4

2.4

97.1

3.0

101.1

1.8

D-Neopterin

102.4

4.2

97.4

2.3

96.4

2.1

6-Biopterin

97.6

3.0

104.7

3.2

102.3

2.7

Xanthopterin

81.3

4.2

91.4

2.7

93.4

2.5

6-Hydroxymethylpterin

103.0

2.1

99.2

2.3

98.6

1.6

Pterin

97.8

2.7

96.5

2.4

93.1

2.2

Isoxanthopterin

104.5

4.5

100.3

3.8

102.8

4.0

6,7-Dimethylpterin

89.4

3.6

89.7

2.4

93.7

1.8

Pterin-6-carboxylic acid

84.1

5.7

91.3

5.5

93.4

5.3

†

†

Creatinine spiked recoveries were made at 500, 1000, and 3000 µg/L in to better

represent creatinine concentrations in real urine samples.

6,7-Dimethylpterin, 6Hydroxymethylpterin

acid, 6,7Dimethylpterin, 6-

KI-I2
20
0.035-0.100

KI-I2
7.5
0.025-0.5

Run-to-Run Time (minutes)

Limits of Detection (µg/L)

Yes

No

Pterin-6-Carboxylic acid,

Pterin-6-Carboxlyic acid, Biopterin, 6-

Pterin-6-Carboxlyic

Hydroxymethylpterin

Biopterin, L-Monapterin,

Neopterin, 6-Biopterin,

0.007-0.360

19

MnO2

No

Neopterin

Neopterin, 7-

6-Biopterin, 7-

0.2-6.1

39

KI-I2 and KMnO4

Yes

Biolumazine

Hydroxylumazine,

Hydroxylumazine, 7-

Lumazine, 6-

6-Hydroxymethylpterin,

Neopterin, Biopterin, 7-

Isoxanthopterin,

Neopterin, 6-Biopterin,

Isoxanthopterin,

Isoxanthopterin,

Pterin, Xanthopterin,

LC18

Isoxanthopterin,

Pterin,

LC-MS/MS22

Pterin, Xanthopterin,

CE-LIF15

Pterin, Xanthopterin,

MS/MS

Proposed HPLC-

Oxidation Method

Quantification

Simultaneous Creatinine

Pteridines Investigated

Technique

Table 4. Comparison of the proposed HPLC-MS/MS technique with the model CE-LIF technique and two previously reported LC and
LC-MS/MS techniques.
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3.6. Real Urine Analysis
The newly developed HPLC-MS/MS method was ultimately validated in 25 real
urine samples provided by Mercy Hospital (Springfield, MO) through a double-blind
study. The sample set consisted of 13 benign breast cancer samples and 12 malignant breast
cancer samples, with pathologies determined independently by Mercy Hospital. At 200fold dilution, six of the eight pteridines were detected with 6,7-dimethylpterin and pterin6-carboxylic acid remaining undetected except for in concentrated specimens (N=6). At
100-fold dilution, the compounds were detected in 16 of the samples. Lower dilution folds
resulted in significant ion suppression caused from ion saturation. This phenomenon is
especially evident for creatinine which experienced complete saturation near 10 µg/L.
Therefore, 100-fold dilutions were considered as the absolute lowest dilution factor in order
to simultaneously quantify the pteridines and creatinine. Moreover, without further sample
preparation or the addition of a desalting or trap column, lower dilution factors risked the
longevity of the column and the mass spectrometer. Other studies have also reported low
urinary concentrations for these two pteridines, although the authors expected to detect
these two compounds at a 200-fold dilution based on previously reported ranges and the
supporting spiked recovery data.15 The apparent inability to monitor these two pteridines
in urine is currently pending further investigation. Hence, the proposed technique may not
be valid for 6,7-dimethylpterin and pterin-6-carboxylic under the conditions described
herein. Nevertheless, the remaining six pteridine and creatinine concentrations were found
in similar ranges to those previously reported. These encountered pteridine ranges have
been summarized in Table 3.

Despite being a method development study, we further examined the potential
ability of urinary pteridines to discern benign from malignant breast cancer samples. This
limited real sample study, designed solely to validate the presented method, should not be
considered conclusive; rather, more detailed clinical trials are needed to confirm urinary
pteridines as useful breast cancer biomarkers. Pathological correlations were calculated
with Minitab Statistical Software by rejecting or accepting the null hypothesis that mean
pteridine levels in malignant breast cancer samples are lower than or equal to those from
benign specimens. Interestingly, the HPLC-MS/MS technique failed to show any
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pathological correlations with any of the creatinine-normalized pteridines. These findings
were validated by analyzing the same 25 samples with the model CE-LIF technique. As
shown in Table 5, neither technique afforded positive pathological correlations with any
of the eight pteridines. Thus, urinary pteridines may not be able to differentiate benign and
malignant breast cancers. Since only an age range for the samples analyzed herein were
provided through the double blind study, it possible that the control (benign) population
differed significantly from the positive (malignant) population. While baseline urinary
pteridine levels are currently unknown in large populations, urinary creatinine levels are
known to be age- and gender-dependent where levels are substantially elevated in younger
individuals.25,

26

Moreover, urinary creatinine by itself may not be an appropriate

normalization factor for breast cancer since breast cancer has been reported to adversely
affect both creatinine production and clearance.27, 28 To at least preliminarily address this
issue, pathological correlations for unnormalized urinary pteridine levels were determined
(Table 5). Although neglecting creatinine afforded no statistically significant correlations,
nearly all correlations improved with the HPLC-MS/MS technique, while sparse
improvements were seen with the CE-LIF technique, supporting this conjecture to some
extent.

Table 5. Pathological correlations (P-values) of eight creatinine-normalized and
unnormalized urinary pteridines determined by UFLC-MS/MS and CE-LIF techniques.
UFLC-MS/MS
Pteridine

CE-LIF

Normalized

Unnormalized

Normalized

Unnormalized

6-Biopterin

0.604

0.608

0.732

0.728

Pterin

0.638

0.275

0.546

0.549

Neopterin

0.529

0.413

0.47

0.845

Xanthopterin

0.274

0.149

0.759

0.931

Pterin-6-carboxylic Acid

N/A

N/A

0.995

0.73

6,7-Dimethylpterin

N/A

N/A

0.725

0.474

6-Hydroxymethylpterin

0.837

0.11

0.636

0.755

Isoxanthopterin

0.234

0.22

0.704

0.471
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Moreover, direct comparison of the two techniques revealed that xanthopterin and
isoxanthopterin concentrations determined by the CE-LIF technique were on average 5and 30-fold higher, respectively, than those reported by the proposed HPLC-MS/MS
technique. Based on the high quality method validation data for the proposed HPLCMS/MS technique and the inherently non-specific nature of CE-LIF, it is possible that these
concentration discrepancies arise from co-eluting interferences or different oxidation states
of pteridines in the CE-LIF approach. This phenomenon is under further investigation.
Nevertheless, the new method may be used to determine urinary pteridines and creatinine
simultaneously for biomedical studies, in which the pteridines need to be quantified.

4. CONCLUSION
A simple, rapid, specific, and sensitive HPLC-MS/MS method was developed for
simultaneous analysis of six urinary pteridines and creatinine, which has not been
previously reported to the best of our knowledge, especially toward application of breast
cancer detection. Additionally, cationic adduct formation for urinary pteridines analyzed
with ESI-positive ionization have been reported for the first time. The HPLC-MS/MS
platform allows for greatly enhanced run times and increased specificity over previously
reported CE-LIF approaches. The method was validated through evaluation of spiked
recoveries, reproducibility (represented by RSD), MDLs, and application in 25 real urine
samples from breast cancer positive and negative samples. Results from the real samples
have finally led to the conclusion that improved validation studies with sufficient statistical
power and the utilization of an alternative renal dilution factor to creatinine are needed for
clinical confirmation of urinary pteridines as breast cancer biomarkers. Finally, the
disclosed technique may be applied to other diagnostic studies in addition to breast cancer.
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ABSTRACT
Background: Urinary biomarkers, such as pteridines, require normalization with
respect to an individual’s hydration status and time since last urination. Conventional
creatinine-based corrections are affected by a multitude of patient factors whereas urine
specific gravity (USG) is a bulk specimen property that better resists those same factors.
In this study, we examined the performance of traditional creatinine adjustments relative
to USG to six urinary pteridines in aggressive and benign breast cancers in addition to high
grade bladder cancers.
Methods: 6-Biopterin, neopterin, pterin, 6-hydroxymethylpterin, isoxanthopterin,
xanthopterin, and creatinine were analyzed in 66 urine specimens with a previously
developed liquid chromatography – tandem mass spectrometry technique. Creatinine and
USG performance was evaluated with non-parametric Mann-Whitney hypothesis testing.
Results: USG and creatinine were moderately correlated (r = 0.857) with deviations
occurring in dilute and concentrated specimens. In 48 aggressive and benign breast cancers
and 16 bladder cancer and healthy specimens, normalization by USG significantly
outperformed creatinine adjustments which marginally outperformed uncorrected
pteridines in predicting pathological status. In addition, isoxanthopterin and xanthopterin
were significantly higher in pathological specimens when normalized by USG.
Conclusion: USG, as a bulk property, can provide better performance over creatininebased normalizations for urinary pteridines in cancer detection applications.

KEY WORDS
Pteridine, Urine Specific Gravity, Creatinine, Breast Cancer, Renal Dilution, Urine
Normalization
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1. INTRODUCTION
The past five years have witnessed a renewed interest in urinary pteridines as
noninvasive, metabolic biomarkers for early cancer detection [1]. Recent advances aimed
at improving pteridine urinalysis have overcome many of the early challenges facing
pteridine research including molecular speciation and physiologically low urinary
concentrations [2-6]. Equipped with powerful, new analytical techniques, exploratory
studies continue to associate elevated pteridine levels with cancer, although a biological
premise for these associations remains unclear [7-9]. Despite these encouraging
preliminary findings, pteridine urinalyses have not yet matured to a level acceptable for
comprehensive clinical assessment. Particularly, urinary biomarkers like pteridines must
be adjusted to reflect an individual’s hydration level and time since last urination [10].
While many pteridine studies employ creatinine-based adjustments, one study recently
questioned the validity of normalizing urinary pteridines to creatinine after reporting that
pteridines could not distinguish benign and aggressive breast cancers [2].

Creatinine is an endogenous byproduct of muscle activity produced with
supposedly little day-to-day variation in a given individual [11]. In addition, serum
creatinine is constantly cleared from the bloodstream by the kidneys, leading many to
consider creatinine as an acceptable measure of renal dilution [12]. This has resulted in the
common practice of reporting urinary analytes as a ratio of the analyte to creatinine (mol
analyte / mol creatinine). There is growing evidence, however, that creatinine excretion is
not consistent, following repeated challenges to creatinine’s usefulness as a normalization
factor [13-15]. In particular, creatinine has been linked to: age, race, sex, and gender [1618]; physical activity and muscle mass [19]; diet [20-22]; normal physiological functions
including menstrual cycles [23]; and an increasing number of pathological conditions
including diabetes and breast cancer [24, 25]. Hence, creatinine may not be an appropriate
renal dilution factor for certain sample populations.

Urine specific gravity (USG) is the dimensionless ratio between the density of a
urine specimen and that of pure water under given conditions. As a bulk property that is
representative of the entire urine specimen, USG is presumably less affected by the same
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individual factors that influence creatinine [26]. Importantly, the urine density which
provides a useful measure of total urine concentration (g/L), is based not only on the
number of solute particles, but also on their molecular mass. Thus, abnormal urinary
constituents such as protein and glucose, in addition to physiological albumin, sulfates,
phosphates, and other heavy species can erroneously inflate USG [27, 28]. Conversely, low
density ketones, which are excreted under states of dehydration, starvation, or high fat
metabolism common to diabetic patients suffering from ketoacidosis, can deflate USG
values [29, 30]. Unlike creatinine, however, USG may be easily corrected with routine
clinical urinalyses for many of these factors [31].Moreover, USG can withstand multiple
freeze/thaw cycles and long-term storage at -20°C or colder [32, 33]. Consequently, USG
has been extensively used as an alternative renal dilution factor to creatinine in primarily
toxicological applications [34-36]. In contrast USG corrections have currently found
limited utility in clinical settings, presumably from a lack of relevant performance
evaluations [10, 37].

Methods employing USG normalizations have generally adopted the correction
protocol proposed by Levine and Fahy [38]:
𝐶𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 = 𝐶𝑟𝑎𝑤 ×

𝑈𝑆𝐺𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 − 1
𝑈𝑆𝐺𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 − 1

where Ccorrected is the adjusted analyte concentration, Craw is the uncorrected analyte
concentration, USGreference is a reference USG for a given population, and USGexperimental is
the experimentally determined USG. A USGreference value of 1.020 is typically applied to
U.S. populations, although minor variations can be made to account for differing salts and
ingested fluids [35, 38].

To the best of our knowledge, the performance of USG corrections relative to
creatinine has not been thoroughly studied in candidate biomarkers for cancer, and
specifically, urinary pteridines. In this study, breast cancer was identified as a useful
paradigm for performance evaluations based on the recent conflicting reports concerning
the ability of urinary pteridines to distinguish benign and aggressive breast cancers in
sample populations possibly inappropriate for creatinine normalization [2, 7]. Creatinine
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and USG adjustments of urinary pteridines in benign and aggressive breast cancers were
therefore compared to evaluate their performance in this double-blind study. We further
applied the study to a small scale specificity study involving bladder cancers to demonstrate
the utility of USG normalized pteridines beyond breast cancer.

2. MATERIALS AND METHODS
2.1. Samples and specimens
Fifty women 35-85 years of age (mean age: 61 years; standard deviation: 13 years)
were recruited by the Mercy Hospital Breast Cancer Treatment Center in Springfield,
Missouri [2]. All participants provided written consent, and the collection was approved
by the Institutional Review Board at Mercy Hospital in Springfield, Missouri. No monetary
compensation was provided. All participants had been recently referred to the Breast
Cancer Treatment Center following positive indications by routine clinical breast
examinations. Urine specimens were collected early, before 10:00 a.m., but did not
necessarily constitute first morning voids. New specimens were stored up to two weeks in
a freezer at -20°C at Mercy Hospital. Urine specimens were shipped weekly by frozen
ground freight whereby they were transferred to a -80°C freezer until thawing, aliquoting,
centrifugation, and assaying one to three months later. Between sample collection and final
pteridine assays, samples underwent 2-3 freeze-thaw cycles. No dietary restrictions were
placed on the participants prior to sample collection. Pathologies were independently
determined by Mercy Hospital pathologists using a combination of clinical breast
examinations, mammography, ultrasound and MRI imaging, and biopsy methods [2].
Anonymous pathological reports including diagnoses were disclosed in a double-blind
manner at the end of the study.

Sixteen additional specimens from men and women 26-70 years of age (mean age:
52 years; standard deviation: 14 years) were collected in spring 2010 by the Rolla Urology
Clinic for the bladder cancer component of the study [7]. All participants provided written
consent, and the collection was approved by the Institutional Review Board at Missouri
University of Science and Technology. No monetary compensation was provided. Four
men and women had untreated, high grade bladder cancers that were diagnosed within the
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past five years. Twelve more specimens were collected from healthy, age-matched men
and women. Urine specimens were thawed immediately, aliquoted, and centrifuged at 5000
rpm (2571 g) at 4°C for 20 minutes. Centrifuged aliquots were immediately stored at -80°C
for three years. Between sample collection and final pteridine assays, samples underwent
2-3 freeze-thaw cycles.

2.2. Chemicals and materials
Isoxanthopterin, pterin, D-neopterin, xanthopterin, 6-biopterin, ammonium
oxalate, and ammonium hydroxide were purchased from Sigma-Aldrich (St. Louis, MO,
USA). 6-Hydroxymethylpterin was obtained from Schircks Laboratories (Jona,
Switzerland). Potassium iodide and iodine were purchased from Fisher Scientific (New
Jersey, USA). Synthetic urine was obtained from CST Technologies Incorporated (New
York, USA). Ultrapure water was generated by a Milli-Q Advantage® A10 and Millipore
Elix® water purification system.

2.3. Assays
The pteridine assay that was used has been described elsewhere [2]. Briefly, a liquid
chromatography – tandem mass spectrometry (LC-MS/MS) technique was used to separate
and quantify urinary pteridines. Separation was achieved with a Phenomenex Luna phenylhexyl column (3.0µm, 3.0 x 150 mm) and a Shimadzu UFLC system (Columbia, MD,
USA) comprised of a degasser (DGU-30A3), two pumps (LC-20 AD XR), an autosampler
(SIL-20AC XR), and a column oven (CTO-20A) operating under HPLC conditions. An
API 4000Q trap MS/MS system from Applied Biosystems (Foster City, CA, USA)
quantified urinary pteridines under scheduled multiple-reaction monitoring (MRM) mode
with ESI-positive ionization. Pteridines were quantified over a linear range of
approximately 0.25 µg/L to 1000 µg/L. Spiked recoveries in real urine samples ranged
from 81% to 105% with relative standard deviations (RSDs) between 1% and 6% [2]. Urine
specimens were centrifuged at 5000 rpm (2571 g) at 4°C for 20 minutes and pre-treated
with 2M ammonium hydroxide and a 4:2% w/v potassium iodide to iodine solution in order
to promote fully oxidized pteridines. Ammonium oxalate was used as a sodium adduct
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suppressor at a final concentration of 10 µg/L. Urine specimens were diluted a total of 200fold prior to analysis. All samples were run as true triplicates.

Creatinine was quantified simultaneously with pteridines by the same LC-MS/MS
technique using a non-linear calibration curve [2]. The non-linear calibration curve
produced spiked recoveries ranging from 95.4% to 101.1% and RSDs between 1.8% and
3.0% for creatinine concentrations between 500 µg/L and 5,000 µg/L. Overly concentrated
specimens in which creatinine was unquantifiable by the non-linear calibration curve were
diluted 2000-fold and reanalyzed.

Because USG is most accurately determined refractometrically [31], a Carl Zeiss
Abbe refractometer. (No. 51865) was used for USG quantification. Prior to analysis,
thawed, centrifuged urine specimens were equilibrated at 25°C for 20 minutes. Refractive
indices were converted to USG values via a Reichert total solids refractometer conversion
table. Ultra-pure water and synthetic urine of known specific gravity were additionally
used as quality control standards. The USG assay had inter- and intra-assay CVs of 0.18%
and 0.07%, respectively. USG normalizations followed Levine-Fahy protocol using a
reference value of 1.020.

2.4. Statistical analysis
Final pteridine concentrations were reported in molar units. Creatinine-corrected
pteridines were expressed as mol pteridine/mol creatinine while USG-corrected pteridines
remained in molar units. Minitab 16 Statistical Software was used to perform all statistical
analyses. Pearson correlations were used to describe the relationship between USG and
creatinine. Regular outliers found in aggressive cancers in this study (normality P-value =
0.001) and previous findings suggested a Student’s t-Test, which assumes a normal
distribution, would erroneously inflate statistical significance [2, 7]. Therefore, nonparametric, one-tailed Mann-Whitney hypothesis testing that offers improved efficiency
for non-normal distributions was used to evaluate mean differences among normalized
pteridines and pathologies at a 5% significance level (P-value < 0.05). Finally, two overly
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dilute specimens in which pteridines were unquantifiable were excluded from statistical
analysis.

3. RESULTS AND DISCUSSION
Spot urine samples, like those taken during clinical tests, come from a patient of
unknown hydration status and void time. Analytes of interest must therefore be adjusted to
consider the dilution-concentration of the urine specimen. In this study, we examined the
performance of traditional creatinine adjustments relative to USG. A direct comparison
between urinary creatinine and USG from 48 urine specimens in the breast cancer study
was made in Figure 1. The Pearson correlation (r = 0.857, P-value = 0.0000, SE = 0.0058
USG) indicated a moderately strong relationship between urinary creatinine and USG, in
agreement with previous findings [34]. Moreover, as a primary component of urine that is
presumably constantly excreted, creatinine was expected to model USG in a linear fashion.
Significant deviations were nevertheless observed in overly concentrated (creatinine > 250
mg/dL) and overly dilute (creatinine < 50 mg/dL) specimens. Similarly, it has become
common practice, particularly in toxicological applications, to reject overly dilute
(creatinine < 50 mg/dL, USG < 1.010) and overly concentrated (creatinine > 300 mg/dL,
USG > 1.030) urine specimens [10, 13, 35]. However, these conventional creatinine and
USG requirements may be too restrictive for clinical practice; as shown in Figure 1, 26%
of our specimens had unacceptable creatinine levels and 42% failed to meet these USG
requirements. Such a considerable number of low urinary creatinine and USG specimens
in this study may be explained by a recent finding that women 50 years or older have
unusually low urinary creatinine and USG [35]. In addition, such sample discarding is
impractical in a clinical setting and creates additional economic and emotional burden on
the patient by requiring another specimen provided at a later date. For these reasons, some
studies have proposed relaxed concentration-dilution requirements down to 10 mg/dL and
1.002 for the minimum acceptable creatinine and USG levels, respectively [34]. In contrast
this study excluded samples with unquantifiable pteridines rather than based on creatinine
and USG values resulting in the exclusion of only two urine specimens. Finally, it is
important to note that we did not correct USG to conditions including glucosuria,
proteinuria, and ketonuria. In addition, study participants were not screened for diabetes.

72
Thus, these USG-based results may be further optimized in future studies by considering
these pathological conditions.
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Aggressive
Benign

Urine Specific Gravity

1.04
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Creatinine (mg/dL)

300
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Figure 1. Relationship between USG and creatinine in benign (n = 27) and aggressive
breast cancers (n = 21).

USG and creatinine normalization performance were evaluated by statistical
hypothesis testing that assumed mean pteridine levels were higher in aggressive cancers
based on earlier clinical studies [7]. P-values from non-parametric Mann-Whitney mean
difference tests for each pteridine in aggressive and benign breast cancers were
summarized in Table 1. Summed P-values for all six pteridines were provided for simple
comparisons among normalization methods, although each pteridine must be considered
individually for clinical assessment.
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Table 1. P-values from non-parametric Mann-Whitney one-tailed mean difference tests
between aggressive breast cancer (n = 21) and benign breast cancer (n = 27) urine
specimens.
Normalization Method

Uncorrected

Creatinine

USG

6-Biopterin

0.4787

0.4111

0.3776

Pterin

0.2094

0.1277

0.1968

Neopterin

0.5000†

0.5000†

0.3935

Xanthopterin

0.4736

0.3956

0.0090

6-Hydroxymethylpterin

0.1799

0.1586

0.0767

Isoxanthopterin

0.1651

0.1417

0.0011

Summed P-values

2.0067

1.7347

1.0547

† Uncorrected

and creatinine adjusted mean neopterin values in aggressive cancers

were less than those in benign samples.

Interestingly, creatinine normalization (summed P-value = 1.7347) provided only
a marginal 13.6% improvement over uncorrected pteridines (summed P-value = 2.0067).
In addition, no pteridines adjusted by creatinine were found to have significantly different
(P-value < 0.05) mean levels between benign and aggressive breast cancers, rendering any
clinical utility useless. These results corroborated similar findings published in a recent
study evaluating pteridines adjusted to creatinine in benign and aggressive breast cancers
[2]. In comparison USG normalization (summed P-value = 1.0547) yielded an overall
47.4% improvement in pathologically correlating pteridines over uncorrected pteridines
and outperformed creatinine by a factor of 3.5. Statistical mean differences for all six
pteridines except pterin increased with USG normalization, which is reflected by its
significantly lowered summed P-value. Isoxanthopterin (P-value = 0.0011) and
xanthopterin (P-value = 0.0090) had significantly elevated levels in aggressive breast
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cancers compared with benign breast cancers. In addition, 6-hydroxymethylpterin, which
was unquantifiable in 22% of samples, also demonstrated some ability to differentiate
benign and aggressive breast cancers, although the difference in 6-hydroxymethylpterin
values was not statistically significant (P-value = 0.0767). Neopterin, which had lower
uncorrected mean values in aggressive breast cancers than in benign, highlights the need
for urine concentration-dilution normalization. Mean neopterin levels became marginally
biased toward aggressive cancers when normalized with USG. Basic statistical information
for USG normalized pteridines from the breast cancer study was summarized in Table 2.

Table 2. Basic statistical summaries for six urinary pteridines normalized to USG as well
as raw creatinine and USG values in aggressive and benign breast cancer urine samples.

6-Biopterin (M)
Pterin (M)
Neopterin (M)
Xanthopterin (M)
6-Hydroxymethylpterin
(M)
Isoxanthopterin (M)
Creatinine (mg/dL)
USG

Mean Aggressive
(n = 21)

Mean Benign
(n = 27)

Variance
Aggressive

Variance
Benign

1.55E-05
2.89E-06
1.42E-05
9.05E-06

1.00E-05
1.99E-06
9.65E-06
5.62E-06

5.62E-10
1.64E-11
4.28E-10
7.40E-11

1.17E-10
6.86E-12
8.70E-11
1.31E-11

4.73E-06

3.37E-06

6.16E-11

4.07E-11

3.55E-06
99.3
1.012

1.03E-06
122.2
1.017

3.25E-11
52.4
0.009

8.43E-13
94.0
0.013

The implications of xanthopterin and isoxanthopterin in aggressive breast cancers
in this study prompted further investigation of their potential clinical utility. Boxplots
detailing the pathological differences observed in this study for xanthopterin and
isoxanthopterin were shown in Figures 2 and 3, respectively. As seen in Figure 2,
xanthopterin values associated with aggressive breast cancers were defined as several
significantly elevated outliers with a majority of values similar to benign breast cancers.
Hence, xanthopterin may not serve as a particularly reliable standalone biomarker for
discerning aggressive and benign breast cancers. In contrast isoxanthopterin values from
aggressive breast cancers were visibly elevated indicating isoxanthopterin may have
superior predictive power which is reflected by its lower P-value. Where previous pteridine
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studies have focused on individual pteridine diagnostic utilities, we additionally coupled
xanthopterin and isoxanthopterin to produce a bivariate indicator of aggressive breast
cancers with enhanced diagnostic utility. A corresponding scatterplot of this approach has
been provided in Figure 4. A remarkably clear distinction between benign and aggressive
breast cancers was observed with the bivariate approach in comparison with those
presented in the individual boxplots shown in Figures 2 and 3.

USG Normalized Xanthopterin

0.000025

0.000020

0.000015

0.000010

0.000005

0.000000
Aggressive

Benign

Figure 2. Boxplot of USG normalized xanthopterin levels in aggressive (n = 21) and benign
(n = 27) breast cancer urine samples.
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USG Normalized Isoxanthopterin

0.000004

0.000003

0.000002

0.000001

0.000000
Aggressive

Benign

Figure 3. Boxplot of USG normalized isoxanthopterin levels in aggressive (n = 21) and
benign (n = 27) breast cancer urine samples.

Applying arbitrary thresholds at 5 µM xanthopterin and 1.5 µM isoxanthopterin,
this bivariate approach afforded 87.5% diagnostic sensitivity, 70% specificity, 70%
positive predictive value, and 87.5% negative predictive value in discerning aggressive
from benign breast cancers. While the individual implications of xanthopterin and
isoxanthopterin were supported by numerous other implications of xanthopterin and
isoxanthopterin in a variety of pathological conditions, to the best of our knowledge,
similar bivariate approaches have not been considered before for pteridines [4-7]. In
addition, the isoxanthopterin and xanthopterin results from this study differed significantly
from an earlier study using capillary electrophoresis – laser-induced fluorescence (CE-LIF)
that also implicated urinary isoxanthopterin and xanthopterin in breast cancers [7]. While
it been suggested that the CE-LIF technique may have co-eluting interferences for
xanthopterin and isoxanthopterin, an observation supported by unusually high urinary
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concentrations compared with LC-MS/MS methodologies, it is also important to note the
differences in normalization methods and sample exclusion protocol between this study
and that study [2]. Importantly, the CE-LIF study utilized healthy controls that were not
gender- and age-matched. As Carrieri and co-workers have demonstrated, creatinine varies
considerably more with age and gender than does USG [35]. These considerations
alongside new reports indicating that creatinine is affected by menstrual cycles and breast
cancer suggest that creatinine may not be an appropriate normalization factor for urinary
breast cancer biomarkers [10, 23-25]. While benign and aggressive breast cancers in this
study were gender- and age-matched, a clinically wide range of ages were encountered
which merited additional correlation studies. Pearson correlations were made for USG,
creatinine, xanthopterin, and isoxanthopterin with respect to patient age. Urinary
xanthopterin (r = 0.048, P-value = 0.754) and isoxanthopterin (r = -0.113, P-value = 0.500)
clearance were largely age-independent. In contrast, creatinine (r = -0.321, P-value =
0.026) was moderately correlated with age with a relationship similar to that reported by
Rowe and colleagues [39]. Interestingly, USG (r = -0.185, P-value = 0.224) was also
weakly correlated with age but did not conflict with larger USG studies. In addition, this
study had a significant bias toward women over 50 years of age (mean age = 61 years),
which represents a subpopulation in which USG has not been sufficiently studied.
Nevertheless, the relatively age-independent nature of xanthopterin, isoxanthopterin, and
USG in comparison with creatinine provided a useful interpretation of the observed
normalization performance parameters. Because xanthopterin and isoxanthopterin has now
been shown to not vary with age within these demographics, their normalization by agedependent creatinine was reasonably inappropriate. Although these findings were highly
encouraging, it should be stressed that a biological premise for pteridines like xanthopterin
and isoxanthopterin in cancer has not been firmly established. More importantly, the study
results indicated that USG normalization may provide superior performance to creatininebased adjustments, particularly to age-independent biomarkers like pteridines.
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Figure 4. Scatterplot of urinary xanthopterin and isoxanthopterin in 48 benign and
aggressive breast cancers.

Finally, the applicability of USG normalization of urinary pteridines was
considered through a small-scale bladder cancer study. The results of that study were
summarized in Table 3 in the form of P-values. Similar to breast cancers, USG
normalization afforded optimal P-values (summed P-value = 0.9109) compared with
creatinine normalization (summed P-value = 1.8224) which again provided only a marginal
improvement over uncorrected pteridines (summed P-value = 1.9714). Isoxanthopterin (Pvalue = 0.0105) and xanthopterin (P-value = 0.0220) were again implicated as potentially
useful biomarkers. It should be noted that 6-hydroxymethyl pterin was strongly
uncorrelated with pathology whereas pterin showed some ability, although not statistically
significant (P-value = 0.0736). Hence, 6-hydroxymethylpterin and pterin may be useful in
discerning breast and bladder cancers, although further study is required. As a final note,
the bladder cancer study, which was comprised of four untreated, high grade bladder cancer
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specimens and 12 normal, healthy specimens, lacked sufficient statistical power to form
any conclusions. For this reason, basic statistical information from this study has not been
provided and the study is purely demonstrative. A more robust sample set was not pursued
based on a lack of appropriate urine specimens. Nevertheless, the preliminary results from
this comparison study again suggest that USG normalization of urinary pteridines may be
more efficient than creatinine adjustments.

Table 3. P-values from non-parametric Mann-Whitney one-tailed mean difference tests
between pathological bladder cancer (n = 4) and normal (n = 12) urine specimens.
Normalization
Method

Uncorrected

Creatinine

USG

6-Biopterin

0.4274

0.3784

0.2463

Pterin

0.2144

0.4485

0.0736

Neopterin

0.3797

0.2683

0.1285

Xanthopterin

0.2011

0.1400

0.0220

6Hydroxymethylpterin

0.4844

0.3422

0.4300

Isoxanthopterin

0.2644

0.2450

0.0105

Summed P-values

1.9714

1.8224

0.9109

4. CONCLUSION
In this study, we compared the performance of USG and creatinine normalizations
of six urinary pteridines in discerning aggressive from benign breast cancers in 50 genderand age-matched urine specimens. The basis of the study was premised on reports that
commonly used creatinine normalizations may be inappropriate for clinical biomarkers due
to its influence by a variety of patient factors whereas USG may be a more tolerant urine
concentration-dilution indicator. Urinary creatinine was found to be well correlated with
USG with deviations occurring in overly dilute and overly concentrated specimens. In
addition, creatinine was found to be moderately correlated with patient age while USG,
xanthopterin, and isoxanthopterin were reported to be relatively age-independent. This age
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dependence was observed in a clinical performance comparison where USG-adjusted
pteridines significantly outperformed creatinine-adjusted pteridines which only marginally
outperformed uncorrected pteridines in discerning aggressive from benign breast cancers.
In addition, isoxanthopterin and xanthopterin were reported to be significantly elevated in
aggressive cancers when normalized by USG in comparison to creatinine. Moreover, these
pathological correlations were enhanced by coupling xanthopterin and isoxanthopterin to
form a bivariate indicator of cancer aggression with remarkable diagnostic sensitivity and
specificity. These trends were also replicated in a similar small scale study involving
bladder cancers. Hence, these findings indicated that USG normalization offers improved
performance for clinical biomarkers and particularly urinary pteridines. In addition, these
results strongly recommend that biomarker studies consider sample population
demographics in order to choose the most appropriate normalization factor. Finally, larger
studies are required to confirm the conclusions made by this study.
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ABSTRACT
Pteridines are a diverse family of endogenous metabolites that may serve as useful
diagnostic biomarkers for disease. While many preparative and analytical techniques have
been described for analysis of selected pteridines in biological fluids, broad intracellular
pteridine detection remains a significant analytical challenge. In this study, a novel, specific
and sensitive extraction and high performance liquid chromatography – quadrupole timeof-flight – mass spectrometry (HPLC-QTOF MS) method was developed to
simultaneously quantify seven intracellular pteridines and monitor 18 additional, naturallyoccurring intracellular pteridines. The newly developed method was validated through
evaluation of spiked recoveries (84.5% - 109.4%), reproducibility (2.1% – 5.4% RSD),
method detection limits (0.1 – 3.0 µg/L) and limits of quantitation (0.1 – 1 µg/L), and
finally application to non-small cell lung cancer A549 cells. Twenty-three pteridine
derivatives were successfully detected fromcell lysates with an average RSD of 12%
among culture replicates. Quantified intracellular pteridine levels ranged from 1 to 1000
nM in good agreement with previous studies. Finally, this technique may be applied to
cellular studies to generate new biological hypotheses concerning pteridine physiological
and pathological functions as well as to discovery new pteridine-based biomarkers.

KEY WORDS
HPLC-QTOF MS, A549, pteridinic profiling, pteridines, pteridine extraction
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1. INTRODUCTION
Pteridines are endogenous metabolites that function broadly in the human body as
cofactors and intermediates for an array of metabolic pathways. Reported associations
between pteridine levels and actively proliferating cells have prompted efforts to evaluate
pteridine derivatives as novel indicators of disease and especially cancer [1]. Consequently
the clinical significance of a handful of pteridine derivatives has been established over the
past several decades [1-3]. Neopterin in particular has been comprehensively studied
leading to an improved understanding of its pathomechanistic production and related
diagnostic utility. Briefly, neopterin production has been linked to the stimulation of human
monocytes by T-lymphocytes- and natural killer cell-derived cytokines and is related to a
variety of pathological conditions such as infection, cancer, autoimmune diseases and
rejected organ transplants [4-7]. Similarly, the cytokine-induced synthesis of
tetrahydrobiopterin (BH4), a cofactor for nitric oxide synthase that is further related to
vascular dysfunctions, has also been widely reported [8-10]. Hence, some pteridine
derivatives like neopterin and BH4 appear to reflect activated immune systems in response
to disease and associated inflammation. While such pteridine biomarkers fail to constitute
classical tumor markers, other pteridine derivatives like xanthopterin, isoxanthopterin,
oncopterin, pterin-6-carboxylic acid, 6-biopterin, among others have been widely
speculated as candidate cancer biomarkers with pathomechanistic production thought to be
related to perturbed cancer cell metabolisms. However, the lack of rigorous clinical
validation and a poor understanding of how these pteridine derivatives specifically relate
to cancer suggest further study is urgently required [1, 3, 11]. Moreover, with a large
number of pteridine derivatives relatively unstudied and multiple, previously studied
pteridine derivatives already having reported diagnostic value, the inclusion of broader
pteridine panels in new analytical methods is urgently needed. These serious issues facing
general pteridine research and efforts to establish pteridine derivatives as useful biomarkers
for disease have arisen in part from complex bioanalytical and clinical challenges related
to the accurate and specific detection of pteridine derivatives under native speciation [11,
12].
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Pteridine analysis in biological fluids has progressed significantly in the past
several years. These method development studies have met varied challenges ranging from
physiochemical properties and sample preparation issues to clinical considerations and
limited pteridine profiling. Physiochemical complications include trace concentrations in
biological fluids, pteridine derivatives with multiple oxidation states, and species labile to
heat, light, and auto-oxidation [11, 12]. For these reasons, various oxidative pre-treatments
have often been utilized by a wide range of techniques and sample matrices to oxidize any
residual reduced pteridine derivatives to facilitate the analysis of more stable and more
fluorescent, oxidized forms [13-19]. The resulting destruction of biologically useful
information related to the reduced pteridine derivatives by these oxidative pre-treatments
has prompted recent efforts to develop new techniques capable of simultaneously
determining pteridines in their native oxidation states[20-22]. This trend toward total,
native pteridine detection has become increasingly important as efforts to clinically
validate pteridines continue to expand. In addition, the role of creatinine as an appropriate
normalization factor in noninvasive urine-based strategies has been recently questioned for
applications involving certain populations [14]. In response, urine specific gravity has been
proposed as a more tolerant indicator of urine concentration-dilution for pteridine-based
discrimination of benign and aggressive breast cancers [23]. Finally, new methods continue
to improve detection limits and overcome these and other bioanalytical challenges
following the rapid development of multiple, sensitive and specific pteridine detection
techniques utilizing a variety of platforms including capillary electrophoresis – laserinduced fluorescence (CE-LIF) [19], high-performance liquid chromatography –
fluorescence detection (HPLC-FD) [13, 15, 22, 24], high-performance liquid
chromatography – mass spectrometry (HPLC-MS) [25], high-performance liquid
chromatography – tandem mass spectrometry (HPLC-MS/MS) [14], and synchronous
fluorescence spectroscopy [26]. These techniques have expanded beyond urinary pteridine
detection [13, 14, 19, 24-26] to include serum [15] and cerebrospinal fluid [22] analyses as
well, although these additional matrices remain relatively underdeveloped.

In comparison, intracellular pteridinic profiling, central to both elucidating
pathomechanistic production of pteridine derivatives and discovering new, clinically useful
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pteridine biomarkers, remains remarkably underdeveloped. Current techniques have been
generally limited to analysis of biopterin and neopterin derivatives using a combination of
HPLC-ED, HPLC-FD and ELISA methods with the exception of a recent HPLC-MS/MS
technique for biopterin derivatives [20, 27-29]. Specific analytical difficulties such as polar
metabolite extraction, interference minimization, and instrument compatibility especially
with mass spectrometry, have complicated efforts to further intracellular pteridinic
profiling. For example, while fluorescence-based techniques, such as capillary
electrophoresis – laser-induced fluorescence (CE-LIF) and liquid chromatography –
fluorescence detection (LC-FD), have remained popular for pteridine detection due to their
high sensitivities and effective separations, such techniques require chemical standards for
compound confirmation and are particularly sensitive to fluorescent interferences and UVabsorbing material. Similarly, conventional quadrupole tandem mass spectrometry
techniques (e.g. LC-MS/MS) offer competitive sensitivities without the need for complete
separation, but lack the high mass resolution currently to reliably semi-quantitatively
monitor additional pteridine derivatives without the use of often expensive and otherwise
difficult-to-obtain chemical standards. In comparison, high resolution, high-performance
liquid chromatography – quadrupole time-of-flight mass spectrometry (HPLC-QTOF MS)
provides adequate sensitivity, greatly improved selectivity, and the ability to perform
MS/MS experiments in combination with comprehensive database integration to provide a
platform suitable for both quantitative and semi-quantitative profiling of a robust pteridine
panel.
In this study, a combination pteridine extraction and high resolution HPLC-QTOF
MS detection method was developed for the quantitative determination of seven selected
pteridines (Figure 1) and the semi-quantitative analysis of 18 additional pteridines to
profile a complete panel of 25 pteridines in cell lysate matrices (Figure 2). Basic
information for the 25 selected pteridine derivatives have been provided in Table 1. The
validated method was finally applied to non-small cell lung cancer A549 cells to
demonstrate the robustness of the newly developed method.
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Figure 1. Chemical structures of seven quantitatively measured cellular pteridine
derivatives: (1) pterin, (2) xanthopterin, (3) isoxanthopterin, (4) d-neopterin, (5) 6,7dimethylpterin, (6) pterin-6-carboxylic acid, and (7) 6-biopterin.

Figure 2. General schematic of the newly developed extraction and quantitative techniques
for broad intracellular pteridinic profiling.
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Table 1. Basic information for 25 monitored intracellular pteridine derivatives
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Quantitative

Semi-quantitative

Semi-quantitative

Quantitative

Semi-quantitative

Semi-quantitative

Semi-quantitative

Semi-quantitative

Quantitative

Quantitative

Semi-quantitative

Semi-quantitative

Semi-quantitative

Semi-quantitative

Quantitative

Analysis Type
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2. MATERIALS AND METHODS
2.1. Chemicals and Materials
Isoxanthopterin, pterin, D-neopterin, xanthopterin, 6,7-dimethylpterin, and
dithiothreitol were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). 6-Biopterin,
pterin-6-carboxylic acid, ammonium hydroxide, formic acid, and ascorbic acid were
purchased from J&K Scientific, LTD (Beijing, China). Trypsin and Dulbecco’s Modified
Eagel’s Medium (DMEM) used in the cell culture preparation were also purchased from
Sigma-Aldrich.

2.2. Instrumentation
A Venusil XBP phenyl-hexyl column (5.0 μm, 4.6×150 mm, Bonna-Agela
Technologies Inc., USA) and an Agilent LC 1200 HPLC system (Santa Clara, California,
USA) comprised of a degasser (G1322A), a binary pump (G1312B), an autosampler
(G1367D), an autosampler thermostat controller (G1330B), and a column oven (G1316B)
were used for the separation of the selected cellular pteridines. Separation was carried out
at 25 °C with a flow rate of 0.25 mL/min using mobile phase that had the following
composition, A: 0.1% (v/v) formic acid in water and B: 0.1% (v/v) formic acid in
acetonitrile. A gradient program was used to enhance separation that initialized at 50% B
followed by a linear decrease to 20% B at 3 minutes followed by a linear increase to 80%
B at 8 minutes. This composition was held for the remainder of the run. Run-to-run time
was 25 minutes with a sample injection volume of 5 μL.

An Agilent 6530 high resolution QTOF mass spectrometer with positive-ion ESI
was used to detect and quantify the selected pteridines. The QTOF mass spectrometer was
operated under untargeted MS/MS mode for characterization and semi-quantitative
analysis of selected pteridines lacking standard reagents. Optimized operational parameters
included: gas temperature: 325 °C; drying gas: 6 L N2/min; nebulizer pressure: 30 psig;
sheath gas temperature: 350 °C; sheath gas flow: 7.5 L N2/min; ESI voltage: +3500 V; TOF
fragmenter voltage: 130 V; skimmer voltage: 65 V; quadrupole RF Vpp voltage: 750 V.
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2.3. Standard Preparation
Approximately 4 mg of each pteridine standard was accurately weighed to 0.01 mg
precision and dissolved in a 0.1% (w/v) dithiothreitol (DTT) solution comprised of 9.8 mL
ultrapure water and 200 µL 2 M ammonium hydroxide. Ultrasonication and vortexing were
used together to facilitate the dissolution process. A stock mixture containing 10 mg/L of
each pteridine standard was prepared daily and maintained at 4 °C under dark conditions.
Calibration standards were prepared from the stock mixture by serial dilution in a 0.1%
(w/v) DTT solution prepared from ultrapure water.

2.4. Cell Cultures and Preparation
A549 adenocarcinoma human alveolar basal epithelial cells were obtained from the
American Type Culture Collection (Manassas, Virginia, USA). Cells were suspended in
DMEM with 10% fetal bovine serum (FBS). Cells were cultivated in 10 cm Petri dishes in
a controlled incubator maintained at 37 °C and 5% carbon dioxide under dark conditions.
Cells were harvested by incubating at 37 °C and 5% carbon dioxide with 1 mL trypsin
solution and immediately counted with a hemocytometer. After centrifuging the
trypsinized cells at 200 g for 5 minutes at 4 °C, the trypsin supernatant was carefully
aspirated and the cell pellets were washed twice with ultrapure water. The cells were then
resuspended in 500 µL chilled ultrapure water containing 0.1% DTT followed by manual
homogenization to lyse cellular membranes. The homogenized cells were then further
snap-frozen with liquid nitrogen for 1 minute and allowed to gradually thaw to 4 °C. A 500
µL addition of cold (-20 °C) methanol containing 0.1% DTT and 10 mM ammonium
hydroxide was made to the thawed lysate and the extract was allowed to incubate for 10
minutes on ice. Insoluble portions were subsequently removed by centrifugation at 20,000
g for 20 minutes at 4 °C. A 500 µL aliquot of the undiluted supernatant was transferred to
a 1.5 mL vial and placed in a dark, thermostated (4 °C) autosampler. A 5 µL aliquot was
injected for pteridinic profiling of the cell lysate.
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3. RESULTS AND DISCUSSION
3.1. Pteridine Extraction
Similar to pteridine analysis, intracellular pteridine extraction is complicated by the
unique physiochemical properties of pteridines, specifically poor solubility in many
aqueous and organic solvents, trace biological concentrations, and high polarity. While
pteridine extraction from insect tissue and animal irises using basic buffers followed by
fluorimetric detection has been widely reported, pteridine extraction protocol for either
mammalian cells or MS-compatible detection has remained limited [30-32]. Fismen et al
reported biopterin derivative extraction from cell lysates using a combination of
trichloroacetic acid, acetic acid, and EDTA, but did not consider other extraction solvents
or other pteridine derivatives [20]. Therefore, previously reported comparisons made
among common metabolite extraction techniques for similarly polar nucleotide-derived
compounds and amino acids were used to develop candidate pteridine extraction
techniques [33]. The selected extraction solvents included 100% cold (-20 °C) methanol,
50% cold (-20 °C) aqueous methanol, and hot (60 °C) water, all of which contained 0.1%
DTT to prevent auto-oxidation of reduced pteridine species [13] and 5 mM ammonium
hydroxide [14] to improve pteridine solubility. Systematic comparison of DTT
concentrations on a variety of reduced pteridines has previously demonstrated 0.1% DTT
effectively maintains reduced pteridine stability in complex biological matrices [13]. It
should be noted that 50% aqueous acetonitrile was not examined due to pteridine solubility
concerns. A standard extraction volume of 1000 µL was used, although this parameter
remains to be optimized for given cell counts. It was noted that extraction volumes larger
than 5000 µL for approximately 1•107 A549 cells resulted in non-detection of some
pteridine derivatives. In addition, cryogenic cell lysis through liquid nitrogen exposure
significantly improved pteridine extraction over manual homogenization alone which was
indicative of more complete lysis. Normalized extraction efficiencies were determined by
normalizing the extracted concentrations of the seven, quantitatively monitored pteridines
to the highest performing extraction solvent.

Pure organic solvent (100% cold methanol) failed to appreciably extract pteridines
with an average extraction efficiency of 41%. The resulting poor extraction efficiency may
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be attributed to the limited solubility of polar pteridines in cold, pure organic solvent.
Pteridine extraction by hot water provided 122% extraction efficiency, but was
characterized by high inter-experimental variability and markedly decreased reduced
pteridine derivatives. These data indicate hot water extractions may promote the nonspecific oxidation of reduced pteridine derivatives to more oxidized forms. Meanwhile,
50% cold methanol afforded optimal extraction efficiencies without significantly affecting
reduced pteridine species, although it remains unclear to what extent these oxidation
processes may have occurred. These extraction comparisons supported similar findings for
the extraction of polar nucleotide-derived compounds and amino acids [33]. In addition, 5
mM ammonium hydroxide significantly improved pteridine extraction for all extraction
solvents studied. Oxidative influence on reduced pteridine derivatives by ammonium
hydroxide was not appreciably observed in the presence of 0.1% DTT. Higher ammonium
hydroxide concentrations posed MS compatibility concerns and often resulted in the
formation of a viscous precipitate after centrifugation that rendered removal of the
supernatant difficult and resulted in decreased pteridine levels. This phenomenon has been
reported with similar potassium hydroxide-assisted extractions [33]. Finally, a wider range
of inorganic solvents may further improve extraction efficiencies, but are not compatible
with HPLC-QTOF MS analysis.

3.2. MS/MS Optimization
Seven, quantitatively monitored pteridines were mass optimized with respect to
their precursor and two most abundant product ions. Quantitative analysis of these seven
pteridines implemented a 20 ppm symmetric expansion about these optimal masses to
provide high-resolution extracted ion chromatograms for each pteridine derivative.
Previous work has reported optimal positive-ion ESI using 0.1% (v/v) formic acid in
aqueous and organic mobile phases [14, 25]. Therefore, 1000 µg/L pteridine standards
were prepared in 0.1% (v/v) aqueous formic acid and injected into the high resolution
QTOF mass spectrometer via direct infusion at a rate of 0.3 mL/hour. Ions were monitored
under full scan mode between 150 m/z and 300 m/z for one minute to determine the crude
average ion mass. The pteridine standard was reexamined under Selected Ion Monitoring
(SIM) scan mode for one minute centered on the crude average ion mass with a 200 ppm
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symmetric expansion. The new centroid mass from the SIM scan was used as the
experimentally optimized precursor ion mass. To optimize product ion masses, targeted
MS/MS acquisition was used on the infused standard centered on the optimized precursor
ion mass with a 20 ppm symmetric expansion and a collision energy of 20 eV which was
preliminarily found to afford the optimal product ion intensities. MS/MS spectra were
acquired for one minute, and the average masses for the two most abundant product ions
were used as the optimized product ion masses for confirmation purposes. The precursor
and production ion masses determined were similar to those reported by studies using lower
mass resolution instruments [14]. Notably, primarily [M+H]+ ions were observed with
negligible formation of ammonium adducts, [M+NH3]+ and [M-H+2NH4]+, in xanthopterin
and pterin-6-carboxlyic acid. These differences may be attributed to different positive-ion
ESI conditions, such as a lower capillary voltage (3500 V vs 4500 V) and significantly
higher gas flow rates. Hence, under the given MS/MS conditions, the assumption that
similar pteridine derivatives will form [M+H]+ appeared reasonable. The optimized
MS/MS parameters were summarized in Table 2.

3.3. HPLC Optimization
The separation of the seven, quantitatively monitored pteridines was based
on chromatographic conditions described in our previous work with some notable
modifications [14]. In this study, a larger Venusil XBP phenyl-hexyl (5.0 μm, 4.6×150
mm) column, in comparison with a Phenomenex Luna phenyl-hexyl (3.0 μm, 3.0×150 mm)
column, was selected to separate the seven pteridines based on column availability.
Resulting differences in retention time, retention order, and peak shape were noted in
comparison with the previously described method. Therefore, the separation was evaluated
and optimized under a range of flow rates from 0.10 mL/min to 0.40 mL/min with a variety
of mobile phase compositions (0.0-0.2% formic acid in water, methanol, and acetonitrile).
Briefly, it was observed that initially high aqueous mobile phase (>50%) compositions
resulted in loss of retention and the occurrence of significant peak tailing while very high
organic compositions (>80%) resulted in complete retention. The resulting optimized
conditions may be found in Section 2.

208.0462
180.0516
254.0884
180.0516
238.0935
164.0567
192.0880

Isoxanthopterin

D-Neopterin

Xanthopterin

6-Biopterin

Pterin

6,7-Dimethylpterin

Precursor Ion
(m/z)

Pterin-6-carboxylic acid

Compounds

147.0672

119.0674

220.0789

163.0256

206.0815

163.0256

190.0334

Confirmation
Ion #1 (m/z)

175.0576

91.0745

178.0788

135.0263

190.0747

135.0263

162.0398

Confirmation Ion #2
(m/z)

0.5-5,000

0.5-10,000

0.5-10,000

0.8-10,000

0.1-10,000

3-10,000

0.5-5,000

Linear Range
(µg/L)

0.9985

0.9996

0.9994

0.9999

0.9997

0.9994

0.9994

R2

0.5

0.5

0.5

0.8

0.1

3

0.5

Method
Detection
Limit (µg/L)

10.96

9.97

9.55

9.50

9.42

8.87

8.61

Retention
Time (min)

Table 2. Monitored masses, linear range, linearity, method detection limits, and retention times of seven selected pteridines for
quantitative analysis
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A representative chromatogram, including separation of the structural isomers,
xanthopterin and isoxanthopterin, was shown in Figure 3. In addition, significant
equilibriation volumes were required for reproducible separations involving real cell
lysates, necessitating longer 25 minute run-to-run times. Peak resolution also decreased as
a result of the larger column, indicating that smaller HPLC and UPLC columns with more
efficient packing may further improve method separation. Nevertheless, it is clear from
Figure 3 that the quantitatively measured, structural isomers xanthopterin and
isoxanthopterin remained completely resolved. Moreover, matrix interference concerns
were further minimized through high resolution QTOF MS and MS/MS monitoring with
20 ppm symmetric expansions to facilitate compound identification and confirmation.

Figure 3. Overlaid extracted ion chromatograms (EIC) of seven quantitatively monitored
pteridine derivative standards at nominal concentrations of 100 µg/L.

3.4. Method Performance
Method performance parameters for the seven quantitatively monitored pteridine
derivatives were determined in similar extraction solvent matrices without the presence of
cell lysate material which presented matrix reproducibility challenges. Hence, possible
matrix effects were not present for this component of the study, but were quantitatively
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evaluated later in the real cell study. Under the optimized HPLC-QTOF MS conditions,
calibration curves for all seven quantitatively monitored pteridines were constructed to
demonstrate linearity under a broad analytical range. As shown in Table 2, all seven
pteridines performed linearly over multiple orders of magnitude with linear regression
coefficients (R2) above 0.9985. Moreover, the method was found to be highly sensitive
with method detection limits ranging from 0.1 to 3 µg/L and limits of quantitation ranging
from 0.1 to 10 µg/L. These detection limits were comparable to previously reported
pteridine detection limits with fluorescence detectors and mass spectrometry techniques.
In addition, spiked recoveries were performed at low (10 µg/L), medium (100 µg/L) and
high (1,000 µg/L) concentrations to determine technique precision and reproducibility. The
data in Table 3 demonstrated high recovery accuracies ranging from 94.5% to 109.4% with
deviations ranging from 1.2 to 5.4% RSD. These figures of merit indicated the quantitative
HPLC-QTOF MS technique is both accurate and precise as well as comparable to other
pteridine analyses developed for biological fluid analysis.

Table 3. Triplicate spiked recovery results of seven selected pteridines at three varying
concentrations.
Low (10 µg/L)
Compound

†

Medium (100 µg/L)

High (1000 µg/L)

Recovery

RSD

Recovery

RSD

Recovery

RSD

D-Neopterin

109.4

4.0

105.4

3.5

102.9

2.8

6-Biopterin

104.5

3.8

105.1

3.2

101.7

2.4

Xanthopterin

94.7

3.4

102.4

4.4

97.8

2.7

Pterin

98.7

2.1

95.1

3.0

95.6

3.4

Isoxanthopterin

100.2

3.7

102.1

4.3
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3.9

6,7-Dimethylpterin
Pterin-6-carboxylic
acid

105.7

5.4

103.2

5.2

97.8

4.2

94.5

4.2

95.7

3.4

95.9

4.7

All values are presented as a percentage (%).

100
3.5. Application to Real Cell Cultures
The newly developed extraction and HPLC-QTOF MS methods were applied to
real cell cultures to demonstrate method validation and feasibility. A549 adenocarcinomic
human alveolar basal epithelial cells were selected as a useful model due to their
widespread occurrence in biomedical research, consistent cell growth and size, and relative
ease of culturing. Biological and analytical triplicate cell cultures were examined to provide
quantitative figures of merit for the combined extraction and quantitative techniques.
Summarized results have been shown in Table 4. Under the optimized conditions, all 25
selected pteridine derivatives except oncopterin (expected 295.15131 m/z) were detected.
The presence of an unidentified system peak centered at 294.13091 m/z with significant
[A+1] and [A+2] isotopic ions obfuscated possible oncopterin signals. Moreover, all seven
quantitatively monitored pteridines were quantifiable from the cell lysate except neopterin
and isoxanthopterin which was generally detected but unquantifiable with an average
signal-to-noise ratio (SNR) of 2.1. Among the semi-quantitatively monitored pteridine
derivatives, 12 were identified by the elution of a single peak at the expected precursor ion
using a 20 ppm symmetric expansion as well as confirmation by MS/MS fragmentation
and comparison with MS/MS spectra provided in the Human Metabolome Database.
Multiple elution peaks and lacking relevant MS/MS fragmentation spectra complicated the
confirmation of six additional pteridine derivatives. For these compounds, all elution peaks
for a respective precursor ion were monitored for the purpose of this study. The inability
to confidently confirm these particular pteridine derivatives with MS/MS spectra reflects
the often poorly studied nature of many of these compounds within broader mass
spectrometry applications. Further study of these compounds is therefore urgently required.
Combined technique reproducibility among the pteridine derivatives was nevertheless
generally good with an average RSD of 12%. Accuracy limitations related to the cell
hemocytometer and incomplete trypsin solution removal during the extraction process may
further improve technique reproducibility and accuracy. Nevertheless, these data indicated
the newly developed technique was suitable and useful for broad intracellular pteridine
profiling from cell lysates.
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Table 4. Summarized results of 25 intracellular pteridine derivatives in A549 cells
Retention
Time (min)

Average Peak
Area

RSD2

Oncopterin

N/A

N/A

N/A

-

Pterin-6-carboxylic Acid

8.61

6280

22.32

111

6-Hydroxymethylpterin

8.64

66838

19.76

-

6-Hydroxylumazineb

8.66

67828

1.98

-

6-Formylpterin1

8.75

21702

5.06

-

Monapterind

8.87

14224

4.92

-

7,8-Dihydroneopterin1

8.92

39599

13.31

-

7-Hydroxylumazineb

8.95

52077

19.81

-

Lumazine1

9.00

21733

1.03

-

Sepiapterinc

9.05

23446

30.68

-

6-Formylpterin-21

9.41

5410

68.29

-

Neopterind

9.42

4199

6.92

<MDL

7,8-Dihydroneopterin-21

9.62

361

17.61

-

Isoxanthopterina

9.76

4426

24.27

<MDL

5,6,7,8-Tetrahydroneopterin

9.78

2050489

5.27

-

6-Biopterinc

9.87

20780

4.69

379

Biolumazine

9.98

2928486

9.56

-

5,6,7,8-Tetrahydrobiopterin

9.99

195769

10.82

-

7,8-Dihydrobiopterin

10.00

7386079

8.92

-

7,8-Dihydropterin

10.10

20807

8.45

-

6-Methylpterin1

10.22

2599

79.85

-

Xanthopterina

10.22

8371

3.25

475

7,8-Dihydroxanthopterin1

10.25

84546

14.99

-

Pterin

10.27

13786

13.85

280

6-Formylpterin-31

10.27

82467

8.81

-

Lumazine-21

10.28

7098

27.79

-

6,7-Dimethylpterin

10.96

4107

15.36
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5,6,7,8-Tetrahydropterin1

11.39

8844

8.15

-

6-Methylpterin-21

11.54

19914

4.67

-

6,7-Dimethyltetrahydropterin1

13.32

44649

17.46

-

6-Methylpterin-31

13.42

12646

14.59

-

5,6,7,8-Tetrahydropterin-21

13.49

55897

22.62

-

7,8-Dihydroneopterin-31

13.49

16328

9.61

-

6,7-Dimethyltetrahydropterin-21

14.92

211973

7.67

-

Compound

7,8-Dihydroxanthpterin-21

19.43
1607940
27.08
These pteridines are structural isomers with equivalent precursor ion exact masses.

a-d

1

The identities of these compounds were not confirmed after database lookup.

2

All values are presented as a percentage determined from analytical triplicates.

Intracellular
Conc. (nM)

-
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In addition, the intracellular concentrations of the seven quantitatively monitored
pteridine derivatives were determined. Molar concentrations within the 1 mL extract were
converted to moles pteridine derivative and normalized by the estimated number of cells
determined by the manual hemocytometer to yield average moles pteridine per cell. An
average A549 cytosolic volume of 1204 µm3 was finally used to determine average molar
pteridine concentrations per cell.[34] Selected intracellular pteridine concentrations ranged
from 1 nM to 1000 nM. Limited data concerning absolute intracellular pteridine
concentrations rendered literature comparisons difficult. Total biopterin has been reported
in hepatocytes using HPLC-FD near 9.0 µM with BH4 comprising nearly 8.6 µM and
dihydrobiopterin (BH2) comprising the remaining 0.4 µM [35]. Fismen et al reported
similar BH4 values in HUVEC cells with an HPLC-MS/MS technique while also reporting
negligible BH2 and biopterin content [20]. The BH4, BH2, and biopterin levels reported
herein appeared to be in agreement with these previous studies. For example, while this
study successfully detected biopterin from the cell lysates, the reported levels were beneath
the detection limits reported by these previous studies. Similarly, BH2 and BH4 were also
reported herein with vastly higher peak areas than biopterin, although the semi-quantitative
nature of their analysis and their co-elution under the given conditions limited further
comparisons. While co-elution and differences in ionization efficiencies may limit the
extent of this observation, there is some evidence of non-specific oxidation of BH4 to BH2
based on reportedly higher BH2 peak areas in this study. EDTA may therefore serve as a
useful addition to the extraction solvent to chelate free metal ions to improve reduced
pteridine derivative quantitative analyses [20, 36]. In addition to biopterin, reported
intracellular xanthopterin levels compared well with previously reported xanthopterin
levels in red blood cells [37]. With respect to neopterin, Werner and colleagues also
reported undetectable neopterin levels in A549 cells using HPLC-FD and oxidative
treatment [29]. Curiously, fully reduced 5,6,7,8-tetrahydroneopterin generated a significant
peak, although its occurrence merits further study. The abundant prevalence of biolumazine
was also unexpected and is most likely a result of its co-elution with BH2 and BH4. The
general agreement between the intracellular pteridine levels reported in this study and
others supported the accuracy and precision of the newly developed extraction and
quantitation techniques. Moreover, the intracellular pteridine detection method described
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herein provides several distinct advantages over previous techniques. First, these data
indicate significantly broadened application potential by enabling quantitative analysis of
reduced and oxidized pteridine derivatives. This marks a substantial improvement over
previous intracellular pteridine techniques that typically examine no more than three
pteridine derivatives. This technique may therefore be applied to multiple cell lines to
generate novel pteridine profiles to generate new biological hypotheses and to discover
new pteridine-based biomarkers for pathological conditions. In addition to quantitatively
monitoring selected pteridine derivatives in perturbed metabolic pathways, additional
pteridine derivatives may now be semi-quantitatively monitored without the need for
expensive and difficult-to-obtain chemical standards. Second, the utilization of a chemical
stabilizer through DTT absolves the need for oxidative pre-treatments that may destroy
useful reduced pteridine derivative information as well as minimizes the introduction of
procedural artifacts that may lead to inaccurate measurements. Finally, the authors note
that this component of the study did not aim to generate any biological hypotheses
concerning pteridine derivatives in pathological conditions.

4. CONCLUSIONS
A novel, specific, and sensitive extraction and HPLC-QTOF MS method was
developed for simultaneous analysis of seven intracellular pteridines with the ability to
semi-quantitatively monitor 18 additional, naturally-occurring pteridines which has not
been previously reported to the best of our knowledge. Additionally, multiple extraction
solvents and conditions were evaluated to provide an optimized pteridine extraction
protocol from cell lysates. Method validation through evaluation of spiked recoveries,
reproducibility (represented by RSD), MDLs, and application in A549 cell cultures
indicated the newly developed method was suitable for the detection of various pteridine
derivatives in endothelial cells with high precision and accuracy. This technique has
significantly advanced intracellular pteridine detection by substantially expanding the
number of pteridine derivatives that may be simultaneously detected, either quantitatively
or semi-quantitatively. Finally, this technique may be applied to cellular studies to generate
new biological hypotheses concerning pteridine physiological and pathological functions
as well as to discovery new pteridine-based biomarkers.
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ABSTRACT
Background: Urinary metallomics is presented here as a new “omics” approach that aims
to facilitate personalized cancer screening and prevention by improving our understanding
of urinary metals in disease.
Methods: Twenty-two urinary metals were examined with inductively-coupled plasma –
mass spectrometry in 138 women newly diagnosed with breast cancer and benign
conditions. Urinary metals from spot urine samples were adjusted to renal dilution using
urine specific gravity.
Results: Two urinary metals, copper (P-value = 0.036) and lead (P-value = 0.003), were
significantly elevated in the urine of breast cancer patients. A multivariate model that
comprised copper, lead, and patient age afforded encouraging discriminatory power (AUC:
0.728, P-value < 0.0005), while univariate models of copper (61.7% sensitivity, 50.0%
specificity) and lead (76.6% sensitivity, 51.2% specificity) at optimized cutoff thresholds
compared favorably with other breast cancer diagnostic modalities such as mammography.
Correlations found among various metals suggested potential geographic and dietary
influences on the urine metallome that warrant further investigation.
Conclusions: In summary, this proof-of-concept work introduces urinary metallomics as
a noninvasive, potentially transformative “omics” approach to early cancer detection.
Urinary copper and lead have also been preliminarily identified as potential breast cancer
biomarkers.

KEY WORDS
Breast cancer metallomics, urinary metallomics, ICP-MS, urinary lead, urinary copper,
noninvasive breast cancer screening
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1. INTRODUCTION
Metallomics is an emerging field concerned with the comprehensive analysis of
metal and metalloid species within a biological system [1, 2]. The extensive and essential
roles of metal and metalloids in pathophysiology lend suitability to metallomics as a novel
approach to disease detection and monitoring. For example, metalloproteins represent
approximately one third of the known proteome and have wide-ranging roles in
biologically important processes such as oxygen and electron transport, biosynthesis and
biodegradation, and hydrolysis of amides and esters, and others [3]. Metalloprotein
dysregulation is frequently associated with pathological status, such as metallothionein
overexpression in certain invasive ductal breast cancers [4-6]. Moreover, metal ions are
presumed to be highly regulated [7, 8] owing to their critical roles in maintaining cellular
redox status and regulating protein expression [9-11]. A comprehensive understanding of
metal content, speciation, localization and function under various pathophysiological
conditions is therefore becoming increasingly important in understanding disease
mechanisms and discovering novel diagnostic, prognostic, and therapeutic targets.

The role of metallomics in understanding breast cancer has led to novel insights
into metal functionality in breast cancer carcinogenesis and metastasis. For example,
copper hyperaccumulation in cancer cells is required for angiogenesis and tumor growth
[12]. Similarly, dysregulated copper transport leads to oxidative stress and perturbed cell
signaling pathways via the copper transport protein CTR1 while copper transport protein
CTR2 expression has been linked to breast cancer prognosis and cisplatin drug resistance
[13]. Intracellular copper additionally stimulates breast cancer metastasis via redox
regulation such as inducing reactive oxygen species generation in cellular structures
associated with cell motility [14]. Consequently, novel chemotherapy sensitizers that
function as redox modulators via copper(II) chelation have emerged [15]. Similarly,
intracellular zinc is physiologically highly regulated in order to maintain cellular redox
status [16], but becomes deregulated in breast tumors. Metallothioneins, antioxidant
proteins with high binding affinities for essential metals like copper and zinc, are also
poorly regulated in invasive ductal carcinomas [17], resulting in increased free cytosolic
zinc and copper ions [18]. Zinc importer protein overexpression and zinc
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hyperaccumulation have similarly been well documented in heterogeneous breast cancers
[18-22]. For these reasons, researchers have explored the utility of copper and zinc as
diagnostic biomarkers for breast cancer, such as low serum zinc [23] and high serum Zn/Cu
serum ratios [24]. Furthermore, divalent transition metals including copper, cobalt, lead,
mercury, tin, and chromium have been shown to activate estrogen receptor-α and
consequently cell proliferation [25]. Other metals, like lead, have been associated with
selenium antagonism, which minimizes the anti-carcinogenic effect of selenium, leading
to higher risk for developing breast cancer [26]. Together, these pathophysiological
metallomic changes provide a new molecular modality for earlier detection of aggressive
breast cancer.
Comprehensive metallomic screening techniques essential to discovering new
clinically useful metallomic biomarkers have become popular following advances in
advanced analytical techniques that have enabled researchers to study otherwise trace
metals in biologically relevant matrices. Inductively-coupled plasma – mass spectrometry
(ICP-MS) in particular has emerged as a powerful platform based on its unparalleled
sensitivity and throughput. Recent efforts have already used this approach to implicate high
lead, uranium [27] in addition to antimony and cadmium [28] in hair samples of breast
cancer patients. Urinary cadmium, another selenium antagonist, has recently been
proposed as a noninvasive indicator of breast cancer through multiplicative interactions
with selenium [29]. However, application of metallomics to urinalysis remains
underdeveloped, despite its distinct advantages that include reduced sample preparation
and noninvasive detection modality. While concentration ranges of many urinary metals in
healthy populations have been widely reported, other trace elements and concentration
ranges in clinically relevant populations, such as women with newly diagnosed breast
cancer or with suspected breast cancer, have yet to be described or critically reviewed. This
study therefore examined 22 urinary metals using ICP-MS in a proof-of-concept study
involving 138 women with newly diagnosed breast cancer and benign conditions in order
to quantify the clinical applicability of urinary metals in breast cancer detection and
prognosis.
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2. MATERIALS AND METHODS
2.1. Patients and specimens
A total of 138 women 33-84 years of age were recruited to provide urine specimens
for this proof-of-concept study and other studies at the Mercy Breast Center - Springfield
(Springfield, Missouri) between July 2013 and December 2014. Study protocol was
approved by the Mercy Medical Research Institute Institutional Review Board (IRB) and
participants were required to provide informed consent. Inclusion criteria for participants
included new referrals to the Mercy Breast Center - Springfield following possible
indication for breast cancer that required further biopsy and immunohistochemical
characterization. Exclusion criteria included individuals with a previous history of cancer
and/or any known comorbidities. All women resided in the Southwest Missouri region
which is a predominate lead and zinc mining area. Additional demographic, metal
exposure, and patient health information were not collected owing tothe retrospective
nature of this study. Spot urine specimens comprising first morning and second morning
voids were collected for the study and immediately stored at -20°C for 1-6 days at Mercy
Breast Center – Springfield followed by shipment to Missouri University of Science and
Technology via next-day frozen ground freight for analysis. Urine aliquots were stored at
-80°C and underwent 2-4 freeze/thaw cycles prior to analysis which occurred 1-6 months
after specimen collection. Urinary metals were shown to be freeze/thaw resistant with
minimal metal adsorption on container walls after five freeze/thaw cycles across six
months storage at -80°C. Patient diagnoses were independently determined by qualified
Mercy Breast Center – Springfield staff using a combination of ultrasound-guided core
biopsies and pathological stains. The study was conducted in a double-blind manner. Data
and resources including patient urine specimens, pathological reports, and metallomic
results were anonymized with numerical identifiers.

2.2. ICP-MS Urinary Metal Assay
Twenty-two urinary metals including vanadium (V), chromium (Cr), manganese
(Mn), cobalt (Co), nickel (Ni), copper (Cu), zinc (Zn), gallium (Ga), arsenic (As), selenium
(Se), rubidium (Rb), strontium (Sr), molybdenum (Mo), silver (Ag), cadmium (Cd), tin
(Sn), antimony (Sb), cesium (Cs), barium (Ba), tellurium (Tl), lead (Pb), and uranium (U)
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were quantified using a previously described ICP-MS technique with several significant
modifications [30]. Briefly, 2 mL urine specimen aliquots were equilibrated to room
temperature and diluted fivefold with 1% Optima grade nitric acid (Fisher Scientific Inc,
#A467-1) and internal metal standards 45Sc, 89Y, and 159Tb (PerkinElmer Inc, N9303834)
in nitric acid pretreated sample tubes. Two calibration standard mixtures (PerkinElmer Inc,
N9300233 and N9301721) comprising the 22 metals were used for instrument calibration.
Samples were injected into a NexION 350D ICP-MS (PerkinElmer Inc) using an
autosampler and peristaltic pumps. The ICP-MS was operated in kinetic energy
discrimination (KED) mode using ultra-high purity helium with a flow rate of 3.9 mL/min
for As and Se, and 4.7 mL/min for other metals to minimize polyatomic interferences that
may arise in complex urine matrices. Quantitation isotopes included 51V, 52Cr, 55Mn, 59Co,
60

Ni, 63Cu, 66Zn, 69Ga, 75As, 77Se, 85Rb, 88Sr, 97Mo, 107Ag, 111Cd, 118Sn, 121Sb, 133Cs, 137Ba,

205

Tl,

208

Pb, and

238

U, while confirmation isotopes included

53

Cr,

62

Ni,

65

Cu,

68

Zn,

82

Se,

86

Sr, 95Mo, 110Cd, 117Sn, 123Sb, 135Ba, 203Tl, 206Pb, and 235U. ICP-MS operational parameters

included: RF power, 1600 W; plasma gas flow, 18 L/min; auxiliary gas flow, 1.20 L/min;
and nebulizer gas flow: 1.06-1.08 L/min. Urinary metal concentrations were adjusted by
internal standard responses and dilution.

Urinary metals were quantified over an element dependent linear range from 0.01
µg/L to 100 µg/L using matrix-matched calibration standards. Matrix-matched calibration
standards were prepared using fivefold synthetic urine (CST Technologies Inc, UriSub®)
to mimic the high salt content and formation of polyatomic interferences in real urine
specimens. A freeze-dried reference urine standard (UTAK Laboratories Inc, Product
#12110) with certified metal concentrations was also used as an indicator of trueness.
Duplicated samples and spiked recoveries of urine specimens were additionally used to
measure reproducibility and accuracy of the technique. Method accuracy ranged from 87%
to 127% at biologically relevant concentrations (Table 1) while intra- and inter-run
reproducibility were calculated as 1-7% and 2-12% relative standard deviation,
respectively. Metal concentrations measured below the limit of quantitation (LOQ) were
taken as one half the quantitation limit (LOQ/2) for statistical analysis.

b

a

Tb

159

Y

89

Sc

45

0.29
0.19
0.11
0.30
0.04
0.26
0.35
0.02
0.03
0.02
0.03
0.01
0.34
0.002
0.01
0.002

0.09
0.07
0.32
0.01
0.09
0.14

Quantification
Limita
(μg/L)

N/A
3.96
55.3
N/A
N/A
71.9
N/A
0.04
N/A
N/A
N/A
N/A
N/A
0.29
N/A

517

UTAK
Certified
Value
(μg/L)
0.08
1.18
0.84
0.68
2.29
25.2

UTAK
Measured
Valueb
(μg/L)
<LOQ
1.33 (0.11)
1.07 (0.09)
0.69 (0.04)
2.40 (0.13)
25.78 (1.20)
498.60
(17.58)
N/A
5.64 (0.21)
48.01 (4.92)
N/A
N/A
67.62 (1.69)
N/A
<LOQ
N/A
N/A
N/A
N/A
N/A
0.30 (0.04)
N/A
N/A
142
87
N/A
N/A
94
N/A
<LOQ
N/A
N/A
N/A
N/A
N/A
103
N/A

96

<LOQ
113
127
101
105
102

Accuracy
(%)

Quantification limits were calculated as 10×STD of seven replicates and not adjusted for dilution.
Measured values are expressed as mean (SD) for triplicate samples.

75

Ga
As
77
Se
85
Rb
88
Sr
97
Mo
107
Ag
111
Cd
118
Sn
121
Sb
133
Cs
137
Ba
205
Tl
208
Pb
238
U

69

Zn

66

52

V
Cr
55
Mn
59
Co
60
Ni
63
Cu

51

Analyte

Internal
Standard

105
153
80
100
95
99
88
102
103
103
100
102
98
100
98

107

98
96
98
97
98
96

Spiked
Recovery
(%)

Table 1. Method performance parameters for the detection of 22 urinary metals using ICP-MS operating in KED mode.
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2.3. Urine specific gravity assay
Urinary metals were adjusted for patient hydration-dilution status using urine
specific gravity (USG). Conventional creatinine normalizations were excluded since
urinary creatinine varies with age [31], diet [32], physical activity [33], and presence of
breast cancer [34]. USG was measured using a temperature-corrected Reichert TS 400
clinical refractometer. Bulk urine specimens were allowed to equilibrate to room
temperature followed by analysis of a 200 µL aliquot. Ultra-pure water (USG = 1.000) and
synthetic urine (USG = 1.022) of known specific gravity were used as reference standards.
USG was measured with inter- and intra-assay RSDs of 0.12% and 0.04%, respectively.
Biomarker concentrations were adjusted to USG using the Levine-Fahy equation and a
reference USG of 1.020:
𝐶𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 = 𝐶𝑟𝑎𝑤 ×

𝑈𝑆𝐺𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 − 1
𝑈𝑆𝐺𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 − 1

where Ccorrected is the adjusted analyte concentration, Craw is the uncorrected analyte
concentration, USGreference is a reference USG for a given population, and USGexperimental is
the measured USG.

2.4. Statistical analyses
Anderson-Darling normality tests indicated non-normal distributions for all 22
urinary metals (Anderson-Darling > 3.5, P < 0.005), while log10 transformation failed to
approximate the normal curve (Anderson-Darling > 3.0, P < 0.005). For this reason,
nonparametric analyses were performed on untransformed USG-adjusted metal
concentrations and the covariates USG and patient age. Mann-Whitney U analyses were
used to compare women newly diagnosed with breast cancer and benign conditions.
Kruskal-Wallis and Dunn’s multiple comparisons tests were used to compare urinary metal
concentrations across individual carcinoma types and grades. Correlations among different
urinary metals and clinicopathological factors were measured with Pearson correlations.
Logistic regression analyses were used to generate classification models, compute oddsratios, and construct receiver-operating characteristic (ROC) curves for metals that were
found to be associated with breast cancer. Odds-ratios were computed using interquartile
range (IQR) increments for each covariate. The ROC curves evaluated the potential of each

117
classification model to distinguish invasive breast cancer across all thresholds and were
constructed by plotting sensitivity vs. 1-specificity. Statistical uncertainty was quantified
with 95% confidence intervals where appropriate. A P-value below 0.05 was considered
statistically significant.

3. RESULTS
3.1. Patient Population
One hundred thirty-eight urine specimens were collected among which seven were
excluded for being overly dilute or concentrated, defined as having a USG value below
1.003 or above 1.030, respectively. These cutoff thresholds were selected based on the
diminished ability of USG to accurately model patient hydration-dilution status beyond
these points [35]. The remaining 131 eligible patients were classified as 79 (60%) women
diagnosed with benign fibroadenomas, fibrocystic changes, benign papillomas, and stromal
fibrosis, and 52 (40%) women with newly diagnosed breast carcinomas. Carcinomas were
further characterized as comprising 12 ductal carcinomas in situ (DCIS), 38 invasive ductal
carcinomas (IDC), and 2 invasive lobular carcinomas (ILC) (Fig. 1).

Figure 1. Patient enrollment flowchart including excluded specimens.
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Low-grade DCIS cases (n = 5) were considered pre-invasive, indolent disease [36],
which resulted in their classification as a benign condition. The retrospective nature of this
study, whereby samples were originally collected for a different purpose, precluded the
inclusion of healthy, age-matched controls. As a proof-of-concept study, the benign cases,
which lacked known comorbidities, previous history of cancer, and had pathologically
confirmed absence of breast cancer were used as approximate controls. However, future
studies should include healthy control populations since urinary metals may associate with
benign conditions of the breast.

3.2. Association of Urinary Metals with Breast Cancer
Urinary metal concentrations encountered in the two patient groups were
summarized in Table 2. All 22 urinary metals were reliably detected by the ICP-MS
analysis with the exceptions of V, Mn, Ag, and U. Trace levels of Cr and Ga were also
unquantifiable (signal-to-noise < 10) in a majority of samples. Notably, the heavy metals
Cu (P-value = 0.036) and Pb (P-value = 0.003) were significantly elevated in the women
with newly diagnosed breast cancer. Weak associations from Cd (P-value = 0.163) in
addition to non-significant increases in Zn, Ba, and Rb were also observed. Patient age was
additionally considered a disease correlate (P < 0.0005) with means (SD) of 64.7 (10.9)
years in the breast cancer group and 56.7 (11.8) years in the benign group. Patient age was
not found to correlate with any of the urinary metals, which indicated that patient age was
not a confounding factor for the observed relationships between metals and breast cancer.
USG was not associated with presence of breast cancer and had a pooled mean (SD) of
1.013 (0.001).

Logistic regression models were used to evaluate the clinical performance of
various classification models in distinguishing invasive breast cancer. Univariate models
were independently developed for Cu (odds-ratio increment = 4.48 µg/L) and Pb (oddsratio increment = 0.368 µg/L) owing to their significant elevation in breast cancer patients.
Both Cu (odds-ratio: 1.77, 95% CI: 1.15-2.72, P-value = 0.008) and Pb (odds-ratio: 1.65,
95% CI: 1.14-2.40, P-value = 0.005) were found to be significant factors for having breast
cancer. A multivariate model that comprised Cu, Pb, and patient age (odds-ratio increment
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= 19 years) was additionally constructed where Cu (odds-ratio: 1.52, 95% CI: 0.95-2.43,
P-value = 0.079) and Pb (odds-ratio: 1.46, 95% CI: 0.97 – 2.18, P-value = 0.064) did not
significantly contribute to the regression line which was dominated by patient age (oddsratio: 2.77, 95% CI: 1.44-5.32, P-value < 0.0005).

Table 2. Comparison of USG-adjusted urinary metal levels in women with benign
conditions (n=84) and breast cancer (n=47). All data are expressed as median (IQR).
LOQa

Cancer Patients

Benign Patients

(µg/L)

(µg/L)

(µg/L)

V

0.45

<LOQ

<LOQ

N/A

52

Cr

0.35

0.175 (0.175-0.580)c

0.175 (0.175-0.424)c

0.541

55

Mn

1.60

<LOQ

<LOQ

N/A

0.05

0.316 (0.235-0.439)

0.254 (0.191-0.431)

0.405

60

Ni

0.45

1.28 (0.99-2.75)

1.54 (0.99-2.39)

0.730

63

Cu

Metal
51

59

Co

0.70

9.35 (7.43-13.61)

8.47 (6.92-10.46)

0.036

66

Zn

1.45

447 (286-757)

386 (263-664)

0.272

69

Ga

0.95

0.475 (0.475-1.152)c

0.475 (0.475-1.047)c

0.310

75

As

0.55

4.15 (2.94-6.34)

4.28 (2.74-6.44)

0.981

77

Se

1.50

36.66 (29.07-53.26)

38.92 (29.64-49.10)

0.726

85

Rb

0.20

1318 (1104-1747)

1239 (958-1819)

0.330

Sr

1.30

123.43 (84.27-162.41)

123.00 (80.45-167.46)

0.814

Mo

88
97

1.75

38.43 (26.43-56.69)

42.33 (29.85-70.92)

0.420
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Ag

0.10

<LOQ

<LOQ

N/A

111

Cd

0.15

0.669 (0.440-1.262)

0.611 (0.472 – 0.885)

0.163

118

0.10

0.482 (0.191-1.475)

0.469 (0.137-1.005)

0.467

121

Sb

0.15

0.163 (0.075-0.234)

0.075 (0.075-0.210)

0.348

133

Cs

0.05

6.01 (5.25-8.57)

6.58 (4.56-9.00)

0.950

137

Ba

Sn

1.70

2.82 (0.85-4.71)

2.19 (0.85-3.38)

0.205

205

Tl

0.01

0.165 (0.131-0.223)

0.175 (0.129-0.256)

0.781

208

Pb

0.05

0.578 (0.395-0.876)

0.388 (0.260-0.597)

0.003

0.01

<LOQ

<LOQ

N/A

238

U

a

P-valueb

LOQs and urinary concentrations were adjusted by a 5-fold dilution factor.

b

P-values represent group comparisons between women newly diagnosed with breast
cancer and benign conditions using nonparametric Mann-Whitney U analyses.
c

Unquantifiable levels of Cr, Ga, Sb, and Ba in some samples were taken as LOQ/2..
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ROC analysis suggested clinical performance of individual models was ordered as
follows: Cu < Pb < Patient Age < Multivariate Model (Fig. 2). Specifically, Cu poorly
distinguished invasive breast carcinomas across all thresholds (AUC: 0.611, 95% CI:
0.510-0.712, P-value = 0.035) while Pb demonstrated slightly improved discriminatory
power (AUC: 0.659, 95% CI: 0.562-0.756, P-value = 0.003). Although patient age
possessed marginally better discriminatory power (AUC: 0.685, 95% CI: 0.593 – 0.778, Pvalue < 0.0005), the combined multivariate model provided optimal results (AUC: 0.728,
95% CI: 0.641-0.816, P-value < 0.0005). The univariate Cu and Pb models both had 19.2%
sensitivity (95% CI: 9.2%-33.3%) and 91.2% specificity (95% CI: 83.6%-96.6%) while
the multivariate model afforded 36.2% sensitivity (95% CI: 22.7%-51.5%) and 88.1%
specificity (95% CI: 79.2%-94.1%). While characteristic performance permits objective
classification model ranking, clinical applicability is better assessed at optimal cutoff
thresholds. To this end, Cu had 61.7% sensitivity (95% CI: 46.4%-75.5%) and 50.0%
specificity (95% CI: 38.9%-61.1%) using a cutoff of 8.50 µg/L, while Pb had 76.6%
sensitivity (95% CI: 62.0%-87.7%) and 51.2% specificity (95% CI: 40.0%-62.3%) using
an optimal threshold of 0.400 µg/L.

Figure 2. ROC data comparing incremental increases in diagnostic performance for the
univariate models of Cu and Pb and the multivariate model comprising Cu, Pb, and patient
age in women newly diagnosed with breast cancer (n=47) and benign conditions (n=84).
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3.3. Correlations among urinary metals and clinicopathological factors
It was also of interest to identify potential correlations among different urinary
metals to better understand exposure routes and possible pathophysiological mechanisms.
Significant correlations (|Pearson r| > 0.3, P-value < 0.05) among different urinary metals
were summarized in Table 3. Notably, twice as many correlations were noted in breast
cancer patients compared with women with benign conditions, although this finding may
result from the limited sample size of the breast cancer group. Among the benign condition
group, interactions among Ba, Sr, and Ga were the strongest. Moderate correlations
included those between Cu with Ni, Zn, and Cs in addition to those among trace essential
metal Se with Zn and Cu, and heavy metal Sn with Co and Zn. The correlations from the
breast cancer subgroup were markedly different from those observed in the benign
condition group, although strong interactions among Ba, Sr, and Ga were similarly
observed. Urinary Cd was correlated with several heavy metals including As, Zn, Sb, Tl,
Rb, and Cu. The heavy metal Cr was also found to be correlated with Sn, Ni, Se, and Sb.
Urinary Pb was correlated with Se, Ni, and Zn. Correlations among USG, patient age, Cu,
and Pb also suggested Pb was weakly correlated with both USG (r = 0.201, P-value =
0.021) and age (r = 0.178, P-value = 0.042).

Prognostic immunohistochemical factors including progesterone receptor status,
estrogen receptor status, Her-2/neu, and Ki67 cell proliferation marker for the 45 invasive
breast cancers were compared with the 22 urinary metals to identify possible prognostic
capabilities. Urinary As was found to have a weak inverse relationship with progesterone
receptor status (r = -0.294, P-value = 0.023) and Her-2/neu (r = 0.362, P-value = 0.028).
Other correlations included Sr and estrogen receptor status (r = 0.340, P-value = 0.037),
Mo and Her-2/neu (r = -0.350, P-value = 0.034), and Cd and estrogen receptor status (r =
-0.334, P-value = 0.04). Urinary Pb correlated moderately with estrogen receptor status (r
= -0.441, P-value = 0.006), progesterone receptor status (r = -0.315, P-value = 0.044), and
Ki67 (r = 0.385, P-value = 0.017).
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Table 3. Significant correlations among USG-adjusted urinary metals.
Benign Conditions
Correlation

Pearson
Correlation, r

Breast Cancer
P-value

Correlation

Pearson
Correlation, r

P-value

Sn-Zn

0.305

0.005

Zn-Cu

0.304

0.038

Sn-Co

0.307

0.004

Cd-As

0.318

0.029

Mo-Se

0.307

0.005

Zn-Ni

0.323

0.027

Cs-Sr

0.307

0.004

Cd-Zn

0.325

0.026

Cs-Rb

0.333

0.002

Pb-Se

0.327

0.025

Se-Cu

0.347

0.001

Sn-Cr

0.337

0.020

Se-Zn

0.365

0.001

Sb-Cu

0.357

0.014

Sb-Mo

0.381

<0.0005

Cs-Rb

0.359

0.014

Cu-Ni

0.427

<0.0005

Sn-Cu

0.360

0.013

Tl-Sr

0.433

<0.0005

Ni-Cr

0.371

0.010

Cs-Cu

0.470

<0.0005

Mo-Sr

0.384

0.008

Zn-Cu

0.506

<0.0005

Mo-Se

0.391

0.007

Sr-Ga

0.543

<0.0005

Ba-Se

0.394

0.006

Ba-Sr

0.666

<0.0005

Ni-Cu

0.415

0.004

Ba-Ga

0.874

<0.0005

Pb-Ni

0.415

0.004

Sr-Ga

0.419

0.03

Se-Cr

0.422

0.003

Sb-Cd

0.431

0.002

Cs-Co

0.433

0.002

Pb-Zn

0.443

0.002

Sb-Ni

0.457

0.001

Tl-Cd

0.462

0.001

Sn-Ni

0.510

<0.0005

Sb-Cr

0.528

<0.0005

Se-Zn

0.551

<0.0005

Cd-Rb

0.581

<0.0005

Ba-Sr

0.652

<0.0005

Cd-Cu

0.656

<0.0005

Ba-Ga

0.838

<0.0005
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Finally, the correlation between Pb and Cu with cancer progression was explored
using Kruskal-Wallis analyses and Dunn’s multiple comparisons tests. The highly limited
sample size of the DCIS subgroups warrant cautious interpretation of their results. Urinary
Pb levels were arranged in the following order: Benign Condition < Grade 3 DCIS < Grade
1 DCIS < Grade 2 DCIS < Grade 1 IDC ≤ Grade 2 IDC < Grade 3 IDC. The difference
between Grade 3 IDC and benign conditions was most significant (Dunn’s multiple
comparisons P-value = 0.0006). Similarly, urinary Pb was weakly correlated with cancer
grade using cancer grade as a continuous variable (r = 0.265, P-value = 0.002). No
significant differences among cancer grades were noted for urinary Cu, which was ranked
in the following order: Benign conditions < Grade 2 DCIS < Grade 1 DCIS < Grade 1 IDC
< Grade 3 DCIS < Grade 2 IDC < Grade 3 IDC. Weak correlations between urinary Cu
and continuous variable cancer grade (r = 0.254, P-value = 0.003) were similarly noted.

4. DISCUSSION
We investigated 22 urinary metals in women newly diagnosed with breast cancer
and benign conditions in a proof-of-concept study to determine whether urinary
metallomics may serve as a useful platform for biomarker discovery. In this study, two
metals, copper and lead, were encountered at significantly elevated levels in the urine of
breast cancer patients. This finding is consistent with a growing body of literature
concerned with in vivo metallomics of breast cancer tissue. For example, copper
hyperaccumulation occurs in breast carcinomas [12] through dysregulated copper transport
proteins [13]. Importantly, the association of urinary copper with high-grade breast cancers
in particular appeared to reflect copper-based mechanisms related to cancer motility in
metastatic breast carcinomas [15]. Elevated urinary lead concentrations were similarly
more pronounced in high-grade breast carcinomas. Environmental lead exposure, a salient
consideration for our study population, is associated with risk for developing breast cancer
while recent work has suggested that lead functions as a selenium antagonist that
competitively binds selenium [26]. The significant indirect correlation between lead and
selenium in breast cancer patients observed in this study appears to support this proposed
mechanism. While urinary cadmium weakly associated with breast cancer, no
multiplicative interactions with selenium were observed (r = -0.02, P-value = 0.82) as
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previously cited, presumably due to substantial differences in environmental cadmium
exposure between our study population and that of Wei [29]. Although univariate
classification models for copper and lead demonstrated limitations in breast cancer
diagnostics, the multivariate model that included patient age performed remarkably well.
The clinical performance of copper and particularly lead at optimized cutoff thresholds
compared favorably with other breast cancer diagnostic modalities such as clinical breast
examinations and mammography [37]. This diagnostic performance appears promising
given the inexpensive and noninvasive character of urinary metal screening. However, the
authors acknowledge the limited sample size of this study and point out that larger clinical
studies are required to validate these preliminary findings.

Moreover, our results suggest that diagnostic performance may be further improved
through enhanced understanding of metal and metalloid exposure routes. For example,
numerous correlations among various metals in this study provided pertinent information
regarding common exposure routes that include dietary intake, residential exposure,
occupational exposure, and more broadly, environmental exposure. For instance, barium,
strontium, and gallium, which together represented the strongest metal-metal correlations,
are typically co-present in ore-bearing rock. The interaction between nickel and copper
among other interactions may be similarly attributed to shared geochemical distribution
[38]. Although this study was not designed to evaluate the influence of local mineralogy
on urinary metal epidemiology, we feel it necessary to mention that geochemical
distributions likely represent a major determinant of biometal concentrations. Supporting
this claim is a comparison of previously reported urinary metal concentrations in baseline
populations and those reported from our southwest Missouri cohort which demonstrates
that while many essential metals obtained primarily from dietary exposure were in good
agreement [39, 40], trace and toxic metals like cadmium varied considerably [29].
Differences arising from unique local geochemistry will additionally be influenced by
environmental regulations. For example, the similar urinary lead values reported in our
study population compared with other reported industrialized country populations likely
reflects lead removal from drinking water. Further investigations into local geochemical
distributions and metallomic correlations will be needed to qualify these considerations.
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Finally some correlations, such as those between copper, zinc, and nickel, may additionally
reflect dietary supplement use and other dietary fortifications. Hence, characterization of
the exposure routes to urinary metals of interest is critical to advancing urinary metal
molecular pathological epidemiology.
Finally, the correlations between urinary metals and clinicopathological factors
provided new insights into disease mechanisms and clinical applicability of urinary metals
in breast cancer patients. Notably, both copper and lead correlated weakly with cancer
progression and peaked in high-grade IDC patients. This observation suggests copper and
lead may have applicability in the detection of early stage breast cancer, an observation
that merits further investigation. The ability to detect early stage breast cancer is especially
critical given the potential to reduce tumor upstaging and improve patient mortality.
Finally, several metals and particularly lead were shown to have potential use in
prognostics. Because prognostic capability was not directly quantified, future studies
should aim to quantitatively assess urinary metals for their ability to predict breast cancer
outcome. Such a finding would render urinary metals a valuable supplementary technique
for current immunohistochemical techniques.

5. CONCLUSIONS
In conclusion, this proof-of-concept study introduces urinary metallomics as a
noninvasive platform for biomarker discovery and clinical translational research. This
work provides new insights into the epidemiology of urinary metals in suspected breast
cancer cases. Specifically, this work highlights the potential of urinary copper and lead as
noninvasive diagnostic breast cancer biomarkers in addition to an array of urinary metals
with prognostic capabilities. Future studies should aim to improve understanding of the
relationship between urinary metals and source exposure, to measure the prognostic
capability of individual metals in prospective clinical studies, and to evaluate copper and
lead applicability to early stage breast cancer detection.
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ABSTRACT
Renewed interest in pteridine molecular pathology has generated new details on the
emerging clinical significance of urinary pteridines as putative disease biomarkers. Central
to these efforts is the need to understand the sources and extent of their nonepidemiological variation. In response, this study was designed to characterize two primary
sources of urinary pteridine variance: daily variation and the effect of dietary folate. Daily
variation was studied by collecting urine specimens (n = 81) three times daily for three
days. The effect of dietary folate was investigated in a treatment study in which urine
specimens (n = 168) were collected daily during a control week and a treatment week
during which participants received dietary folate supplements. Measurements of six
urinary pteridines were made using high-performance liquid chromatography – tandem
mass spectrometry. Coefficients of variation were calculated to grossly characterize daily
variance between and within subjects, while nearest neighbor non-parametric analyses
were used to identify diurnal patterns and measure dietary folate effects. This study
confirms that pteridines respond to circadian rhythms with urinary levels that typically
peak in the morning. Similarly this research corroborates previous findings that dietary
folate affects pteridines in a pathway dependent manner that likely impacts endogenous
neopterin and biopterin biosynthesis. Together with preliminary associations between
urinary pteridine levels and different activities, the findings of this study have been used to
gain new insights into the pteridine biosynthetic pathway and the impact of pteridine
variation on molecular epidemiology studies.

KEY WORDS
Urinary pteridines, daily variation, dietary folate, pteridine metabolism
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1. INTRODUCTION
The discovery of fluorescent pteridine derivatives in urine premised new analytical
methodologies for their quantitation and simultaneously renewed interest in understanding
their roles in human health and disease (Stea et al. 1978). Briefly, pteridine derivatives
constitute an extensive class of metabolites that are primarily involved in the biosynthetic
and biodegradation pathways of vitamins and cofactors (Kośliński et al. 2011). Many
pteridines additionally function as regulatory cofactors, such as tetrahydrobiopterin in
aromatic acid biosynthesis and endothelial vasodilation (Thony et al. 2000; Gross and Levi
1992) and neopterin as an agent of cellular immune response (Huber et al. 1983;
Reibnegger et al. 1987). Recent studies have provided new mechanistic insights into the
roles of these compounds in broader pathophysiological contexts. From these studies, it
has become increasingly clear that the unique physicochemical properties of pteridines,
such as their remarkable capacity to generate reactive oxygen species (Lorente et al. 2011;
Thomas et al. 2003; Cabrerizo et al. 2004; Petroselli et al. 2006) and even photosensitize
biologically important biomolecules including DNA (Denofrio et al. 2009; Serrano et al.
2015; Serrano et al. 2012), folic acid (Dántola et al. 2010), and tryptophan (Thomas et al.
2013), carry intriguing biological implications. For these reasons, the photosensitizing
aromatic pteridines derived from folic acid such as 6-carboxypterin, 6-formylpterin, 6hydroxymethylpterin (Fukushima and Shiota 1974) and their downstream derivatives like
xanthopterin and isoxanthopterin have recently come under intense investigation as
putative cancer biomarkers (Ma and Burton 2013). These pteridine biomarker development
efforts have primarily focused on the use of noninvasively monitored urinary pteridine
panels following promising indications from early molecular epidemiological studies
which have implicated these compounds in an assortment of malignancies, including lung
and colon cancers (Gamagedara et al. 2011), bladder cancer (Han et al. 1999; Kośliński et
al. 2014), breast cancer (Gamagedara et al. 2011; Burton et al. 2013, 2014), digestive tract
cancers (Konishi et al. 1999), and brain tumors (Manjula et al. 1993).

One of the key challenges facing pteridine biomarker development is the
determination of their non-epidemiological variation and the individual factors that
influence endogenous pteridine biosynthesis. Daily variation of urinary pteridine levels,
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which includes both diurnal fluctuations in response to circadian rhythms and day-to-day
variance related to microscale changes to feeding and physical activities, is particularly
salient in the context of urinary pteridine screening where spot urine specimen collection
times have varied widely across studies and the differences between pathological and
physiological urinary pteridine levels are often marginally significant (Burton et al. 2014;
Gamagedara et al. 2011). Biological variation, such as genetic heterogeneity, disease
status, environmental factors, as well as long-term lifestyle and dietary factors, has further
complicated efforts to characterize pteridine metabolism and molecular epidemiology.
While certain biological factors such as disease type and progression can be controlled in
well-designed clinical studies, other undetermined factors remain. Dietary folate in
particular has been suggested to function as a key source of biological variation (Burton et
al. 2014) owing to wide discrepancies in total daily folate intake and vitamin
supplementation across different demographic characteristics (Bailey et al. 2010). Finally,
analytical variance related to measurement imprecision is generally marginal with wellvalidated methods in the modern analytical laboratory with the advent of advanced
analytical techniques like tandem mass spectrometry. In this way, daily variation and the
effect of dietary folate on pteridines pose the greatest uncertainty to our understanding of
pteridine metabolism and molecular pathological epidemiology.

Therefore, the purpose of this study was to measure the primary sources of nonepidemiological pteridine variation: daily variation and dietary folate. Six urinary
pteridines, namely neopterin, 6-biopterin, pterin, 6-carboxypterin, xanthopterin, and
isoxanthopterin, were selected owing to their previously reported clinical significance to
disease detection and diagnosis (Gamagedara et al. 2011; Burton et al. 2014). Daily
variation was measured by collecting spot urine specimens at defined time points across
several days. Meanwhile, the effect of dietary folate was measured in a treatment study in
which baseline pteridine levels were determined from individuals during a control week
followed by a treatment week during which participants received daily folate supplements.
Daily urine specimens were collected at reproducible times during the folate study. To the
best of our knowledge, systematic investigations into the non-epidemiological sources of
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pteridine variation are generally lacking. The findings of this study in relation to pteridine
metabolism and its broader pathophysiological implications are discussed.

2. MATERIALS AND METHODS
2.1. Study population
A total of 30 individuals were locally recruited at Missouri University of Science
and Technology (Rolla, MO) to participate in this study between April and June 2015.
Selection criteria included healthy adults without known or suspected medical conditions,
no prior history of cancer, were not actively taking folate supplements, and were not
currently pregnant or planning to become pregnant during the study duration. Participants
were additionally asked to complete a questionnaire which evaluated current vitamin and
supplement use, currently used medications, self-assessed physical activity levels, and
participant height and weight. Study protocol was approved by the Missouri University of
Science and Technology Institutional Review Board (IRB) and informed consent was
obtained from all participants. Demographic composition included 50% females, 46.7%
Asian Americans, 40.0% Caucasians, 6.7% African Americans, and 6.6% Asian Indians.
The mean (SD) age of the participants was 27.3 (11.1) years. The mean weight (SD) of the
study population was 159 (26) lbs.

2.2. Daily variation study
Nine individuals were recruited for the specific purpose of quantifying both the
within-day and between-day variation of urinary pteridines. Midstream spot urine
specimens were collected from these individuals thrice daily consisting of (1) second
morning voids collected between 8 a.m. and 10 a.m., (2) mid-afternoon voids collected
between 12 p.m. and 2 p.m., and (3) evening voids collected between 6 p.m. and 8 p.m. for
a total of three days. At each collection, participants were asked to complete a daily log
that detailed feeding activity and self-assessed physical activity levels since the previous
collection point. Urine specimens (20-60 mL) were collected in sterile biological specimen
containers and immediately stored at -80°C for approximately one month after collection.
A total of 81 urine specimens were collected for this component of the study.
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2.3. Dietary folate effect study
Twenty-one individuals were recruited to study the effect of dietary folate on
urinary pteridine levels. This phase of the study was additionally designed to extend the
results of the diurnal variation experiment by measuring between-day variation across a
larger sample size for a longer period of time. In this experiment, participants were
instructed to provide a single midstream spot urine specimen at reproducible times daily
for two weeks (Monday – Friday). The first week served as a control to establish baseline
urinary pteridine levels for each individual. During the second week, participants were
given one 400 µg (100% recommended daily value) folate supplement. Urine specimens
were similarly collected in sterile biological containers and immediately frozen at -80°C
for approximately one month prior to analysis. Data from participants who missed two or
more collection points were excluded from analysis. A total of 168 urine specimens were
collected for this component of the study.

2.4. Urinary pteridine assay
Six urinary pteridines including xanthopterin (CAS #119-44-8), isoxanthopterin
(CAS #529-69-1), neopterin (CAS #2009-64-5), 6-biopterin (CAS #22150-76-1), pterin
(CAS #218-799-1), and 6-carboxypterin (CAS #948-60-7) were separated and quantified
by a high-performance liquid chromatography – tandem mass spectrometry (HPLCMS/MS) technique that has been described previously (Burton et al. 2013). Briefly, urine
specimens underwent an oxidative pretreatment to oxidize residual reduced pterin species
by treating a 100 µL aliquot of thawed urine prepared in 850 µL of ultra-pure water with
40 µL of 4:2% w/v potassium iodide-iodine solution (I3-) and 10 µL of 2 M ammonium
hydroxide for 30 minutes at 4°C under dark conditions. Following incubation, the treated
samples were centrifuged at 3000 g at 4°C for 20 minutes to remove bulk sediment.
Centrifuged samples were filtered with a 0.22 µm nylon membrane filter and diluted 20fold in ultra-pure water. Ammonium oxalate was prepared at a final concentration of 10
µg/L as a sodium adduct suppressant. Samples were prepared as biological duplicates (n =
2).
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Urinary pteridines were separated using a Phenomenex Luna phenyl-hexyl column
(3.0µm, 3.0 × 150 mm) and a Shimadzu UFLC system (Columbia, MD, USA) comprised
of a degasser (DGU-30A3), two pumps (LC-20 AD XR), a temperature controlled
autosampler (SIL-20AC XR), and a column oven (CTO-20A). Urinary pteridines were
quantified using an AB Sciex 4000 QTrap MS/MS system (Foster City, CA, USA) that
was operated under ESI-positive ionization and scheduled multiple-reaction monitoring
(MRM) scan modes. The six urinary pteridines were quantified over a linear range from
0.10 µg/L to 100 µg/L with representative spiked recoveries that ranged from 80% to 112%
and analytical reproducibility that ranged between 2.3% and 6.8% relative standard
deviation (RSD). Urine specimens that afforded urinary pteridine levels under the
corresponding detection limits were assigned a concentration of one half the limit of
quantitation (LOQ/2).

2.5. Urine specific gravity adjustment
Urinalysis requires adjustments to reflect patient hydration-dilution status and time
since last urination. Urine specific gravity (USG) was used for this purpose since
conventionally used urinary creatinine is dependent on muscle mass and related individual
characteristics (Burton et al. 2014). USG was measured refractometrically using a
temperature-corrected Reichert TS 400 clinical refractometer since this method remains
the most accurate (Miller et al. 2004). Freshly thawed urine specimens were allowed to
equilibrate to room temperature (21-25°) whereby a 200 µL aliquot was analyzed with the
refractometer. Freeze-thaw cycles were preliminarily shown to have no impact on USG
(Online Resource 1). Urine specific gravity was measured with inter- and intra-assay
RSDs of 0.12% and 0.04%, respectively. Urinary pteridine levels were adjusted to USG
using the Levine-Fahy equation and a reference USG of 1.020:
𝐶𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 = 𝐶𝑟𝑎𝑤 ×

𝑈𝑆𝐺𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 − 1
𝑈𝑆𝐺𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 − 1

where Ccorrected is the adjusted analyte concentration, Craw is the uncorrected analyte
concentration, USGreference is a reference USG for a given population, and USGexperimental is
the experimentally determined USG.
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2.6. Statistical analysis
2.6.1. Data processing
Urinary pteridine levels were normalized to USG to compensate for differences in
individual hydration status and time since last urination. Overly dilute and concentrated
urine specimens, defined as having a USG value less than 1.003 or greater than 1.030,
respectively (Bush 2008; Alessio et al. 1985), were excluded from statistical analysis (n =
3). Similarly, urinary pteridine concentrations that fell below their respective limits of
quantitation (n = 6), which have been defined elsewhere (Burton et al. 2013), were taken
as one half their limit of quantitation. Anderson-Darling goodness-of-fit tests indicated
pteridine distributions with substantial right skew (skew range: +0.97 – 1.88) that were
most accurately modeled as lognormal distributions. Although log-transformations have
been previously employed to normalize metabolite concentrations (Thompson et al. 2012),
such an approach is problematic for the study of metabolite variation. Namely,
transformation processes distort coefficients of variation, which serve as a primary measure
in the daily variation component of the study. Secondly, the nearest neighbor ratio analyses
performed in this study would lose intrinsic meaning following a log-transformation since
this process inadvertently reduces resulting ratios to unity. Finally, the paired differences
and ratios that formed the bases of most statistical analyses in this study were acceptably
symmetric about 0 and 1, respectively (Anderson-Darling < 0.5, P-value > 0.05) for all six
pteridines. For these reasons, data were not transformed.

2.6.2. Statistical methods
Coefficients of variation (%CVs) were determined from untransformed data using
the method of moments defined as σ/𝑥̅ where σ is the sample standard deviation and 𝑥̅ is
the sample mean. Our study design permitted determination of two types of daily variation:
(a) within-day and (b) between-day. Within-day variation was calculated as the mean %CV
determined for each day for each pteridine for each individual. Between-day variation was
calculated as the mean %CV for each corresponding time point (e.g. mornings, afternoons,
evenings) across three days for each pteridine for each individual. The averages and %CVs
of the individual daily variations were calculated as the within-individual and betweenindividual variance, respectively.
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Nearest neighbor ratio nonparametric analysis was used to quantify diurnal patterns
by taking the ratios of each successive time point for each pteridine for each individual.
Ratios for major time points (e.g. morning, afternoon, and evening) were combined and
subjected to a Signed Rank test with the null hypothesis that the overall ratio was equivalent
to unity. The paired ratios of the case week to the control week in the folate study were
similarly analyzed with a Signed Rank test. Paired equivalence tests were used to confirm
equivalence where appropriate. Pearson correlations were performed to quantify the
correlation between urinary pteridine values amongst one another and self-reported
parameters of feeding and physical activity. Mann-Whitney U group comparison tests were
used to measure the differences between unpaired data sets. A P-value below 0.05 was
considered statistically significant, except in cases of multiple comparisons wherein
Bonferroni corrections were made.

2.6.3. Sample size and statistical power
This study aimed to quantify the daily variation and effect of dietary folate on six
urinary pteridines. The sample size for the Signed Rank tests for determining these two
types of variation was determined to be 67 using a statistical power of 80%, a 5% Type I
error rate, a minimum effect size of 0.15, and a standard deviation of 0.40. This standard
deviation estimate was premised on the variation of serum acylcarnitines, which may
similarly be considered secondary metabolites (Thompson et al. 2012), as well as
derivations of previously reported clinical investigations of urinary pteridine levels (Burton
et al. 2014). The observed sample sizes, 81 and 168, for the daily variation and folate
experiments, respectively, enabled formative conclusions to be drawn from these analyses,
although the generalizability of these findings may be extended with larger sample sizes.

3. RESULTS
3.1. Daily variation
Daily variation of urinary pteridines was assessed on within-day and between-day
bases for a period of three days with three measurements taken each day at defined times
for a total of nine measurements per individual (Table 1). Briefly, the encountered
pteridine ranges reported in this study population (range: 43 nM 6-carboxypterin – 3,326
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nM neopterin) were comparable to previous accounts, although considerably lower than
previously reported levels in certain cancer patient populations (Gamagedara et al. 2011;
Burton et al. 2013, 2014). Gamagedara and co-workers noted comparable epidemiological
differences in their case-control study that examined a demographically similar control
population and a substantially older case population (Gamagedara et al. 2011).

Within-day variation was studied to determine whether urinary pteridine
concentrations respond to circadian rhythms. Within-subject variance was approximately
35% for all urinary pteridines with the exception of 6-carboxypterin which had
substantially higher variance measured at 72.5%. High urinary 6-carboxypterin variance
was generally observed across the study population as reflected by its lower 36.6%
between-subject variance. The between-subject variance for the other urinary pteridines
remained at ~35%. While these measures of variance provide a characterization of the total
daily and biological variation, they provide little insight into the individual factors that
comprise pteridine variation, such as diurnal trends in relation to circadian rhythms. To this
end, nearest neighbor ratios were determined for each successive time point for each
individual and composited to provide a generalized characterization of daily urinary
pteridine clearance trends (Table 2). Specifically, 6-biopterin, pterin, neopterin, and
isoxanthopterin levels in urine were significantly elevated in the morning (Signed Rank Pvalues < 0.05). Nonsignificant increases (Signed Rank P-values = 0.073) were also
observed in xanthopterin and 6-carboxypterin. Morning pteridine levels were generally
maintained throughout the afternoon (paired equivalence test P-values < 0.05) for all
urinary pteridines except 6-carboxypterin, followed by substantial decreases in the evening
(Signed Rank P-values < 0.05 for 6-biopterin, pterin, neopterin, and isoxanthopterin; Pvalue = 0.064 for xanthopterin; P-value = 0.359 for 6-carboxypterin).

35.2%

35.4%

77.8%

33.1%

69.2%

36.6%

72.5%

6.8%

(33.6)

43.5

6-Carboxypterin

35.1%

41.7%

48.5%

34.0%

43.2%

36.9%

3.8%

(255.0)

514.2

Isoxanthopterin

3

Total daily variation was calculated as the %CV for each pteridine across all measurements for three days.

pteridine.

Between-day variance was calculated as the average %CV for each individual for each corresponding time point for each

24.4%

59.2%

36.2%

56.2%

41.2%

55.6%

2.7%

(1127.5)

1743.6

Xanthopterin

2

42.5%

29.6%

35.7%

23.0%

29.4%

29.5%

2.3%

(1220.5)

3325.8

Neopterin

Within-day variance was calculated as the average %CV for each individual for each pteridine for each day.

32.5%

40.8%

47.6%

33.8%

54.3%

35.9%

2.4%

(261.9)

482.5

Pterin

1

Between-Individual

25.7%

Between-Individual

Variation3

27.5%

Within-Individual

36.3%

39.6%

Between-Individual

Within-Individual

35.4%

Within-Individual

Total Daily

Between-Day2

Within-Day1

(%RSD)

Analytical Precision
3.2%

(580.5)

(Standard Deviation)

(nM)

1060.0

(nM)

Mean Concentration

6-Biopterin

Table 1. Daily variations (%CV) of six urinary pteridines measured at three times daily for three days in nine individuals.
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1.04

1.01
0.86**

Afternoon/Morning

Evening/Afternoon

0.81**

0.87

1.39*

Neopterin

0.75*

1.02
0.79

0.76

1.28*

Isoxanthopterin

0.77

1.39

1.13
0.83

6-Carboxypterin

Xanthopterin

ratio was equivalent to 1.00. * P-value < 0.05, ** P-value < 0.01.

median values have been presented here. P-values were determined from a Signed Rank test under the alternative hypothesis that the overall

For each individual, the ratio of each successive time point was calculated. Corresponding ratios from each day were combined and the

0.85*

1.14*

1.50*

Pterin

Morning/Evening

6-Biopterin

Table 2. Diurnal patterns of six urinary pteridines as determined from nearest neighbor ratio analysis.
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Between-day variation was additionally studied to provide supplemental
information about the individual sources of pteridine variation. For example, urinary pterin
variance was consistently higher when measured between subjects than within subjects. A
comparison of the within-day and between-day variances of urinary pterin on an individual
basis revealed that the two measures were strongly correlated (Pearson r = 0.806, P-value
= 0.029) and were considered equivalent within a 30% margin of difference (paired
equivalence test P-values (lower bound, upper bound) = 0.026, 0.036) for each individual.
The isomers xanthopterin and isoxanthopterin exhibited similar behavior. Specifically,
comparisons between the within-day and between-day variances for xanthopterin were
considered insignificant (Pearson r = 0.706, P-value = 0.076) and statistically equivalent
within a 30% margin of difference (paired equivalence P-values = 0.010, 0.046), while
those of isoxanthopterin displayed a slightly weaker correlation (Pearson r = 0.657, P-value
= 0.109) and were not considered equivalent within a 30% margin of difference (paired
equivalence P-values = 0.067, 0.029).

Total daily variation was studied by combining the nine samples collected for each
pteridine from each individual over the three day period. Representative time series for
xanthopterin and isoxanthopterin are shown in Fig. 1. Nearest neighbor ratios were
tabulated for each individual and then composited to produce a generalized characterization
of urinary pteridine fluctuations with respect to each successive time point (Table 3). This
analytical approach taken together with the self-assessed descriptions of feeding and
physical activities prior to each time point was used to elucidate distinct sources of
pteridine variance. Specifically, individuals who had eaten calorific meals prior to
overnight fasting had significantly lower 6-biopterin levels compared with individuals who
had eaten smaller dinners (Mann-Whitney P-value = 0.004). High-intensity physical
activities that included extended walking (>30 minutes), resistance training, and prolonged
gardening tended to increase urinary neopterin levels (Mann-Whitney P-value = 0.027) up
to several hours after the activity occurred, an observation that has been reported elsewhere
(Sprenger et al. 1992). Exposure to sunlight was also found to substantially attenuate
urinary 6-carboxypterin levels (Mann-Whitney P-value < 0.001) by up to one order of
magnitude. Finally, some urine specimens appeared as elevated outliers in comparison with
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the other urine specimens collected from the same individual. Reproducible times for these
outlier events (e.g. evenings) on an individual basis suggested these events may coincide
with certain activities that merit further investigation.

Figure 1. Representative time series for urinary xanthopterin and isoxanthopterin from nine
repeat measurements taken from two subjects

0.92
0.80
0.58
1.00

Neopterin

Xanthopterin

6-Carboxypterin

Isoxanthopterin

0.68

1.02

0.59

0.76

0.76

1.35

0.99

1.56

1.54

1.90

1.89

Morning

T4

0.75

0.81

0.72

0.70

1.13

0.66

Afternoon

T5

0.85

1.51

0.36

0.84

0.85

0.93

Evening

T6

1.37

0.93

1.78

1.22

1.48

1.04

Morning

T7

1.19

1.12

1.12

1.23

1.18

1.11

Afternoon

T8

0.63

0.51

0.89

0.82

0.88

0.83

Evening

T9

have been presented here.

Consequently, T1 nearest neighbor ratios are not shown as preceding measurements were not available. Median values for the nine individuals

For each individual, the ratio of the current time point over the preceding time point was calculated from the USG-adjusted pteridine values.

0.71

Pterin

0.82

Evening

Afternoon
1.03

T3

T2

6-Biopterin

Pteridine

Table 3. Nearest neighbor ratios for six urinary pteridines measured across nine time points from nine individuals.
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3.2. Dietary folate
Dietary folate has been suggested to serve as a key source of variation of urinary
pteridine derivatives owing to its implicit role in the pteridine biosynthetic pathway as a
major entry point for aromatic pteridine biosynthesis and the wide epidemiological
discrepancies in total daily folate intake. Herein baseline urinary pteridine levels were
established during a control week which generated between-day variations that were
comparable to those shown in Table 1 (2-sample equivalence test P-value = 0.024 for 10%
margin of difference). Urinary pteridines were subsequently measured during the case
week in which study participants were provided one folate supplement at the total daily
recommended value (400 µg). The mean weekly pteridine values for each individual for
each pteridine were compared by taking the ratio of the case week to the control week.
Signed Rank analyses were performed to determine the effect of folate intake on urinary
pteridine levels (Table 4).

Table 4. Effect of dietary folate supplementation on six urinary pteridine levels.
% Change‡

P-Value

6-Biopterin

-31

<0.0001

Pterin

+27

<0.001

Neopterin

-16

0.031

Xanthopterin

-32

0.021

6-Carboxypterin

+11

0.021

Isoxanthopterin

-5

1.000

Pteridine

‡

Data are presented as the percent change between mean urinary pteridine levels between

a control week in which no folate supplementation was given and a case week in which
folate supplementation was provided at a level of 400 µg/day. P-values were calculated
from Signed Rank analyses.
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4. DISCUSSION
Clinical interest in pteridine derivatives as investigative cancer biomarkers has
prompted efforts to study the functionality and biological significance of pteridines in
human health and disease. Central to these efforts is the need to understand the sources and
extent of their non-epidemiological variation. As metabolites, pteridines are subject to
myriad factors capable of effecting their natural variation, which include but are not limited
to circadian rhythms, genetic heterogeneity, disease status, environmental factors, diet and
physical activity. This study was therefore designed to measure the extent of urinary
pteridine variation with respect to daily variation and dietary folate intake, and to lesser
extents, diet and physical activity, which together represent the largest sources of variation.
In doing so, new insights have been gained regarding pteridine metabolism and its
complicated and intersecting biosynthetic pathways.

The daily variation of urinary pteridines was approximately 35% RSD for both
within-day and between-day periods for most pteridines. The extent of this daily variability
is comparable to other metabolites, even highly regulated serum amino acids and
acylcarnitines (Thompson et al. 2012). The clinical significance of this daily variability
should be considered minimal, since pathological epidemiological differences between
healthy individuals and cases typically exceed the daily variability described here. For
example, Burton and co-workers demonstrated that mean urinary isoxanthopterin levels
from breast cancer patients are 350% higher than those of healthy women (Burton et al.
2014). However, pteridine biomarkers with lesser effect sizes will be more acutely affected
by daily variability. For this reason, clinical studies aiming to quantify pteridine biomarker
performance in spot urine samples should collect at consistent time periods. Furthermore,
urinary pteridine variation in this study exhibited diurnal patterns that likely reflected
circadian rhythms that modulate metabolism. These patterns were generally characterized
as peaking in the morning followed by a reduction in urinary pteridine levels later in the
evening. These patterns corroborated similar findings that have been described for urinary
neopterin, which has been more extensively studied as an inflammatory marker (Garcia‐
Gonzalez et al. 2006; Auzéby et al. 1988). These patterns support the hypothesis that
melatonin plays a regulatory role in endogenous pteridine biosynthesis (Jang et al. 2000).
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Specifically, guanosine triphosphate (GTP) is a major entry to the pteridine biosynthetic
pathway and leads to the production of reduced pteridine derivatives, like
tetrahydrobiopterin and dihydroneopterin, that give rise to 6-biopterin and neopterin
(Huber et al. 1984). Jang and co-workers have demonstrated that melatonin modulates
biopterin and neopterin biosynthesis by inhibiting GTP cyclohydrolase I, the initial enzyme
in the GTP pteridine biosynthetic pathway, and downregulating its gene expression (Jang
et al. 2000). Biopterin derivatives have also been shown to modulate neurotransmitters like
melatonin as enzymatic cofactors to tryptophan hydroxylase, suggesting a possible
feedback mechanism (Makoto et al. 1994; Wang et al. 2002). The present study supports
the hypothesis that melatonin regulates endogenous pteridine biosynthesis given the
sensitivity of GTP-derived pteridines, 6-biopterin, neopterin, and pterin, to circadian
rhythms.

In contrast, folate-derived pteridines were not significantly affected by circadian
rhythms in this study. This observation may be attributed to the distinctive biochemistry of
folic acid degradation and resulting pteridine interconversion. Specifically, folic acid
degradation yields 6-formylpterin that is subsequently oxidized to 6-carboxypterin, which
in turn may be further converted to pterin (Off et al. 2005). Xanthine dehydrogenase
catalyzes the formation of xanthopterin and isoxanthopterin from 7,8-dihydropterin and
pterin, respectively (Blau et al. 1996). It has been recognized that folic acid degradation is
accelerated in the presence of UV radiation (Off et al. 2005). Consequently, elevated levels
of folate-derived pteridines have been measured in the skin of patients suffering from
vitiligo, a depigmentation disorder (Schallreuter et al. 2001). This understanding of the
folic acid photodegradation supports the observation that urinary 6-carboxypterin levels
were elevated in study participants who received significant sunlight exposure, although
this study was not designed to measure that effect. More importantly, the relative
contributions of the GTP and folic acid entry points to shared downstream pteridine
derivatives, such as pterin, isoxanthopterin, and xanthopterin, remains poorly understood.
Given current understanding of the folic acid degradation pathway and the lack of diurnal
behavior observed in the present study, these findings suggest that the folic acid entry point
may be the dominant pathway for the formation 6-carboxypterin, xanthopterin, and
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isoxanthopterin. This hypothesis is explored further in the dietary folate supplementation
study.

The effect of dietary folate supplementation elicited varied responses in a
seemingly pathway dependent manner. Specifically, neopterin, biopterin, and xanthopterin
were appreciably downregulated while 6-carboxypterin and pterin were upregulated and
no significant change was observed in isoxanthopterin. Downregulation of the primary
GTP pteridines suggests a possible competitive interaction between the GTP and folic acid
entry points in the pteridine biosynthetic pathway. This novel observation provides for the
first time evidence that folic acid can modulate endogenous neopterin and biopterin
biosynthesis. The biological significance of neopterin and biopterin derivatives in human
and health and disease suggest that folate modulation may have important clinical
implications. Moreover, these interactions provide new insights into the relative
contributions of GTP and folic acid on pteridine production as well as into the crosstalk
between the two metabolic entry points. For example, the non-specific formation of pterin
from ubiquitous pteridines can occur via non-enzymatic side chain cleavage (Kośliński et
al. 2011; Cañada-Cañada et al. 2009). Similarly, 7,8-dihydropteridines, including 7,8dihydrofolate, preferentially oxidize to 7,8-dihydroxanthopterin which is subsequently
oxidized to xanthopterin (Oliveros et al. 2010). The resulting crossover interactions
between the two metabolic entry points has complicated the interpretation of pterin and its
downstream pteridines in clinical epidemiological studies. The present work clearly
demonstrates that folate supplementation augmented urinary levels of 6-carboxypterin and
pterin, suggesting that folate catabolism is a major source of pterin biosynthesis. A 27%
change in urinary pterin levels corresponds to approximately 20 µg folic acid when a
typical 250 mL urine void is assumed. This contribution of folic acid to an individual
pteridine within a spot urine sample is significant given that folic acid is primarily excreted
in the form of its major metabolites, p-aminobenzoylglutamate (pABG) and the acetamide
derivative of p-aminobenzoylglutamate (apABG), the latter of which lacking biological
activity with excretion rates up to 20-fold higher than that of folic acid (Álvarez-Sánchez
et al. 2010; Niesser et al. 2013). Moreover, the insignificant effect of dietary folate
supplementation on isoxanthopterin suggests that alternatives mechanisms for

150
isoxanthopterin biosynthesis possibly involving xanthine dehydrogenase appear likely
(Blau et al. 1996). Finally, decreases in xanthopterin levels suggest that urinary
xanthopterin is primarily driven from the GTP entry point through the nonspecific
oxidation of reduced GTP pteridine derivatives. With this new information, we have
proposed a pteridine biosynthetic pathway that for the first time comprehensively bridges
the GTP and folic acid entry points (Fig. 2). Further in vitro work will be needed to confirm
this proposed pathway.

Figure 2. Simplified schematic of the proposed pteridine biosynthetic pathway. Pteridine
derivatives in bold were monitored in this study

Finally, there were several limitations to the present study that may be improved
upon to gain more conclusive findings. Namely, a limited number of measurements (n =
81), representing three samples collected daily for three days from nine individuals was
taken to study the daily variation of urinary pteridines. Larger sample sizes and a greater
number of time points may extend the generalizability of these findings across different
patient populations and timespans, which may provide additional insights into the finer
patterns in urinary pteridine variation. Similarly, this study was not designed to measure
the effect of specific physical activities, environmental factors, and diet on urinary
pteridine variation which represent useful directions on which to extend these findings.
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Self-reporting of disease status additionally has intrinsic limitations, as was evidenced by
the development of a bladder infection in one of the study participants which resulted in
their immediate exclusion from the study. Finally, long-term studies of dietary folate
supplementation would benefit from the secondary half-life of folic acid that occurs after
approximately 100 days that is associated with the decay of existing body folate pools.
Together these areas provide new research directions based on the findings of this study
for future studies aiming to study pteridine metabolism and urinary excretion.

5. CONCLUDING REMARKS
In summary, this study aimed to quantify the daily variation and effect of dietary
folate on urinary pteridine levels. Urinary pteridines were confirmed to exhibit diurnal
patterns in response to circadian rhythms marked by rising levels in the morning that
decrease later in the evening. Dietary folate was similarly demonstrated to have a
pronounced effect on urinary pteridine levels in a pathway dependent manner. This
pathway dependence suggests dietary folate may modulate endogenous neopterin and
biopterin biosynthesis. A number of secondary associations between urinary pteridine
levels and various feeding and physical activities were additionally made. Together these
newly quantified sources of variation have provided new insights into the pteridine
biosynthetic pathway and their broader effects on human metabolism, health, and disease.
Better understanding of pteridine metabolism through these findings will enable more
accurate interpretation of pteridine molecular pathological epidemiology and elucidate an
obscure branch of metabolism with wide-reaching physiological implications.
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ABSTRACT
Pteridines have evoked considerable interest from the scientific community owing
to their prominent roles in human health and disease. The availability of analytical
methodologies suitable for comprehensive pteridine profiling, termed here as
“pterinomics”, has been limited by inconsistent sample preparation and the exclusion of
lesser studied pteridine derivatives. In response, the present study describes a new
pterinomics workflow using a high-performance liquid chromatography – tandem mass
spectrometry (HPLC-MS/MS) methodology for the simultaneous analysis of 15 pteridine
derivatives including five structural isomers, marking the largest quantitative pteridine
panel that has been studied to-date. The validated method possessed excellent sensitivity
with method detection limits (0.025 µg L-1 to 0.5 µg L-1) that were comparable or superior
to existing techniques. Spiked recovery studies demonstrated the technique was both
accurate (88-112%) and precise (RSD: 0-6%). A comparative study of commonly used
oxidative pretreatments, including triiodide, permanganate, and manganese dioxide,
revealed that the oxidative mechanisms were inefficient, complex, and concentration
dependent. Finally, 50 clinical urine specimens were examined with the new technique
wherein 10 pteridine derivatives were quantified and population ranges have been given.
This technique can be used to examine pteridine molecular epidemiology and biochemistry
to support related research applications, and may further be readily extended to include
additional pteridine derivatives and biological matrices for specific applications.

KEY WORDS
Pteridines, oxidative pretreatment, urine, HPLC-MS/MS, pterinomics
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1. INTRODUCTION
Pteridines have evoked interest from the scientific community since their successful
isolation from butterfly wings by Hopkins in 1889 [1]. The structural elucidation of their
pyrazine [2,3-D]pyrimidine ring system that followed in the early 1940s prompted
tremendous efforts to catalogue their biological and chemical diversity that continue to this
day [2-4]. From these studies have emerged an extensive and complex family of
metabolites related to the biosynthesis and biodegradation of vitamins and cofactors [5].
The key finding that 5,6,7,8-tetrahydrobiopterin is an obligatory cofactor for aromatic
amino acid hydroxylases [6, 7] and nitric oxide synthase [8, 9], as well as the cytokineinducible biosynthesis of neopterin [10, 11], has furthered research into the function of
pteridine derivatives in human health and disease. In recent years, these efforts have
expanded to include the aromatic pteridines derived from folic acid catabolism [12],
including

6-formylpterin,

6-carboxypterin,

6-hydroxymethylpterin,

pterin,

and

isoxanthopterin [13]. Aromatic pteridines, and to lesser extents their semi-reduced and
reduced counterparts, have remarkable photocatalytic and oxidoreductive properties,
including a considerable capacity to generate reactive oxygen species [14-17] and even
photosensitize important biomolecules including DNA [18-20], folic acid [21], and
tryptophan [22], which has led researchers to postulate that pteridines may actively
participate in molecular pathology [13]. Similarly, the overexpression of the endocytic
folate receptor α in solid epithelial tumors [23-25] has presented a novel pathomechanistic
premise for the clinical observation of elevated levels of folate-derived pteridines in the
urine of patients suffering from lung and colon cancers [26], bladder cancer [27, 28], breast
cancer [26, 29, 30], digestive tract cancers [31], and brain tumors [32].

However, current understanding on the biochemistry and molecular pathology of
mammalian pteridines remains fragmented [33]. As Rembold and Gyure presciently
remarked over forty years ago, analytical limitations related to the general instability and
trace levels of biogenic pteridines have precluded detailed studies of the prevalence and
role of many lesser known derivatives [13, 34]. More recent efforts have seen an attempt
to develop robust analytical methodologies using advanced instrumental platforms and
oxidative pretreatments to enable sensitive detection of biologically significant pteridine
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derivatives. To this end, a multitude of competent analytical techniques have emerged over
the past several years using an array of sensitive instrumental platforms including capillary
electrophoresis – laser-induced fluorescence (CE-LIF) [35], high-performance liquid
chromatography – fluorescence detection (HPLC-FD) [28, 36-40], high-performance
liquid chromatography – mass spectrometry (HPLC-MS) [41], high-performance liquid
chromatography – tandem mass spectrometry (HPLC-MS/MS) [29, 42-44], hydrophilic
interaction chromatography – tandem mass spectrometry (HILIC-MS/MS) [45], and
synchronous fluorescence spectroscopy [46, 47], which have been summarized in Table 1.

Nevertheless, the availability of analytical methods suitable for comprehensive
pteridine analysis, termed here as “pterinomics”, has been limited by several notable
factors. First, fragmented understanding of the pteridine biosynthetic pathway alongside
the tendency to select pteridine derivatives with previously established biological
significance have generally limited the inclusion of lesser known derivatives in new
analytical techniques. The interconversion of 6-substituted pteridines to 7-substituted
isomers via biochemical processes that are unrelated to classical pteridine biosynthetic
pathways presents an additional class of pteridine derivatives with probable biological
significance that have otherwise received little attention thus far [48, 49]. Secondly, the
problematic practice of using a variety of oxidative and anti-oxidative pretreatments, as
recently reviewed by Tomšíková and co-workers [50], has led to inconclusive or
inconsistent findings. Although a number of oxidative pretreatments have been proposed
and optimized for selected pteridine derivatives, comparative studies of oxidative
efficiency and byproduct formation for a wide panel of pteridine derivatives are lacking.
An alternative strategy to oxidative pretreatments has more recently focused on the
investigation of pteridine derivatives in their native oxidative states [40-42, 51], although
the relative abundance and interconversion of semi-reduced and reduced pteridine
derivatives in biological fluids, and particularly urine, remains disputed [36, 52-54]. For
these reasons, new methods are urgently needed to study expanded pteridine panels,
including structural isomers, alongside improved knowledge on the effectiveness of
oxidative pretreatments to advance pteridine research in human health and disease.
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Table 1. A summary of recently developed quantitative analytical methodologies for
biogenic pteridines.
Technique

CE-LIF

HPLC-FD

Pteridines1
PTE, XAN, ISO, NEO, 6-BIO, 6-CAP,
6,7-DMP, 6-HMP
PTE, NEO, 6-BIO, XAN, ISO
PTE, XAN, ISO, NEO, 6-BIO, 7-BIO,

HPLC-FD

MNP, 6-CAP, 6-HMP, LUM, 6HLUM, 7-HLUM, BLUM

HPLC-FD
HPLCMS/MS
HPLC-MS

PTE, ISO, 6-BIO, 7-BIO, NEO, MNP
PTE, XAN, ISO, NEO, MNP, NH2, 6BIO, BH2, 6-HMP, 6-MP, 6-CAP

HPLC-

PTE, XAN, ISO, NEO, 6-BIO, 6-CAP,

MS/MS

6,7-DMP, 6-HMP

HPLC-FD

HPLC-FD

HPLC-FD

1

PTE, NEO, 6-BIO; XAN, ISO

6-BIO, BH2, BH4, NEO, NH2
PTE, XAN, ISO, NEO, 6-BIO, 6-CAP,
6,7-DMP, 6-HMP
PTE, XAN, ISO, NEO, MNP, 6-BIO,
7-BIO, 6-CAP, 6-HMP

HPLC-

Quantitative: PTE, XAN, ISO, NEO,

MS/MS

6-BIO, 6-CAP, 6,7-DMP, 6-HMP

UHPLC-

PTE, XAN, XH2, NEO, NH2, 6-HMP,

MS/MS

6-HMDP, 6-FOP, 6-CAP

Proposed

PTE, XAN, XH2, ISO, NEO, MNP, 6-

HPLC-

BIO, SEP, 6-CAP, 6,7-DMP, 6-MP, 6-

MS/MS

HMP, LUM, 6-HLUM, 7-HLUM

Oxidative

Run Time

Pretreatment

(min)2

Alkaline I3-

20

None

16

Alkaline I3- and
KMnO4

39

None

16

Acidic MnO2

19

None

30

Alkaline I3-

7.5

None

16

Alkaline I3- and
KMnO4

25

Acidic I3-

29

None

25

Mn2O5

8

None

7

Reference
Gibbons et al
(2009)[35]
De Llanos et al
(2011)[39]
De Llanos et al
(2011)[39]
Culzoni et al
(2011) [40]
Allegri et al
(2012)[44]
Girón et al
(2012)[41]
Burton et al
(2013)[29]
Guibal et al
(2014)[38]
Kośliński et al
(2014)[28]
Tornero et al
(2014)[37]
Burton et al
(2015)[42]
Van Daele et al
(2016)[43]

--

PTE: Pterin; XAN: Xanthopterin; ISO: Isoxanthopterin; NEO: Neopterin; 6-BIO: 6-Biopterin; 6-CAP: 6-

Carboxypterin; 6,7-DMP: 6,7-Dimethylpterin; 6-HMP: 6-Hydroxmethylpterin; 7-BIO: 7-Biopterin; MNP:
Monapterin; LUM: Lumazine; 6-HLUM: 6-Hydroxylumazine; 7-HLUM: 7-Hydroxylumazine; BLUM:
Biolumazine; NH2: 7,8-Dihydroneopterin; BH2: 7,8-Dihydrobiopterin; 6-MP: 6-Methylpterin; BH4:
Tetrahydrobiopterin; XH2: 7,8-Dihydroxanthopterin; PH2: Dihydropterin; PH4: Tetrahydropterin; 6,7Dimethyltetrahydrobiopterin; NH4: Tetrahydroneopterin; 6-HMDP: 6-Hydroxymethyldihydropterin; 6FOP: 6-Formylpterin; SEP: Sepiapterin;
2

Run time includes pre- and post-equilibration and cleaning procedures.
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In the present study, we described a new workflow for the quantitative analysis of
15 pteridine derivatives in urine using a novel HPLC-MS/MS methodology. The pteridines
investigated in this study were selected primarily as folate-derived pteridines with cancer
biomarker applications [55] and include five structural isomers, multiple lesser known
derivatives, and two semi-reduced compounds (Figure 1). However, the analytical
workflow has been designed with extensibility to additional pteridine derivatives and
biological matrices for specific applications. This new technique was subsequently used to
systematically study the in-source oxidation, interconversion, and efficiency of several
commonly used oxidative pretreatments in an attempt to standardize pteridine sample
preparation. The resulting standardized technique was used to profile pteridine derivatives
in the urine of healthy individuals, breast cancer patients, and prostate cancer patients.

Figure 1. Chemical structures of: (1) pterin, (2) xanthopterin, (3) isoxanthopterin, (4) 7,8dihydroxanthopterin, (5) 6-carboxypterin, (6) 6-hydroxymethylpterin, (7) 6,7dimethylpterin, (8) 6-methylpterin, (9) neopterin, (10) L-monapterin, (11) 6-biopterin, (12)
sepiapterin, (13) lumazine, (14) 6-hydroxylumazine, and (15) 7-hydroxylumazine.
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2. MATERIALS AND METHODS
2.1. Chemicals and Materials
Pterin, xanthopterin, 7,8-dihydroxanthopterin, isoxanthopterin, 6-biopterin,
sepiapterin, neopterin, monapterin, 6-carboxypterin, 6-hydroxymethylpterin, 6,7dimethylpterin, 6-methylpterin, lumazine, 6-hydroxylumazine, 7-hydroxylumazine, 6formylpterin, leucopterin, and folic acid were purchased from Schircks Laboratory (Jona,
Switzerland). LC-MS grade ammonium hydroxide and formic acid were purchased from
Fisher Scientific (New Jersey, USA). Potassium iodide, iodine, ascorbic acid, and
dithiothreitol were purchased from Sigma-Aldrich (St. Louis, USA). Synthetic urine was
obtained from CST Technologies Inc. (New York, USA). Ultrapure water was generated
by a Milli-Q Advantage® A10 and Millipore Elix® water purification system.

2.2. Instrumentation
Pteridine derivatives were separated using a Luna phenyl-hexyl column (3.0 μm,
3.0×150 mm) and accompanying guard column (Phenomenex, Torrance, CA) in
conjunction with a Shimadzu UFLC system (Columbia, MD) that included a degasser
(DGU-30A3), two pumps (LC-20 AD XR), a temperature controlled autosampler (SIL20AC XR) and a column oven (CTO-20A). Chromatography was performed at 40°C with
a flow rate of 0.45 mL min-1 using a 50 µL injection volume. A binary gradient flow system
was used to separate pteridine derivatives using the following mobile phase compositions:
A: 0.025% (v/v) formic acid in 99% water / 1% acetonitrile; B: methanol. The gradient
profile included an initial two-minute period in which the composition of mobile phase B
was increased linearly from 7% to 20%, followed by another two-minute period in which
mobile phase B was held at 20%, and rapidly returned to 7% for the final two minutes. A
one-minute pre-equilibration as well as a 200 µL post-injection needle rinse procedure
were added to reduce carryover effects between biological samples. The total run-to-run
time was 7.0 minutes. Samples were stored in the autosampler at 4°C for a period lasting
no longer than six hours.

An AB Sciex 4000 QTrap MS/MS system (Foster City, CA, USA) was used to
quantify pteridine derivatives. The ion source was operated in positive-ion ESI mode with
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the following flow injection parameters: ion spray voltage: +5500 V; source temperature:
600°C; curtain gas: 45 psi N2; GS1: 25 psi N2; GS2: 35 psi N2; heated interface. Scheduled
multiple reaction monitoring (MRM) experiments were operated with 44 second scan
windows and individual target scan times of 0.7 seconds to quantify selected ions
transitions. Collisionally-activated dissociation (CAD) of pteridine derivatives was
achieved using 12 psi ultra-pure N2 gas in the collision chamber.

2.3. Standard Preparation
Between 2 and 5 mg of each pteridine standard was dissolved in in 13 mL of
ultrapure water and 500 µL of 2 N ammonium hydroxide in amber glass vials. Sonication
was used to enhance dissolution of poorly soluble species, namely, 6,7-dimethylpterin, 6methylpterin, pterin, and leucopterin. Dilutions from these individual standard stock
solutions were used for direct infusion analysis to optimize MS/MS conditions. A stock
mixture solution was similarly prepared at 10 mg/L each component from these individual
stock solutions using ultra-pure water. Aliquots of the individual and stock mixture
solutions were wrapped in aluminum foil and were stored at -80°C. Fresh calibration
standards were prepared from these aliquots daily using serial dilutions in ultra-pure water
and/or 1% synthetic urine.

2.4. Analysis of Urine Samples
Urine specimens (n = 50) were collected from consenting women 33-87 years of
age (mean: 60.0 years) at Mercy Breast Center – Springfield (Springfield, MO) between
October 2014 and December 2014 in a consecutive case series manner. Selection criteria
included women referred to the medical center for biopsy characterization with no copresent medical conditions or previous history of cancer. Participants were drawn from a
local patient population with the following demographics: 88.7% Caucasian, 3.3%
Hispanic or Latino, 3.2% African American, 1.8% Asian, and 3% other or two or more
races. Spot urine specimens consisting of first morning and second morning voids were
collected prior to biopsy and immediately stored at -20°C for 1-6 days. Specimens were
shipped to Missouri University of Science and Technology for analysis via next-day frozen
ground freight. Upon arrival, specimens were thawed, aliquoted, and refrozen at -80°C
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until analysis. Mercy Breast Center pathologists disclosed anonymized diagnostic reports
at the conclusion of the study.

Under dark conditions, urine sample aliquots were gradually thawed to room
temperature and thoroughly vortexed. The urine specific gravity (USG) was determined
from 200 µL sample using a temperature-corrected Reichert TS 400 clinical refractometer.
USG was used to adjust urinary pteridine concentrations to patient hydration-dilution status
and time since last urination in accordance with prior work [30]. Another 100 µL sample
was diluted tenfold in ultra-pure water in a yellow centrifuge tube. Diluted samples were
centrifuged at 3000 g for 20 minutes at 4°C and filtered with a 0.22 µm Nylon membrane
to remove sediment, proteins, and epithelial cells. Another tenfold dilution in ultra-pure
water was made into a 1.5 mL amber glass vial and was subsequently vortexed and
submitted to HPLC-MS/MS analysis. The total dilution factor for urine samples was 100fold.

3. RESULTS AND DISCUSSION
3.1. MS/MS Optimization
Individual pteridine derivatives were infused at a concentration of 100 µg L-1 in
mobile phase A (0.025% (v/v) formic acid in 99% water / 1% acetonitrile) at a flow rate of
0.2 mL hour-1. Ion source conditions included: ion spray voltage: +5500 V; source
temperature: 30°C; curtain gas: 10 psi N2; GS1: 10 psi N2; GS2: 10 psi N2; heated interface.
A combination of quadrupole (Q1) and linear ion trap (EMS) survey scans operating under
Multiple Channel Analyzer (MCA) mode were used to study pseudomolecular ions.
Sodiated and ammoniated molecular ions were present in standard stock solutions, owing
to the dissolution of pteridine derivatives in ammonium hydroxide and ubiquitous sodium,
respectively. The relative contributions of these adducts were consistent with previous
reports [29], which may be generalized as the following: pteridines with electron
withdrawing substituents favored the formation of ammoniated molecular ions whereas
unsubstituted pteridines and pteridines with electron donating substituents favored the
formation of sodiated molecular ions. Since molecular adducts contribute to decreased
sensitivity and may require complicated ion summing procedures, infusion analysis of
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pteridine standards in 1% synthetic urine was performed to study adduct formation under
simulated salt concentrations. In this case, ammoniated molecular ions were not
significantly observed while sodiated molecular ions remained prevalent. Sodiation was
effectively controlled by applying sufficiently high declustering potentials to the orifice,
which was automatically optimized by the Analyst 1.5.2 software.

In addition to pteridine ammoniation and sodiation, 6-formylpterin exhibited insource oxidation to 6-carboxypterin (approximately 60% of the [M+H]+ molecular ion) as
well as significant [M+15]+ and [M+H+32]+ molecular ions in the presence of methanol
(representing 20% and 50% of the [M+H]+ molecular ion, respectively). The latter two ions
were attributed to gas-phase aldol reactions between protonated aromatic aldehydes and
methanol in the ion source [56]. These two species also did not appear in the linear ion trap
EMS scans. Co-infusion of 100 µM ascorbic acid or dithiothreitol was found to limit its insource oxidation to 6-carboxypterin. Furthermore, 6-formylpterin and 6,7-dimethylpterin
are isobaric compounds with nearly identical fragmentation spectra with the exceptions of
m/z 106 derived from 6,7-dimethylpterin and m/z 67, 92, and 119 derived from 6formylpterin. Commonly used ion transitions for these compounds, such as 192  147 and
192  165, should be avoided since these two pteridine derivatives have similar
chromatographic retention times on conventional columns [29, 43]. In addition to its
negligible solubility in aqueous solutions, leucopterin suffered poor ionization efficiencies
where only high declustering potentials resulted in a weak [M+H]+ molecular ion and a
weak [M-36]+ molecular ion related to loss of water from its two ketone functionalities.
For these reasons, leucopterin was not added to the current HPLC-MS/MS method. 7,8Dihydroxanthopterin was found to have exhibited negligible in-source oxidation to
xanthopterin (<5% of the [M+H]+ molecular ion). The limited extent of this in-source
oxidation was contradictory to recent reports by Van Daele and co-workers who suggested
a thermally facilitated oxidative process [43]. However, infusion at higher temperatures
(e.g. 500°C) did not meaningfully increase in-source oxidation rates; rather, in-source
oxidation of 7,8-dihydroxanthopterin appeared to be solvent mediated and may be
manipulated by additive selection (e.g. acetic acid). A more detailed discussion on the
oxidation of 7,8-dihydroxanthopterin and its derivatives is provided in the following
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sections. The optimized MRM transitions have been summarized in Table 2. Flow
injection analysis was performed for these optimized MRM transitions to enable systematic
optimization of the ion source parameters.

Table 2. Optimized ion pairs for MRM detection. Unlabeled ion pairs located directly
below a labeled compound represent confirmation ion pairs.
Compound
6-Carboxypterin
6,7-Dimethylpterin
6-Formylpterin
6-Hydroxylumazine
6-Hydroxymethylpterin
6-Methylpterin
7,8-Dihydroxanthopterin
7-Hydroxylumazine
Biopterin
Folic Acid
Isoxanthopterin
Lumazine
Monapterin
Neopterin
Pterin
Sepiapterin
XantHopterin

Ion Pairs
(m/z)
208.1/164.3
208.1/190.1
192.2/165.2
192.2/106.2
192.1/147.2
192.1/149.2
181.1/164.2
181.1/108.1
194.1/106.1
194.1/176.2
178.2/106.1
178.2/133.2
182.1/126.2
182.1/154.2
181.1/110.1
181.1/55.2
238.1/220.2
238.1/178.3
442.2/176.3
442.2/295.4
180.1/135.1
180.1/163.2
165.1/69.1
165.1/93.1
254.1/206.1
254.1/236.3
254.0/206.2
254.0/236.3
164.1/92.1
164.1/119.1
238.1/192.3
238.1/165.3
180.1/135.2
180.1/163.1

Declustering
Potential
(DP, V)
46
46
11
11
76
76
76
76
61
61
1
1
71
71
76
76
66
66
56
56
71
71
71
71
71
71
76
76
71
71
61
61
76
76

Collision
Energy
(CE, V)
23
21
31
39
31
29
23
35
37
23
41
31
29
25
31
49
23
29
55
21
33
27
55
41
27
21
27
23
43
33
23
33
31
25

Collision Cell
Potential
(CXP, V)
10
12
10
6
8
8
10
6
18
12
6
8
22
10
6
8
14
12
10
8
8
10
12
4
14
16
12
16
4
6
12
10
24
10
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3.2. HPLC Optimization
Separation parameters were initially adapted from a previously developed HPLC
method using a Luna phenyl-hexyl column [29]. However, using 0.1% aqueous formic acid
and acetonitrile resulted in co-elution of three of the four structural isomer pairs.
Adaptation of the selective HPLC technique developed by Girón and colleagues, in which
the prescribed Zorbax Eclipse XDB-C18 column was substituted with a Kinetex C18
column (2.6 μm, 3.0×150 mm), similarly failed to separate isobaric compounds and at
greatly increased run times. Since acetonitrile and formic acid contain pi electrons that can
suppress pi-pi interactions between analytes and phenyl bonded phases, the Luna phenylhexyl column was reevaluated using methanol and lower formic acid compositions.
Separation of the neopterin/monapterin and 6-hydroxylumazine/7-hydroxylumazine
isomer pairs were inversely affected by solvent composition, where high formic acid
concentrations (>0.1% v/v) promoted neopterin/monapterin separation and high
acetonitrile compositions promoted 6-hydroxylumazine/7-hydroxylumazine separation.
Overall method selectivity was greatly improved using methanol and sufficient amounts of
formic acid for efficient analyte ionization. Therefore, trace amounts of acetonitrile were
added to the aqueous phase to enable separation of the hydroxylumazines. The optimal
solvent composition that permitted separation of isobaric pairs at minimal run times was
determined to be 0.025% v/v formic acid in 99:1% water:acetonitrile and pure methanol.

Furthermore, elevated column temperatures enhanced the separation of the
hydroxylumazines, xanthopterin and isoxanthopterin, but partially merged neopterin and
monapterin. It should be noted that 6-formylpterin and folic acid exhibited large peak
widths and asymmetry on the reversed-phase Luna phenyl-hexyl column, which have been
reported elsewhere [57]. The Kinetex C18 column meanwhile demonstrated superior
selectivity and retention for these compounds. However, since the abundance of folic acid
in urine relative to its primary degradation products, para-aminobenzoylglutamate (pABG)
and para-acetamidobenzoylglutamate (apABG), is minimal [58], and 6-formylpterin is
considered a reactive species that is not appreciably present in urine, both folic acid and 6formylpterin were excluded from the validated method. Future studies aiming to quantify
folic acid degradation byproducts such as 6-formylpterin should utilize alkyl- or polar-
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bonded phases. An optimized overlaid extraction ion chromatogram (XIC) of the
quantitative ion pairs has been provided in Figure 2.

Figure 2. Overlaid extracted ion chromatograms (XIC) of the quantitative ion pairs of
fifteen pteridine derivatives prepared at 10 µg/L in synthetic urine.

Since urine is a complex matrix, potential interferences with equivalent MRM
transitions and precursor ions were identified using unscheduled MRM experiments and
linear ion trap enhanced product ion (EPI) scans. The EPI results were used in combination
with MassBank spectral databases and chemical reference standards to make tentative
assignments. Special attention was given to the presence of reduced pteridine derivatives,
such as 5,6,7,8-tetrahydrobiopterin, that were not included in the pteridine panel
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investigated in this study. For example, 7,8-dihydrobiopterin was observed at
approximately 2.85 min in untreated urine. In-source oxidation of 5,6,7,8tetrahydrobiopterin chemical reference standard and EPI fragmentation patterns that
matched those reported by Fismen et al [52] strongly suggested that this compound was
7,8-dihydrobiopterin. Similarly, a small peak at 2.1 min was observed using the MRM
transition for neopterin/monapterin. Survey scans at this chromatographic time point
suggested the presence of 7,8-dihydroneopterin, as evidenced by major fragmentation
patterns that included 256  165, 178 [43]. An unidentified compound that partially eluted
with pterin was found to have the following ion transitions 164  61, 73, 87, 101, 103,
119, 147, including the shared 164  119 transition. For this reason, the less abundant m/z
92 fragment of pterin was selected as the quantitation ion. Tentative assignments were
made for 7-methylguanine (R.T. = 3.15 min) and phenylalanine (R.T. = 4.10 min) while
searching for 7,8-dihydropterin (m/z 166). Tyrosine (R.T. = 3.1 min) was also identified at
m/z 182 with dissimilar fragmentation to 7,8-dihydroxanthopterin. Interestingly, a
significant peak was located at m/z 180 at 4.2 min with a fragmentation pattern analogous
to xanthopterin and isoxanthopterin. Further characterization revealed major fragmentation
pathways of 180  71, 110 and minor fragmentation pathways of 180  68, 80, 93, 108,
135, and 137. This pattern appeared to be indicative of pyrazine ring opening in
xanthopterin, although its occurrence could not be modulated by triiodide and UV
oxidative pretreatments. Further characterization will be required for structural assignment.

3.3. Comparative Study of Oxidative Pretreatments
As Tomšíková and co-workers recently reviewed, a remarkably large number of
oxidative and antioxidative pretreatments have been used to quantify pteridines in
biological matrices [50]. Since comparative studies of these pretreatments have been
incomplete or lacking, particularly in regard to semi-reduced and folate-derived pteridines
like 7,8-dihydroxanthopterin, the newly developed HPLC-MS/MS method was used to
quantify the oxidative efficiency of several commonly used techniques, including Lugol’s
solution (I3-), manganese dioxide, and potassium permanganate. Specifically, Lugol’s
solution, comprising a 4%:2% (w/v) mixture of potassium iodide-iodine, is the most
commonly used oxidative pretreatment for pteridine analysis and was evaluated herein in
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both alkaline and acidic environments per previously developed protocol [27, 35, 37].
Permanganate and acidic manganese dioxide oxidative efficiency were also investigated
using earlier developed methods [28, 44]. A summarized comparison of the effects of these
pretreatments on pteridine standards prepared in synthetic urine has been provided in Table
3. From these data it becomes clear that oxidative pretreatment leads to degradation of both
aromatic and reduced pteridine derivatives. Alkaline triiodide was considered the gentlest
pretreatment strategy with the exceptions of pteridines with electron withdrawing
substituents at the 6-position, such as xanthopterin, 6-carboxypterin, and 6hydroxylumazine. However, the oxidation of 7,8-dihydroxanthopterin was remarkably
complex with mass balance calculations indicating that the oxidative efficiency of the
preferred conversion to xanthopterin was only 7%. Infusion of untreated and oxidized 7,8dihydroxanthopterin revealed possible oxidative byproducts centered at m/z 175, 205, and
213, although the structures of these compounds remain undefined. An additional 5% of
7,8-dihydroxanthopterin was lost to in-source oxidation during ionization. Acidic triiodide
performed similarly to alkaline triiodide with the notable absence of xanthopterin which
eluted much later (R.T. = 7.2 min). The effect of triiodide concentration was also
considered by comparing a typical addition of 150 µM to 15 µM where higher
concentrations led to increased pteridine degradation. The possibility that this observation
may be attributed to ion suppression rather than an oxidative reaction was rejected since
iodide ions were found to elute at the column dead time under similar chromatographic
conditions. Permanganate pretreatments resulted in substantial loss of both aromatic and
semi-reduced pteridines. These permanganate findings generally agreed with those
reported by Kośliński and colleagues, and were attributed to opening of the pteridine ring
system [28]. Similarly, pretreatments using manganese dioxide contributed to relative
losses for most pteridine derivatives.
In another experiment, we examined the effect of urine concentration-dilution on
oxidative efficiency and pteridine degradation. Since synthetic urine lacks the pool of
oxidizable species present in real urine matrices, it was necessary to investigate this effect
using real urine samples. Alkaline triiodide was selected as the model oxidant owing to its
widespread use and its relatively gentle oxidation. Urine concentration-dilution was
indirectly modeled using USG, a correlate of total dissolved solids, as a surrogate [30].

‡

†

15 µM
alkaline I3102%
102%
99%
97%
96%
94%
93%
91%
91%
85%
80%
68%
62%
0%
0%

15 µM
acidic I3104%
114%
106%
110%
96%
79%
81%
95%
108%
102%
0%
72%
0%
0%
0%

All values are expressed as a percentage of the untreated control group.
Samples were run in triplicate at a concentration of 5 µg/L.

Isoxanthopterin
6,7-Dimethylpterin
Pterin
6-Hydroxymethylpterin
6-Biopterin
6-Methylpterin
Neopterin
7-Hydroxylumazine
Lumazine
Monapterin
Xanthopterin
6-Carboxypterin
6-Hydroxylumazine
Sepiapterin
7,8-Dihydroxanthopterin

Compound

150 µM
alkaline I3100%
106%
51%
107%
86%
78%
87%
79%
79%
72%
63%
76%
63%
0%
0%

Table 3. Effect of oxidative pretreatment on pteridines in synthetic urine.
150 µM
acidic I3100%
99%
103%
114%
92%
48%
80%
73%
85%
74%
0%
52%
0%
0%
0%
73%
88%
31%
40%
91%
93%
45%
37%
35%
41%
0%
49%
26%
0%
0%

KMnO4

Acidic
MnO2
83%
103%
95%
83%
93%
88%
81%
67%
98%
89%
67%
74%
47%
0%
0%
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The percentage of pteridine derivative remaining in oxidized urine specimens,
relative to corresponding untreated urine specimens, were compared with sample USG
ranging from 1.005 to 1.027. Urine specimens (n = 10) were spiked with a 5 µg L-1 mixture
of pteridine standards to ensure detection of all pteridine derivatives. Briefly, xanthopterin
oxidation exhibited a strong positive correlation (Pearson’s r = 0.9949) with urine
concentration-dilution, ranging from 50% to 648% initial levels. Similarly, 6-biopterin
oxidation positively correlated with urine concentration-dilution (Pearson’s r = 0.9566)
and ranged from 135% to 186% initial levels. These correlations were attributed to the
oxidation of reduced derivatives of xanthopterin and 6-biopterin. However, neopterin
oxidation was inversely related to urine concentration-dilution (Pearson’s r = -0.9957),
ranging from 72% in the 1.027 USG sample to 101% in the 1.005 USG sample. Other
pteridine derivatives that exhibited correlations to urine concentration-dilution included 6hydroxymethylpterin (Pearon’s r = 0.9781), monapterin (Pearson’s r = -0.9104), and pterin
(Pearson’s r = 0.7211). The oxidative effects on the other pteridines were generally similar
to those determined in synthetic urine found in Table 3. These new findings are significant
because previous research efforts have questioned whether triiodide ions have been
provided in excess to ensure complete reduced pteridine oxidation [27, 35]. This oxidative
pretreatment dependence on urine concentration-dilution marks a novel discovery and
questions the validity of using oxidative pretreatments for pteridine quantitation.
Moreover, the discovery of complicated oxidation mechanisms in the case of 7,8dihydroxanthopterin casts further doubts on the utility of oxidative pretreatments. While
other analytical techniques have foregone pretreatment to simplify analysis or to preserve
reduced species [38, 39, 42, 43], the present work has now provided compelling and
quantitative evidence that currently used oxidative pretreatments are inefficient for
quantitative pterinomics.

3.4. Method Performance
Performance characteristics for the newly described HPLC-MS/MS method have
been summarized in Table 4. Analytical sensitivity, assessed in terms of method detection
limits (MDLs) and lower limits of quantitation (LLOQs), was comparable or superior to
existing techniques for pteridine quantitation with MDLs ranging from 0.025 µg L-1to 0.5
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µg L-1. Pteridine signal response exhibited considerable linearity (R2 > 0.99) over a wide
linear range that spanned several orders of magnitude. The abundance of 7,8dihydroxanthopterin in urine specimens, which is discussed below, necessitated a higher
operating range up to 1000 µg L-1. Method accuracy was evaluated with spiked recoveries
in a pooled urine specimen (USG = 1.015) which ranged from 88% for low concentrations
of 6-carboxypterin to 112% for high concentrations of 7,8-dihydroxanthopterin. The
method possessed excellent precision that remained below 6% relative standard deviation
for all pteridine derivatives on both intra-daily and inter-daily bases (n = 5). This level of
precision was consistent across concentrations as indicated by the spiked recovery study.

3.5. Analysis of Urine Specimens
The new pterinomics workflow was applied to 50 clinical urine specimens from
women who were diagnosed with either breast cancer or a benign fibrocystic conditions.
This application was selected based on prior reports on the molecular epidemiology of
pteridines in breast cancer [26, 30], but also to determine whether untreated pteridine
derivatives were present in urine at detectable concentrations. The latter investigation is
novel because prior studies either have monitored reduced pteridine derivatives in other
biological fluids or have used inferior methodologies that lack selectivity [39, 43]. At 100fold dilution, ten of the fifteen pteridine derivatives were reliably quantified in all urine
specimens (Figure 3). Those derivatives and their encountered concentration range were
as follows: sepiapterin (22 nM – 4500 nM), isoxanthopterin (250 nM – 2010 nM),
xanthopterin (320 nM – 6000 nM), 6-biopterin (0.1 µM – 9.7 µM), neopterin (0.2 µM – 26
µM), lumazine (190 nM – 1000 nM), 7-hydroxylumazine (67 nM – 465 nM), monapterin
(50 nM – 2400 nM), pterin (150 nM – 2340 nM), and 7,8-dihydroxanthopterin (5 µM –
112 µM). 6-Carboxypterin was present in most urine specimens, but at levels that were not
quantifiable (signal-to-noise range: 0 – 4.2), an observation that supports earlier research
findings [29]. Similarly, 6-hydroxymethylpterin was observed in a majority of samples,
but at unquantifiable levels (signal-to-noise range: 0 – 2.9). Incomplete separation of
neopterin and monapterin coupled with large concentration differences complicated the
quantitation of monapterin.

2.75
2.85
2.9
3.0
3.0
3.1
3.3
3.5
3.8
4.1
4.1
4.7
5.2

Xantopterin

7,8-Dihydroxanthopterin

6-Biopterin

6-Hydroxymethylpterin

Isoxanthopterin

Pterin

6-Hydroxylumazine

Lumazine

7-Hydroxylumazine

6-Carboxypterin

6-Methylpterin

Sepiapterin

6,7-Dimethylpterin

0.1 - 500

0.1 - 500

0.05 - 500

0.5 - 500

0.2 - 500

0.5 - 500

1 - 500

0.1 - 500

0.3 - 500

0.05 - 500

0.1 - 500

0.5 - 1000

0.3 - 500

0.1 - 500

0.1 - 500

0.9995

0.9995

0.9992

0.9993

0.9982

0.9981

0.9955

0.9992

0.9992

0.9983

0.9997

0.9825

0.9995

0.9982

0.9997

2

R

0.05

0.05

0.05

0.3

0.1

0.3

0.5

0.05

0.2

0.025

0.05

0.3

0.2

0.05

0.05

MDLs
(µg L-1)

0.1

0.1

0.1

0.5

0.2

0.5

1

0.1

0.3

0.05

0.1

0.5

0.3

0.1

0.1

LLOQs
(µg L-1)

Recovery %
(10 µg L-1)1
97

100
100
94
98
95
96
103

99
97
100
93
98
100
101

Recovery %
(1 µg L-1)1
96

105
94
91
97
101
96
97

87
94
94
88
92
108
105

107

104

104

95

100

107

96

104

105

94

97

112

97

97

102

Recovery %
(100 µg L-1)1

N.D.

22-4500

N.D.

N.D.

67-465

190-1000

N.D.

150-2340

250-2010

N.D.

110-9700

5000-112,000

320-6000

50-2400

180-26,300

Urinary Range
(nM)

Recovery of pteridine standards spiked into a urine sample at the designated concentrations (n = 5). No oxidative pretreatment

2.3

Monapterin

was used.

1

2.2

Retention Linear Range
Time (min)
(µg L-1)

Neopterin

Compound

Table 4. Performance characteristics of the pterinomics workflow.
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Detection of trace pteridines was improved by using lesser dilutions, such as 20fold dilutions; however, a 100-fold dilution was preferable in order to increase longevity
of the column and mass spectrometer [29]. Non-parametric Mann-Whitney U group
comparison tests revealed that no pteridine derivatives were substantially altered between
the two patient groups, although isoxanthopterin (p-value = 0.063) was non-significantly
increased in the breast cancer group. Hence, future studies that aim to quantify urinary
levels of 6,7-dimethylpterin, 6-carboxypterin, 6-methylpterin, 6-hydroxymethylpterin, and
6-hydroxylumazine may require additional preconcentration or injection at lower dilutions.

Figure 3. Overlaid extracted ion chromatograms (XIC) of the quantitative and confirmation
ion pairs of native pteridine derivatives in 100-fold diluted urine with a typical USG of
1.014.
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Finally, much attention has been given to the stability and interconversion of
reduced and aromatic pteridine derivatives in oxygenated and aqueous environments [50].
Prior work has shown that aromatic pteridines are generally stable at low temperatures,
while the stability of semi-reduced pteridines is considerably less, but still significant [59].
This led us to investigate whether the pteridine profile of fresh urine specimens
significantly differed from that of aged urine specimens. Interestingly, 7,8dihydroxanthopterin was present in fresh urine and accumulated over a period of weeks
and months. This phenomenon was attributed to the non-specific oxidation and hydration
of reduced pteridine derivatives to 7,8-dihydroxanthopterin [59]. For this reason, the
pterinomic profile of a biological sample can be reasonably expected to change over time.
For this reason, future studies should utilize either fresh urine specimens or store specimens
at -80°C to prevent non-specific oxidation of reduced pteridine derivatives.

4. CONCLUSION
A new pterinomics workflow for the simultaneous determination of 15 pteridine
derivatives in urine using HPLC-MS/MS has been described. The methodology expands
on previous techniques by characterizing molecular adduction in ESI sources, separating
five structural isomers, and investigating potential interferences present in complex urine
matrices for the first time. The validated method possessed excellent sensitivity and
precision that was suitable for comprehensive pteridine analysis in urine. The method was
applied to a comparative study of commonly used oxidative pretreatments for pteridine
analysis, revealing that oxidative mechanisms were inefficient, complex, and concentration
dependent. These quantitative findings compellingly demonstrate that oxidative
pretreatments are problematic for pterinomics approaches. In addition, 50 clinical urine
specimens were examined with the new technique wherein 10 pteridine derivatives were
quantified and population ranges have been given. The urinary levels reported in this study
were generally consistent with previous work and indicated the suitability of the new
technique for urinary pteridine analysis. Finally, this technique can be used to examine
pteridine molecular epidemiology and biochemistry to support related research
applications, and may further be readily extended to additional pteridine derivatives and
biological matrices for specific applications.
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SECTION

2. CONCLUSIONS

The work presented in this dissertation explored the application of urinary
metabolomics approaches to cancer biomarker discovery. The first two papers discussed
novel enzymatic methods for the determination of sarcosine, a putative biomarker for
prostate cancer. These studies highlighted the growing need to both identify and eliminate
potential interferences from analytical methods. The next several studies presented new
bioanalytical and clinical translational methods for the determination of urinary pteridines
as putative biomarkers for breast cancer. These studies were embedded with several
innovations, including new methods for the adjustment of urinary biomarkers to urine
concentration-dilution and particularly within the context of clinical breast cancer
screening, mass spectrometry-based methods to minimize undesirable adduction as a
means to enhance method sensitivity, and a novel study design employing rigorous
statistical workflows for the characterization of the biological variation of urinary
metabolites in relation to circadian rhythms and vitamin supplementation. The pterinomics
workflow presented in the final paper additionally outlines the development of a highthroughput method to support investigation of a composite panel of biomarkers for
increased diagnostic accuracy. Finally, the proof-of-concept work presented in Paper VI
that explores the feasibility of using urinary metals as disease biomarkers has introduced
urinary metallomics as a potentially transformative new subfield of urinary metabolomics.
Taken together, this body of work makes significant contributions to the applicability of
urinary metabolomics as a biomarker discovery platform for early cancer detection and
toward understanding the clinical and biological significance of pteridines in cancer.
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